

CITATION REPORT

List of articles citing

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

DOI: 10.1056/nejm199601043340101

New England Journal of Medicine, 1996, 334, 1-6.

Source: <https://exaly.com/paper-pdf/26693907/citation-report.pdf>

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2285	Prognostic factors in early-stage ovarian cancer. 2013 , 7, 325		15
2284	Paclitaxel (Taxol) as salvage therapy for relapsed ovarian cancer. 1996 , 36, 168-70		4
2283	Clinical trials of P-glycoprotein reversal in solid tumours. 1996 , 32A, 1070-81		180
2282	Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1996 , 63, 323-7	4.9	8
2281	Squamous cell carcinoma arising in mature cystic teratoma of the ovary. <i>Gynecologic Oncology</i> , 1996 , 63, 364-70	4.9	85
2280	Oncology. Are Voltaire and Rousseau now wrong?. 1996 , 348 Suppl 2, s117		1
2279	Clinical trials in patients with epithelial ovarian cancer: past, present and future. 1996 , 22, 455-66		18
2278	Clear pharmacokinetic advantages with microemulsion formulation of cyclosporin. 1996 , 7, 6-8		
2277	Erratum to New data show survival advantage for paclitaxel combination. 1996 , 7, 8		
2276	Substitution of cisplatin with carboplatin leads to better tolerability. 1996 , 7, 14-16		1
2275	Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy. 1996 , 35, 733-6		5
2274	Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. 1996 , 1, 326-330		34
2273	Clinical News. 1996 , 7, 5-5		
2272	Clinical News. 1996 , 7, 6-8		
2271	Clinical News. 1996 , 7, 7-8		
2270	Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group. 1996 , 35 Suppl 8, 109-18		6
2269	Clinical Practice Guidelines for Gynecologic Cancers. 1996 , 3, 347-355		

2268	Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. 1996 , 14, 1185-91		51
2267	Topotecan today. 1996 , 14, 3053-5		14
2266	Frontiers of Ovarian Cancer Therapy. 1996 , 3, 137-144		2
2265	Comment: genetics and public health. 1996 , 86, 1701-4		10
2264	Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of life. 1996 , 122, 511-2		28
2263	Is paclitaxel and cisplatin a cost-effective first-line therapy for advance ovarian carcinoma?. 1996 , 77, 2086-91		11
2262	The role of radioimmunoscentigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report. 1996 , 77, 2286-93		14
2261	The National Cancer Data Base report on ovarian cancer treatment in United States hospitals. 1996 , 78, 2236-46		48
2260	Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma: A lifetime cost-effectiveness analysis. 1996 , 78, 2366-2373		23
2259	Peripheral blood stem cell transplantation in common solid tumours: passing phase or new era?. 1996 , 8, 209-11		1
2258	Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. 1996 , 85, 1035-43		20
2257	Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. <i>New England Journal of Medicine</i> , 1996 , 335, 1413-6	59.2	360
2256	Reproductive Health LiteratureWatch. 1996 , 5, 153-168		
2255	Intraperitoneal chemotherapy in the treatment of ovarian cancer. 1996 , 28, 293-6		10
2254	Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. <i>New England Journal of Medicine</i> , 1996 , 335, 1950-5	59.2	1004
2253	New therapy for ovarian cancer. <i>New England Journal of Medicine</i> , 1996 , 334, 50-1	59.2	28
2252	A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. 1996 , 7, 1077-9		5
2251	A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. 1996 , 7, 705-11		17

- 2250 Chemotherapy for ovarian cancer. *New England Journal of Medicine*, **1996**, 334, 1268-9; author reply 1270-1. 6
- 2249 A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer. **1997**, 8, 663-7. 20
- 2248 BRCA1 mutations and survival in women with ovarian cancer. *New England Journal of Medicine*, **1997**, 336, 1254; author reply 1256-7. 59.2 8
- 2247 ?Paclitaxel and ?docetaxel in breast and ovarian cancer. **1997**, 35, 43-46. 3
- 2246 Lack of thermal enhancement for taxanes in vitro. **1997**, 13, 525-33. 28
- 2245 Key dilemmas in prescribing and the provision of health. **1997**, 35, 47-48.
- 2244 More than 20 years second-look surgery in advanced epithelial ovarian cancer: what did we learn?. **1997**, 8, 627-9. 7
- 2243 Response. **1997**, 89, 583-584.
- 2242 Quality improvement in neurology residency programs. Report of the Quality Improvement Committee of the Association of University Professors of Neurology. **1997**, 49, 1205-7. 9
- 2241 Carboplatin (CBDCA) plus ifosfamide (IFO) as first-line chemotherapy in advanced (FIGO III and IV) ovarian cancer. **1997**, 10, 509-14. 1
- 2240 Time trends of consumption and costs of drugs in a cancer referral centre. **1997**, 10, 641-4. 1
- 2239 Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer. **1997**, 11, 175.
- 2238 The role of apoptosis in gynaecological malignancies. **1997**, 29, 121-6. 33
- 2237 Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions. **1997**, 31, 1465-70. 9
- 2236 Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. **1997**, 89, 1803-9. 71
- 2235 Trigeminal neuralgia: gamma radiosurgery may provide new options for treatment. **1997**, 48, 565-6. 13
- 2234 Fatal hepatic coma attributed to paclitaxel. **1997**, 89, 582-4. 9
- 2233 Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer: an effective in vitro drug-sensitization system. **1997**, 43, 268-75. 17

2232	A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. 1997 , 8, 327-33	88
2231	Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival. 1997 , 50, 242-6	21
2230	Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. 1997 , 8, 963-8	199
2229	Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. 1997 , 8, 355-61	27
2228	Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. 1997 , 15, 2183-93	563
2227	Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. 1997 , 94, 2031-5	740
2226	Ovarian cancer. Current outlook on this deadly disease. 1997 , 102, 112-20	13
2225	Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. 1997 , 75, 703-9	14
2224	Activity of anthracyclines in refractory ovarian cancer: recent experience and review. 1997 , 15, 329-34	10
2223	Comments on economic evaluation of chemotherapy. 1997 , 12, 229-31	
2222	The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. 1997 , 48, 353-74	585
2221	Disfunci3n ventricular isqu3mica cr3nica severa. Determinantes del riesgo quir3rgico y del resultado cl3nico a largo plazo. 1997 , 50, 870-881	
2220	Betabloqueantes en la insuficiencia card3ca: ¿deben incluirse siempre en la estrategia terap3utica? Argumentos a favor. 1997 , 50, 300-303	
2219	Betabloqueantes en la insuficiencia card3ca: ¿deben incluirse siempre en la estrategia terap3utica? Argumentos en contra. 1997 , 50, 304-307	
2218	The role of plant-derived drugs and herbal medicines in healthcare. 1997 , 54, 801-40	143
2217	Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. 1997 , 54 Suppl 4, 22-9	58
2216	Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. 1997 , 36, 3554-62	229
2215	Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1997 , 65, 42-5	4.9 7

2214	Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA). <i>Gynecologic Oncology</i> , 1997 , 66, 75-84	4.9	19
2213	Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. <i>Gynecologic Oncology</i> , 1997 , 65, 434-6	4.9	31
2212	Phase II trial of high-dose cisplatin plus ifosfamide as first-line followed by carboplatin as second-line treatment in epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 1997 , 66, 66-70	4.9	3
2211	Arbiter:. 1997 , 33, 18-19		66
2210	Established antiepileptic drugs. 1997 , 6, 159-74		51
2209	Chemotherapy for epithelial ovarian cancer: an update. 1997 , 7, 50-60		
2208	Gemcitabine in ovarian cancer: an overview of safety and efficacy. 1997 , 33 Suppl 1, S31-3		13
2207	A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group study. 1997 , 33, 160-3		11
2206	Paclitaxel changes sympathetic control of blood pressure. 1997 , 33, 1419-24		14
2205	Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. 1997 , 33, 1393-9		60
2204	Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. 1997 , 33, 1400-6		61
2203	Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers. 1997 , 33, 1780-3		22
2202	Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group. 1997 , 33, 1893-5		26
2201	Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. 1997 , 33, 1693-8		45
2200	Paclitaxel in recurrent ovarian cancer: better upfront? Comments on: A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group Study. <i>Eur J Cancer</i> 1977, 33, 160-163. 1997 , 33, 1905-6		
2199	Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. 1997 , 33, 2167-70		97
2198	Good manners for the pharmaceutical industry. 1997 , 350, 370		4
2197	Good manners for the pharmaceutical industry. 1997 , 350, 370-1		2

2196	Epithelial ovarian carcinoma. 1997 , 349, 113-7	121	
2195	Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. 1997 , 15, 1953-64	62	
2194	High-Dose Chemotherapy with Autologous Haematopoietic Stem Cell Support in Advanced Ovarian Cancer. 1997 , 20, 196-202		
2193	Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. 1997 , 8, 351-4	15	
2192	Adjuvant Therapy in Gynecologic Malignancies. 1997 , 6, 813-830	8	
2191	The conundrum of time trends in stroke. 1997 , 90, 138-43	7	
2190	Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. 1997 , 8, 1145-50	14	
2189	High-dose chemotherapy with autologous stem cell support for the treatment of advanced ovarian cancer--initial experience in Uppsala and Turku. 1997 , 76, 363-8		
2188	Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups. 1997 , 75, 710-4	8	
2187	In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. 1997 , 75, 869-77	92	
2186	Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. 1997 , 76, 1181-3	166	
2185	Beta-carotene supplementation and cancer prevention. 1997 , 13, 697-9	18	
2184	Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer. 1997 , 176, 759-66; discussion 766-8	24	
2183	In vitro and in vivo studies on the development of the alpha-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinoma. 1997 , 176, 833-40; discussion 840-1	18	
2182	Reply. <i>Gynecologic Oncology</i> , 1997 , 66, 336	4.9	
2181	Reply. <i>Gynecologic Oncology</i> , 1997 , 66, 338-339	4.9	1
2180	Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 1997 , 66, 454-63	4.9	37
2179	Topotecan in platinum- and paclitaxel-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 1997 , 66, 480-6	4.9	127

2178	Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. <i>Gynecologic Oncology</i> , 1997 , 67, 141-6	4.9	34
2177	Biochemical characterization of primary peritoneal carcinoma cell adhesion, migration, and proteinase activity. <i>Gynecologic Oncology</i> , 1997 , 67, 193-9	4.9	11
2176	[Docetaxel in treatment of other solid tumors]. 1997 , 92 Suppl 4, 16-22		2
2175	[Oncology '96]. 1997 , 92, 83-100		
2174	A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection. 1997 , 5, 489-99		21
2173	The administration of paclitaxel without prophylaxis for the prevention of hypersensitivity reactions: is this a rationale and safe therapeutic strategy?. 1997 , 123, 531-2		1
2172	Assoziierte Symposien. 1997 , 260, 372-377		
2171	Klinik und Grundzüge der Chemotherapie bei Metastasen eines unbekannten Primärtumors. 1997 , 3, 350-353		1
2170	[New hormones and cytostatic drugs in tumor therapy]. 1997 , 38, 1037-44		1
2169	Welche Aussichten ergeben sich durch neuere Chemotherapeutika beim Ovarialkarzinom?. <i>Der Gynäkologe</i> , 1997 , 30, 108	0.1	
2168	Controversies in the management of ovarian cancer. 1997 , 7, 27-32		12
2167	Combination paclitaxel (TaxolR)-cisplatin vs cyclophosphamide-cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer. 1997 , 7, 9-13		8
2166	Combination paclitaxel (TaxolR)-carboplatin as first-line therapy for advanced ovarian cancer. 1997 , 7, 18-22		23
2165	The use of pharmacokinetics to improve the treatment of ovarian cancer: combination paclitaxel (TaxolR)-carboplatin. 1997 , 7, 14-17		3
2164	Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis. 1997 , 79, 2264-6		12
2163	Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. 1997 , 72, 844-50		47
2162	In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). 1997 , 72, 1008-12		28
2161	Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. 1998 , 49, 13-26		20

2160	Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy. 1998 , 16, 29-36		13
2159	Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. <i>Gynecologic Oncology</i> , 1998 , 68, 150-5	4.9	69
2158	Taxol hypersensitivity: rapid retreatment is safe and cost effective. <i>Gynecologic Oncology</i> , 1998 , 68, 25-84.9		42
2157	Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens. <i>Gynecologic Oncology</i> , 1998 , 68, 178-82	4.9	20
2156	Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1998 , 68, 166-8	4.9	6
2155	Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 1998 , 68, 267-73	4.9	25
2154	Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. <i>Gynecologic Oncology</i> , 1998 , 69, 103-8	4.9	417
2153	A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment. <i>Gynecologic Oncology</i> , 1998 , 69, 17-22	4.9	76
2152	Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study Group. <i>Gynecologic Oncology</i> , 1998 , 69, 100-2	4.9	14
2151	Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. <i>Gynecologic Oncology</i> , 1998 , 69, 226-9	4.9	62
2150	Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer. <i>Gynecologic Oncology</i> , 1998 , 70, 123-6	4.9	5
2149	Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. <i>Gynecologic Oncology</i> , 1998 , 70, 272-4	4.9	44
2148	Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups. <i>Gynecologic Oncology</i> , 1998 , 70, 224-30	4.9	26
2147	Paclitaxel-anthracycline combination chemotherapy in relapsing advanced ovarian cancer after platinum-based chemotherapy: a pilot study. <i>Gynecologic Oncology</i> , 1998 , 70, 414-7	4.9	9
2146	Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1998 , 70, 392-7	4.9	43
2145	Selective potentiation of gynecologic cancer cell growth in vitro by electromagnetic fields. <i>Gynecologic Oncology</i> , 1998 , 71, 64-71	4.9	21
2144	A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1998 , 70, 404-9	4.9	36
2143	Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum. <i>Gynecologic Oncology</i> , 1998 , 71, 288-90	4.9	21

2142	A phase I study of paclitaxel, doxorubicin, and cisplatin in patients with previously untreated epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1998 , 71, 450-3	4.9	8
2141	Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in Stage III epithelial ovarian cancer. 1998 , 105, 508-11		22
2140	Phase II trial of ifosfamide and cisplatin in advanced ovarian cancer. 1998 , 28, 403-9		3
2139	Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. 1998 , 78, 375-81		41
2138	Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent. 1998 , 78, 1170-4		18
2137	Chemotherapy for ovarian cancer--a consensus statement on standard practice. 1998 , 78, 1404-6		50
2136	Effect of 2'-OH acetylation on the bioactivity and conformation of 7-O-[N-(4'-fluoresceincarbonyl)-L-alanyl]taxol. A NMR-fluorescence microscopy study. 1998 , 6, 1857-63		27
2135	A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain. 1998 , 83, 719-25		11
2134	Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. 1998 , 83, 1980-1988		11
2133	Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. 1998 , 67, 104-11		14
2132	Paclitaxel as a component of initial chemotherapy of advanced ovarian cancer: is the controversy resolved. 1998 , 124, 1-3		
2131	Primäre Chemotherapie. 1998 , 4, 1131-1139		1
2130	Radiotherapeutische Möglichkeiten beim Ovarialkarzinom. 1998 , 4, 1147-1152		1
2129	Palliative therapeutische Möglichkeiten beim Ovarialkarzinom. 1998 , 4, 1153-1158		3
2128	[Current developments in use of docetaxel (taxotere) in gynecologic oncology]. 1998 , 93 Suppl 3, 4-15		
2127	Establishment and characterization of a novel cancer cell line (SMOV-1), derived from the ascitic fluid of a woman with ovarian cancer who had never responded to chemotherapeutic drugs. 1998 , 3, 108-112		
2126	5-epi-Canadensene and other novel metabolites of <i>Taxus canadensis</i> . 1998 , 54, 15845-15860		21
2125	Altered radiotherapy fractionation: an opportunity not to be missed. 1998 , 10, 150-4		3

2124	Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. 1998 , 77, 777-781	3
2123	Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines. 1998 , 112, 172-80	30
2122	Traditional pharmacology and medicine in Africa. Ethnopharmacological themes in sub-Saharan art objects and utensils. 1998 , 63, 1-175	26
2121	Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. 1998 , 128, 211-8	46
2120	Antioxidant vitamins and nuclear opacities: the longitudinal study of cataract. 1998 , 105, 831-6	116
2119	Platinum alone for chemotherapy for ovarian cancer?. 1998 , 352, 1567-8	2
2118	ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. 1998 , 352, 1571-1576	149
2117	The identification of salicylates as normal constituents of serum: a link between diet and health?. 1998 , 51, 502-5	24
2116	Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer. 1998 , 34, 1175-80	9
2115	Correspondence. 1998 , 34, 1295	1
2114	Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective. 1998 , 34, 1894-901	31
2113	Remarkable response of primary squamous cell carcinoma of the ovary to paclitaxel and cisplatin. 1998 , 91, 844-6	18
2112	Uterine and ovarian conservation in advanced small cell carcinoma of the ovary. 1998 , 91, 846-8	18
2111	Drug resistance in ovarian cancer: from the laboratory to the clinic. 1998 , 92, 312-9	22
2110	Ovarian cancer complicating pregnancy. 1998 , 25, 385-99	98
2109	[Thrombosis and coronary disease: neutrophils, nitric oxide and aspirin]. 1998 , 51, 171-7	3
2108	Should cost be considered in the overall evaluation of phase II clinical trials of new antineoplastic therapies? A response. 1998 , 16, 135-9; discussion 142-3	4
2107	The taxoids. Comparative clinical pharmacology and therapeutic potential. 1998 , 55, 5-30	192

2106	Topotecan. A review of its potential in advanced ovarian cancer. 1998 , 56, 709-23		30
2105	Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. 1998 , 12, 305-34		59
2104	Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. 1998 , 37, 629-40		16
2103	Cancer treatment in Sweden--costs of drugs, inpatient and outpatient care from 1985 to 1996 and cost effectiveness of new drugs. 1998 , 37, 447-53		4
2102	DNA-topoisomerase I activity and content in epithelial ovarian cancer. 1998 , 9, 313-9		15
2101	Long abstracts. 1998 , 9, 9-60		
2100	Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. 1998 , 273, 4928-36		282
2099	Topotecan: a new topoisomerase I inhibiting antineoplastic agent. 1998 , 32, 1334-43		20
2098	Successful treatment with nedaplatin in patients with ovarian cancer that recurred after platinum-containing chemotherapy: report of two cases. <i>Japanese Journal of Clinical Oncology</i> , 1998 , 28, 343-6	2.8	5
2097	Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. 1998 , 77, 777-81		31
2096	Continuous infusion of ifosfamide and cisplatin as first-line therapy of patients with suboptimally debulked stage III-IV epithelial ovarian cancer. 1998 , 8, 138-143		3
2095	Eastern Cooperative Oncology Group experience with chemotherapy in advanced non-small cell lung cancer. 1998 , 113, 13S-16S		9
2094	REMARKABLE RESPONSE OF PRIMARY SQUAMOUS CELL CARCINOMA OF THE OVARY TO PACLITAXEL AND CISPLATIN. 1998 , 91, 844-846		9
2093	DRUG RESISTANCE IN OVARIAN CANCER. 1998 , 92, 312-319		17
2092	Carboplatin versus cisplatin in solid tumors: an analysis of the literature. 1998 , 9, 13-21		205
2091	Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. 1998 , 9, 423-30		68
2090	The Gynecologic Oncology Model. 1998 , 7, 255-262		
2089	Linee Guida Del Tumore Epiteliale Dell'ovaio. 1998 , 84, A23-A31		

2088	Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. 1998 , 16, 2426-34	121
2087	Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors. 1998 , 16, 3483-5	21
2086	BAX protein expression and clinical outcome in epithelial ovarian cancer. 1998 , 16, 2583-90	113
2085	Ovarian Cancer. 1998 , 7, 317-333	12
2084	Il Carcinoma Dell'ovaio Avanzato Stato Dell'arte e Prospettive Future. 1998 , 84, A1-A22	
2083	A Phase I-II Trial of High-dose Ifosfamide in Patients with Ovarian Cancer Refractory or Resistant to Platinum and/or Paclitaxel-containing Chemotherapy. 1999 , 85, 217-219	9
2082	Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. 1999 , 17, 747-55	43
2081	First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. 1999 , 17, 46-51	42
2080	Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. 1999 , 17, 2198-207	21
2079	Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. 1999 , 17, 2553-61	80
2078	Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. 1999 , 17, 2069-80	60
2077	Back to the future: multiagent chemotherapy in ovarian cancer revisited. 1999 , 17, 741-3	10
2076	Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. 1999 , 17, 761-6	90
2075	Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. 1999 , 17, 1288	69
2074	The Gynecologic Oncology Group experience in ovarian cancer. 1999 , 10, S29-S34	2
2073	The role of anthracyclines in epithelial ovarian cancer. 1999 , 10, S43-S50	6
2072	Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner?. 1999 , 10, S9-S15	6
2071	Gemcitabine in the treatment of ovarian cancer. 1999 , 10, S51-S53	1

2070	Intergroup collaboration in ovarian cancer: a giant step forward. 1999 , 10, S83-S86		1
2069	Randomised trials in ovarian cancer: trial design considerations. 1999 , 10, S75-S82		3
2068	First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care?. 1999 , 10, S35-S41		15
2067	Advanced epithelial ovarian cancer: 1998 consensus statements. 1999 , 10, S87-S92		25
2066	Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity. 1999 , 15, 1155-62		4
2065	Increased intracellular cAMP renders HL-60 cells resistant to cytotoxicity of taxol. 1999 , 21, 233-45		7
2064	1998 guidelines for the treatment of sexually transmitted diseases. Introduction. 1999 , 28 Suppl 1, S1-3		
2063	A dose-finding study of nedaplatin and cyclophosphamide for patients with gynecological malignancies. <i>Japanese Journal of Clinical Oncology</i> , 1999 , 29, 299-302	2.8	16
2062	Animal systems for translational research in radiation oncology. 1999 , 38, 829-38		18
2061	Synchronous inflammatory breast cancer and advanced ovarian carcinoma: a case with prolonged disease-free survival. 1999 , 10, 585-8		1
2060	Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. 1999 , 10, 1125-8		54
2059	Gynaecological cancer. 1999 , 75, 332-8		4
2058	A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , 1999 , 29, 434-7	2.8	26
2057	Management of gynaecological cancers. 1999 , 8, 270-9		5
2056	Comparison of long-term survival of cytomegalovirus promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer. 1999 , 18, 93-7		6
2055	Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. 1999 , 91, 1557-63		82
2054	Intraperitoneal chemotherapy. 1999 , 31, 239-46		29
2053	Up date in the management of advanced ovarian carcinoma. 1999 , 32, 49-58		25

2052	Treatment of early epithelial ovarian cancer with chemotherapy and abdominopelvic radiotherapy: results of a prospective treatment protocol. 1999 , 45, 657-65	14
2051	Radical cytoreductive surgery combined with platinum-carboplatin and cisplatin chemotherapy for advanced ovarian cancer. 1999 , 9, 54-60	5
2050	A pharmacokinetic and clinical evaluation of thio-TEPA in combination with cisplatin as first-line chemotherapy for advanced epithelial ovarian carcinoma. 1999 , 9, 110-116	3
2049	Effective desensitization protocol to paclitaxel following hypersensitivity reaction. 1999 , 9, 156-159	14
2048	Prognostic factors in ovarian carcinoma in complete histologic remission at second-look surgery. 1999 , 9, 231-237	4
2047	A phase II study of biweekly administration of paclitaxel in patients with recurrent epithelial ovarian cancer. 1999 , 9, 373-376	5
2046	Tolerance of twenty-four hour paclitaxel and carboplatin as first-line therapy in ovarian, peritoneal and fallopian tube carcinoma. 1999 , 9, 448-451	3
2045	Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. 1999 , 79, 286-92	35
2044	Blood platelets and serum VEGF in cancer patients. 1999 , 79, 370-3	45
2043	The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. 1999 , 80, 629-38	110
2042	Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer. 1999 , 80, 1052-7	29
2041	Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. 1999 , 80, 1162-8	53
2040	Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. 1999 , 23, 763-70	30
2039	Protein kinase C isoform expression and activity alter paclitaxel resistance in vitro. <i>Gynecologic Oncology</i> , 1999 , 72, 171-9	4.9 5
2038	Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1999 , 72, 148-53	4.9 57
2037	A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1999 , 72, 292-7	4.9 4
2036	Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation. <i>Gynecologic Oncology</i> , 1999 , 72, 342-6	4.9 98
2035	Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer. <i>Gynecologic Oncology</i> , 1999 , 73, 96-101	4.9 16

2034	The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 1999 , 74, 272-7	4.9	146
2033	The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy. <i>Gynecologic Oncology</i> , 1999 , 74, 400-7	4.9	20
2032	Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma. <i>Gynecologic Oncology</i> , 1999 , 75, 62-7	4.9	33
2031	First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix--a phase II study. <i>Gynecologic Oncology</i> , 1999 , 75, 334-7	4.9	51
2030	Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin?. <i>Gynecologic Oncology</i> , 1999 , 75, 464-7	4.9	19
2029	CA 125: fundamental and clinical aspects. 1999 , 9, 117-24		62
2028	Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. 1999 , 45, 241-6		17
2027	Current Status and Perspectives in Cancer Chemotherapy. 1999 , 6, 270-274		1
2026	Klinische Aspekte und Pharmakoökonomie beim Ovarialkarzinom. 1999 , 5, 590-597		
2025	Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy. 1999 , 7, 354-61		36
2024	An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. 1999 , 125, 427-9		51
2023	Multidisciplinary treatment with and without hyperthermia for ovarian carcinoma. 1999 , 4, 378-383		
2022	The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma. 1999 , 1, 71-6		5
2021	In vitro chemosensitivity testing and mechanisms of drug resistance. 1999 , 1, 77-84		8
2020	Epithelial ovarian cancer: prevention, diagnosis, and treatment. 1999 , 49, 297-320		110
2019	Effects of testosterone and growth hormone on muscle function. 1999 , 134, 7-10		7
2018	False positive rates of randomized phase II designs. 1999 , 20, 343-52		64
2017	Epithelial ovarian cancer. 1999 , 36, 1-53		11

2016	Evaluation of the genotoxic activity of paclitaxel by the in vitro micronucleus test in combination with fluorescent in situ hybridization of a DNA centromeric probe and the alkaline single cell gel electrophoresis technique (comet assay) in human T-lymphocytes. 1999 , 34, 269-78	57
2015	Chemotherapy for ovarian cancer: current concepts. 1999 , 17, 181-8	19
2014	Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. 1999 , 85, 295-301	97
2013	High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients. 1999 , 85, 1555-64	13
2012	Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro. 1999 , 86, 2066-73	19
2011	A Phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. 1999 , 86, 2291-2300	3
2010	Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study. 1999 , 72, 162-6	11
2009	Oral etoposide for the treatment of recurrent ovarian cancer. 1999 , 58 Suppl 3, 43-9	13
2008	Micropapillary bladder carcinoma: a clinicopathological study of 20 cases. 1999 , 161, 1798-802	159
2007	Pharmacoeconomic considerations in treating patients with acute leukaemia. 1999 , 15, 167-78	4
2006	Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients. 1999 , 17, 559-65	9
2005	Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy. 1999 , 35, 727-32	21
2004	TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. 1999 , 229, 75-81	68
2003	ICON2 trial. 1999 , 353, 588	
2002	Human T-lymphotropic virus type I infection. 1999 , 353, 1951-8	260
2001	Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. 1999 , 353, 1843-7	260
2000	ICON2 trial. EORTC-GCCG, NOCOVA, NCI-C, Scottish groups, and GOG. Gynaecologic Oncology Group. 1999 , 353, 587; author reply 588	3
1999	Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. 1999 , 93, 21-4	96

1998	Future directions with taxane therapy. 1999 , 13, 21-41, vii	5
1997	Recent advances in cancer chemotherapy. 1999 , 6, 696-705	
1996	Cisplatin alone was as effective as cisplatin plus cyclophosphamide for advanced ovarian cancer. 1999 , 1, 95	
1995	Chemotherapy-induced anemia in adults: incidence and treatment. 1999 , 91, 1616-34	703
1994	Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold. 1999 , 318, 456-9	35
1993	Essential drugs for cancer therapy: a World Health Organization consultation. 1999 , 10, 385-90	63
1992	Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma. 1999 , 57, 115-20	32
1991	Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma. 1999 , 57, 10-6	8
1990	Ten-Year Follow-Up of Ovarian Cancer Patients After Second-Look Laparotomy With Negative Findings. 1999 , 93, 21-24	65
1989	Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. 1999 , 10, 355-8	31
1988	Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. 1999 , 11, 407-9	22
1987	High-dose chemotherapy: is it standard management for any common solid tumor?. 1999 , 10, 1145-61	12
1986	Going bare: trends in health insurance coverage, 1989 through 1996. 1999 , 89, 36-42	50
1985	A Phase I/II Study of Dose-Escalated Ifosfamide plus Carboplatin Combination for Advanced Ovarian Carcinoma. 1999 , 22, 212-215	
1984	Dose Escalation of Carboplatin and Cyclophosphamide Supported by GM-CSF in the Treatment of Patients with Advanced Ovarian Cancer (FIGO III and IV) In Phase I Study. 1999 , 22, 502-506	
1983	Natural history of stage IV epithelial ovarian cancer. 1999 , 17, 767-75	91
1982	High-Dose versus Low-Dose Cisplatin Chemotherapy plus Treosulfan in Epithelial Ovarian Carcinoma FIGO III/IV: Results of a Prospective Randomized Trial. 2000 , 23, 232-238	4
1981	Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. 2000 , 18, 102-5	139

1980	High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. 2000 , 133, 504-15	43
1979	Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells. 2000 , 59, 329-35	20
1978	Randomized trial of cisplatin and carboplatin versus cisplatin, vinblastine and bleomycin in ovarian cancer. 2000 , 50, 269-74	17
1977	Die Rolle der Anthrazykline beim Ovarialkarzinom. 2000 , 23, 28-30	
1976	Current strategies for prevention, detection, and treatment of ovarian cancer. 2000 , 40, 392-401	9
1975	Advances in ovarian cancer chemotherapy. 2000 , 12, 481-91	14
1974	Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. 2000 , 23, 569-74	26
1973	A reappraisal of the role of chlorambucil in patients with end stage ovarian cancer who have previously been treated with platinum regimens. 2000 , 45, 51-3	4
1972	Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. 2000 , 23, 473-9	58
1971	HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHODS FOR THE DETERMINATION OF A NOVEL POLYMER-BOUND PACLITAXEL DERIVATIVE AND FREE PACLITAXEL IN HUMAN PLASMA. 2000 , 23, 1233-1251	2
1970	Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer. 2000 , 11, 1603-8	2
1969	A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer. 2000 , 11, 613-6	7
1968	Impairment of heart rate variability during paclitaxel therapy. 2000 , 88, 2149-53	28
1967	Clinical characteristics of clear cell carcinoma of the ovary. 2000 , 88, 2584-2589	611
1966	Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study. 2000 , 89, 1547-54	15
1965	Immunization of ovarian cancer patients with a synthetic Lewisy-protein conjugate vaccine: A phase 1 trial. 2000 , 87, 79-85	110
1964	Retinoids and ovarian cancer. 2000 , 185, 1-20	73
1963	Current management of epithelial ovarian carcinoma: a review. 2000 , 19, 11-9	63

1962	Second-look and second surgery: second chance or second best?. 2000 , 19, 54-61	21
1961	Treatment of advanced ovarian carcinoma with carboplatin and paclitaxel in a patient with renal failure. 2000 , 10, 463-468	25
1960	Paclitaxel in combination with cisplatin is less effective for peripheral blood progenitor cell mobilization. 2000 , 10, 459-462	2
1959	Intravenous chemotherapy for ovarian cancer - the state of the art?. 2000 , 10, 19-25	22
1958	Optimum chemotherapy for ovarian cancer. 2000 , 10, 33-37	124
1957	New cytotoxics and non-cytotoxics in epithelial ovarian cancer. 2000 , 10, 38-43	6
1956	Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. 2000 , 10, 44-46	75
1955	High dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer. 2000 , 10, 53-56	9
1954	Advanced ovarian cancer: update, remarks and conclusions on optimal therapy. 2000 , 10, 57-60	4
1953	Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited. 2000 , 33, 7-23	41
1952	High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results. 2000 , 26, 61-7	18
1951	Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. 2000 , 7, 839-44	64
1950	Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. 2000 , 7, 1925-9	56
1949	Chemotherapy in recurrent epithelial ovarian cancer (EOC): an analysis of prognostic factors. 2000 , 26, 215-22	4
1948	Study finds that hypersensitivity to paclitaxel may not preclude its continued but cautious use. 2000 , 1, 122	
1947	Ovarian cancer gene therapy: repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model. 2000 , 182, 553-9	38
1946	The use of paclitaxel and cisplatin in a patient with epithelial ovarian cancer and human immunodeficiency virus. <i>Gynecologic Oncology</i> , 2000 , 76, 118-22	4.9 9
1945	Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. <i>Gynecologic Oncology</i> , 2000 , 76, 157-62	4.9 109

1944	Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. <i>Gynecologic Oncology</i> , 2000 , 76, 362-8	4.9	35
1943	Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients. <i>Gynecologic Oncology</i> , 2000 , 76, 326-30	4.9	6
1942	Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2000 , 77, 48-54	4.9	4
1941	Choroidal metastasis presented as the initial symptom of the recurrence from ovarian endometrioid adenocarcinoma: A case report. <i>Gynecologic Oncology</i> , 2000 , 77, 219-21	4.9	4
1940	Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. <i>Gynecologic Oncology</i> , 2000 , 77, 258-63	4.9	84
1939	The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2000 , 77, 227-31	4.9	155
1938	Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2000 , 77, 271-7	4.9	3
1937	Reproducibility in the assessment of postmenopausal ovaries with transvaginal ultrasound. <i>Gynecologic Oncology</i> , 2000 , 77, 289-92	4.9	5
1936	Phase II study of mifepristone (RU486) in refractory ovarian cancer. <i>Gynecologic Oncology</i> , 2000 , 77, 429-33	4.9	50
1935	Surgical response of advanced-stage borderline ovarian tumors to paclitaxel and cisplatin chemotherapy. <i>Gynecologic Oncology</i> , 2000 , 77, 343-4	4.9	6
1934	Long-term results and prognostic factors in patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2000 , 78, 21-7	4.9	103
1933	Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125. <i>Gynecologic Oncology</i> , 2000 , 77, 225-6	4.9	13
1932	Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. <i>Gynecologic Oncology</i> , 2000 , 78, 52-7	4.9	73
1931	Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look. <i>Gynecologic Oncology</i> , 2000 , 79, 28-32	4.9	7
1930	Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2000 , 79, 97-100	4.9	0
1929	Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. <i>Gynecologic Oncology</i> , 2000 , 79, 116-9	4.9	50
1928	Phase 2 trial of liposomal doxorubicin (40 mg/m ²) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. <i>Gynecologic Oncology</i> , 2000 , 78, 369-72	4.9	138
1927	High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). <i>Gynecologic Oncology</i> , 2000 , 78, 361-8	4.9	22

1926	Chemotherapy for malignant mixed Müllerian tumors of the ovary. <i>Gynecologic Oncology</i> , 2000 , 79, 196-200	49
1925	Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. <i>Gynecologic Oncology</i> , 2000 , 79, 211-5	49 32
1924	Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer. 2000 , 12, 251-5	4
1923	Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. 2000 , 82, 1138-44	180
1922	Advanced ovarian cancer. 2000 , 1, 139-46	24
1921	Treatment of fallopian tube cancer. Review of the literature. 2000 , 264, 13-9	8
1920	[Genetic risk factors for myocardial infarct]. 2000 , 25, 7-14	4
1919	Genetic risk factors and restenosis after percutaneous coronary interventions. 2000 , 25, 34-46	31
1918	Comparative study on three chemotherapeutic regimens for the treatment of advanced epithelial ovarian cancer. 2000 , 20, 343-4	
1917	Paclitaxel-cisplatin combination in advanced ovarian cancer: a phase II study. 2000 , 5, 85-88	2
1916	Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. 2000 , 126, 168-72	45
1915	Thymidylate synthase expression in epithelial ovarian cancer: relationship with thymidine phosphorylase expression and prognosis. 2000 , 59, 152-7	9
1914	Anthrazykline in der Therapie des Ovarialkarzinoms [Vergangenheit, Gegenwart und Zukunft. 2000 , 23, 46-52	
1913	Trastuzumab in CSF. 2000 , 18, 2349-51	264
1912	Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study. 2000 , 18, 2957-62	19
1911	Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. 2000 , 18, 3093-100	288
1910	Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. 2000 , 18, 2733-9	106
1909	Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. 2000 , 18, 4038-44	54

1908	Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. 2000 , 18, 1193-202	134
1907	Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. 2000 , 18, 3084-92	345
1906	p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. 2000 , 18, 3936-45	123
1905	Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. 2000 , 18, 106-15	501
1904	Correction. 2000 , 18, 2351-2352	5
1903	A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group. 2000 , 11, 1035-40	19
1902	Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer. 2000 , 11, 607-12	8
1901	Ovarian Cancer. 2000 ,	3
1900	Confirmation of the "old" standard of care for ovarian cancer and a challenge. 2000 , 92, 674-5	7
1899	Anti-Inflammatory Compounds as Ligands in Metal Complexes as Revealed in X-Ray Structural Studies. 2000 , 22, 151-186	48
1898	Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. 2000 , 55, 713-5	258
1897	Adjuvant chemotherapy including cisplatin in endometrial carcinoma. 2000 , 50, 127-32	7
1896	Re: randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. 2000 , 92, 1446-7	2
1895	Primary surgical management of ovarian cancer. 2001 , 39, 75-87	
1894	Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid. 2000 , 11, 1657-69	65
1893	Second-line treatment of ovarian cancer. 2000 , 5, 26-35	243
1892	Optimal treatment for ovarian cancer: taxoids and beyond. 2000 , 11 Suppl 3, 131-9	1
1891	Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. 2000 , 92, 699-708	733

1890	Treatment with Paclitaxel Alone Rather than Combination with Paclitaxel and Cisplatin May be Selective for Cisplatin-resistant Ovarian Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2000 , 30, 446-449	28 10
1889	Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. 2000 , 283, 2260-5	416
1888	RESPONSE: re: randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. 2000 , 92, 1446-7	1
1887	Highlights in ovarian cancer. 2000 , 5, 267-73	3
1886	Paclitaxel hypersensitivity reactions related to bee-sting allergy. 2000 , 355, 288-9	26
1885	Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. 2000 , 196, 469-75	28
1884	A new standard of care for treatment of ovarian cancer. 2000 , 36, 10-2	24
1883	Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy. 2000 , 36, 503-7	16
1882	The treatment of ovarian cancer has reached new standards of care. 2000 , 36, 7-9	1
1881	Achievements and future of chemotherapy. 2000 , 36, 1479-87	25
1880	Ovarian cancer. an institutional review of patterns of care, health insurance and prognosis. 2000 , 36, 2061-8	9
1879	p53 and related proteins in epithelial ovarian cancer. 2000 , 36, 2317-28	32
1878	The taxanes: an update. 2000 , 355, 1176-8	304
1877	Regression of liver metastases after high-dose chemotherapy and peripheral-blood progenitor-cell support in Stage IV ovarian cancer. 2000 , 71, 245-8	
1876	Progress in gynecologic cancer detection and treatment. 2000 , 70, 135-47	18
1875	[Should antioxidants be recommended for the prevention of cardiovascular diseases?]. 2000 , 200, 212-7	1
1874	Drug therapy for gynaecological cancer in older women. 2000 , 17, 13-32	11
1873	New developments and approaches in the platinum arena. 2000 , 59 Suppl 4, 29-36; discussion 37-8	82

1872	Marine organisms and other novel natural sources of new cancer drugs. 2000 , 11 Suppl 3, 235-43	33
1871	Modelling in health economic evaluation. What is its place? What is its value?. 2000 , 17, 445-59	92
1870	Pharmacoeconomic considerations in treating ovarian cancer. 2000 , 17, 133-50	7
1869	Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the Gynecologic Oncology Group 111 trial. 2000 , 18, 261-8	3
1868	Taxol in the management of cancers of the breast and the ovary. 2000 , 18, 242-60	42
1867	Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. 2000 , 5, 185-98	147
1866	[Reversible posterior leukoencephalopathy syndrome]. 2000 , 200, 57-9	0
1865	[Spanish Society of Cardiology practice guidelines on arterial hypertension]. 2000 , 53, 66-90	22
1864	Fármacos con actividad de fondo en patolog�a inflamatoria articular (I). 2000 , 8, 1457-1463	
1863	Actitudes terap�uticas. alimentaci�n. actividad f�sica. indicaciones de fisioterapia. indicaciones de tratamiento farmacol�gico. criterios de introducci�n y retirada de fármacos. indicaciones quir�rgicas. 2000 , 8, 1396-1401	
1862	El tratamiento de la insuficiencia card�aca. 2000 , 200, 551-562	3
1861	Fen�menos oxidativos en la fisiopatolog�a vascular. 2000 , 17, 17-21	1
1860	PHASE II STUDY OF PACLITAXEL AND CISPLATIN FOR ADVANCED UROTHELIAL CANCER. 2000 , 164, 1538-1542	50
1859	Risks and benefits of taxanes in breast and ovarian cancer. 2000 , 23, 401-28	84
1858	Prevention and management of antineoplastic-induced hypersensitivity reactions. 2001 , 24, 767-79	129
1857	Intraperitoneal drug delivery of antineoplastics. 2001 , 61, 1057-65	45
1856	Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy. 2001 , 61, 1103-20	5
1855	A Systematic Overview of Chemotherapy Effects in Ovarian Cancer. 2001 , 40, 340-360	62

1854	Ovarian cancer chemotherapy. 2001 , 27, 99-109	15
1853	Autologous, hapten-modified vaccine as a treatment for human cancers. 2001 , 19, 2565-70	34
1852	A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. 2001 , 94, 293-304	332
1851	Is platinum-based chemotherapy with paclitaxel effective in optimally debulked patients with advanced ovarian cancer?. 2001 , 97, 80-4	
1850	Survival analysis in familial ovarian cancer, a case control study. 2001 , 98, 219-23	18
1849	Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells. 2001 , 162, 39-48	26
1848	Prise en charge du cancer de l'ovaire. 2001 , 5, 149s-161s	1
1847	Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. 2001 , 37, 47-53	76
1846	Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. 2001 , 37, 364-8	126
1845	Treatment of advanced ovarian cancer. 2001 , 37 Suppl 9, S1-7	23
1844	Caelyx: phase II studies in ovarian cancer. 2001 , 37 Suppl 9, S8-14	44
1843	Efficacy, safety, and use of sildenafil in urologic practice. 2001 , 57, 1141-4	53
1842	Contemporary management of ovarian cancer. 2001 , 28, 759-73	3
1841	[Treatment of portal hypertension]. 2001 , 201, 528-38	2
1840	[Management of dilated cardiomyopathy]. 2001 , 201, 466-8	
1839	[Prevention of vertical transmission and treatment of infection caused by the human immunodeficiency virus in the pregnant woman. Recommendations of the Study Group for AIDS, Infectious Diseases, and Clinical Microbiology, the Spanish Pediatric Association, the National AIDS Plan and the Spanish Gynecology and Obstetrics Society]. 2001 , 19, 314-35	9
1838	Factores pronósticos y quimioterapia de primera línea de los adenocarcinomas ováricos. 2001 , 37, 1-8	
1837	Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer. 2001 , 19, 1227-59	17

1836	Clinical and pharmacoeconomic aspects both play an important role in the treatment of ovarian cancer. 2001 , 17, 12-15	1
1835	First reports of adverse drug reactions (ADRs) in recent weeks. 2001 , 17, 15	
1834	Recent advances in the treatment of epithelial ovarian cancer. 2001 , 10, 1715-24	36
1833	New developments in the treatment of ovarian cancer. 2001 , 10, 1167-72	3
1832	Cancer Chemotherapy Update: Paclitaxel and Cisplatin (TC) Regimen for Advanced Ovarian Cancer. 2001 , 36, 723-797	
1831	Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study. 2001 , 87, 120-126	63
1830	Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. 2001 , 19, 1183-94	17
1829	Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. 2001 , 19, 1893-900	75
1828	Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. 2001 , 19, 1901-5	78
1827	Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients. 2001 , 12, 1411-5	26
1826	Complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin. 2001 , 52, 210-4	0
1825	High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). 2001 , 12, 693-9	29
1824	Intraperitoneal therapy for ovarian cancer: a sacrifice bunt. 2001 , 19, 921-3	14
1823	Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. 2001 , 25, 667-72	67
1822	Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. 2001 , 12, 647-52	12
1821	Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. 2001 , 12, 315-23	215
1820	Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. 2001 , 12, 485-7	29
1819	Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. 2001 , 12, 23-7	50

1818	Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer?. 2001 , 12, 1023-4	1
1817	Taxanes in the adjuvant treatment of breast cancer: why not yet?. 2001 , 88-95	26
1816	Intra-arterial hepatic chemotherapy (IAHC) for liver metastases from colorectal cancer: need of guidelines for catheter positioning, port management, and anti-coagulant therapy. 2001 , 12, 1023	6
1815	Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynkologische Onkologie (AGO) Ovarian Cancer Study Group. 2001 , 12, 1115-20	50
1814	Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. 2001 , 12, 1195-203	94
1813	A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer. 2001 , 8, 285	
1812	Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. 2001 , 19, 3967-75	46
1811	Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. 2001 , 19, 3312-22	985
1810	Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. 2001 , 19, 1001-7	860
1809	Caelyx: treatment for relapsing ovarian cancer. 2001 , 62, 611-6	1
1808	3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. 2001 , 6, 128-31	2
1807	Pharmacokinetic and pharmacodynamic analysis of combined chemotherapy with carboplatin and paclitaxel for patients with ovarian cancer. 2001 , 6, 248-52	7
1806	Medikamentöse Rezidivtherapie. <i>Der Gynakologe</i> , 2001 , 34, 1020-1023	0.1 2
1805	Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland. <i>Der Gynakologe</i> , 2001 , 34, 1029-1040	7
1804	Advanced ovarian cancer. 2001 , 2, 109-18	34
1803	Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study. 2001 , 6, 271-8	13
1802	High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer. 2001 , 127, 243-50	9
1801	Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. 2001 , 51, 1256-63	35

1800	The integration of anthracyclines in the treatment of advanced ovarian cancer. 2001 , 11, 34-38	13
1799	Developmental chemotherapy in advanced ovarian cancer: Incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group. 2001 , 11, 42-51	11
1798	Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects. 2001 , 11, 295-9	25
1797	The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer. 2001 , 11 Suppl 1, 21-30	19
1796	Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. 2001 , 11 Suppl 1, 57-63	37
1795	High dose chemotherapy in ovarian cancer. 2001 , 11 Suppl 1, 64-7	12
1794	Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG). 2001 , 11 Suppl 1, 73-6	109
1793	Remarks and conclusions on ovarian cancer treatment. 2001 , 11 Suppl 1, 77-81	4
1792	Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. 2001 , 37, 27-34	15
1791	Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer. 2001 , 38, 171-5	13
1790	P53 mutation does not affect prognosis in ovarian epithelial malignancies. 2001 , 194, 68-75	49
1789	Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. 2001 , 91, 90-100	61
1788	A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. 2001 , 92, 1156-67	11
1787	Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer. 2001 , 92, 1856-63	13
1786	Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. 2001 , 92, 2585-91	171
1785	Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. <i>Gynecologic Oncology</i> , 2001 , 80, 16-20.9	44
1784	Cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2001 , 80, 332	4.9
1783	Reply. <i>Gynecologic Oncology</i> , 2001 , 80, 332	4.9

1782	Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2001 , 80, 359-63	4.9	3
1781	Complications associated with intraperitoneal chemotherapy catheters. <i>Gynecologic Oncology</i> , 2001 , 81, 77-81	4.9	78
1780	Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. <i>Gynecologic Oncology</i> , 2001 , 81, 216-24	4.9	8
1779	Chronic administration of single-agent paclitaxel in gynecologic malignancies. <i>Gynecologic Oncology</i> , 2001 , 81, 201-5	4.9	17
1778	Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?. <i>Gynecologic Oncology</i> , 2001 , 81, 1-2	4.9	6
1777	Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. <i>Gynecologic Oncology</i> , 2001 , 81, 398-403	4.9	103
1776	Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). <i>Gynecologic Oncology</i> , 2001 , 82, 317-22	4.9	30
1775	Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?. <i>Gynecologic Oncology</i> , 2001 , 82, 435-41	4.9	117
1774	Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2001 , 82, 550-8	4.9	101
1773	Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , 2001 , 83, 198-204	4.9	8
1772	Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2001 , 83, 128-34	4.9	54
1771	Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2001 , 83, 257-62	4.9	50
1770	Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2001 , 83, 334-42	4.9	29
1769	Factors predicting subcutaneous implanted central venous port function: the relationship between catheter tip location and port failure in patients with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2001 , 83, 533-6	4.9	22
1768	A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. <i>Gynecologic Oncology</i> , 2001 , 83, 394-9	4.9	75
1767	Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. <i>Gynecologic Oncology</i> , 2001 , 83, 599-600	4.9	129
1766	Current and future trends in randomised trials in gynaecological oncology. 2001 , 3, 61-68		
1765	A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. 2001 , 85, 1064-9		43

1764	Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. 2001 , 28, 859-63	4
1763	Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival. 2001 , 8, 1450-5	45
1762	Recent advancements in the treatment of epithelial ovarian cancer. 2001 , 27, 61-75	7
1761	Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin. 2001 , 92, 1242-50	14
1760	Gemcitabine in Ovarian Cancer. 2001 , 28, 62-69	6
1759	Relationship Between Expression of Coactivators and Corepressors of Hormone Receptors and Resistance of Ovarian Cancers to Growth Regulation by Steroid Hormones. 2001 , 8, 104-113	7
1758	Economic Aspects of Chemotherapy. 2001 , 40, 412-433	4
1757	Intraperitoneal chemotherapy in the management of malignant disease. 2001 , 1, 142-8	35
1756	Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. 2001 , 84, 170-8	64
1755	Economic aspects of chemotherapy. 2001 , 40, 412-33	10
1754	DCX in PC12 cells: CREB-mediated transcription and neurite outgrowth. 2001 , 10, 1061-70	29
1753	Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrozole, paclitaxel, bexarotene. 2001 , 6, 4-11	72
1752	Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. 2001 , 93, 516-25	66
1751	Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland: Welchen Einfluss hat die Teilnahme an klinischen Studien? - Ergebnisse einer Umfrage der ORGANKOMMISSION OVAR der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) - 2001 , 61, 863-871	12
1750	Current treatment for ovarian cancer. 2001 , 2, 109-24	40
1749	Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. 2002 , 20, 2365-9	178
1748	Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. 2002 , 277, 33490-500	140
1747	Relapsed ovarian cancer: challenges and management strategies for a chronic disease. 2002 , 7 Suppl 5, 20-8	227

1746 Immunology for Surgeons. **2002**,

1745 Role of chemotherapy in the management of ovarian cancer. **2002**, 2, 90-6

6

1744 A Phase I/II Study of Carboplatin and Paclitaxel in Patients with Epithelial Ovarian Cancer. *Japanese Journal of Clinical Oncology*, **2002**, 32, 128-134

2.8

6

1743 Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. **2002**, 13, 251-7

42

1742 Emerging role of topotecan in front-line treatment of carcinoma of the ovary. **2002**, 7 Suppl 5, 46-55

20

1741 In vitro assay-assisted treatment selection for women with breast or ovarian cancer. **2002**, 9, 171-82

38

1740 Gene therapy for ovarian cancer (review). **2002**, 21, 461

1

1739 [New aspects by the therapy of ovarian cancer--What changes after the ASCO-Meeting 2001]. **2002**, 124, 96-103

1738 Intraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-Up. **2002**, 20, 694-698

54

1737 Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. **2002**, 41, 418-24

107

1736 Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. **2002**, 13, 258-66

47

1735 Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer. **2002**, 20, 1238-1247

56

1734 Short versus long duration infusions of paclitaxel for any adenocarcinoma. **2002**, CD003911

5

1733 Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study. **2002**, 25, 45-7

18

1732 Anemia in oncology practice: relation to diseases and their therapies. **2002**, 25, 371-9

70

1731 Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. **2002**, 13, 777-80

24

1730 Management of recurrent ovarian cancer: evidence-based decisions. **2002**, 14, 519-27

31

1729 Evolving concepts in the pathophysiology of functional gastrointestinal disorder. **2002**, 35, S2-6

16

1728	Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. 2002 , 13, 839-45	22
1727	The immunotherapy of patients with ovarian cancer. 2002 , 25, 189-201	31
1726	Organization, function, and accomplishments of the Gynecologic Oncology Group. 2002 , 20, 787-92	
1725	Preoperative CA 125 Levels. 2002 , 100, 59-64	3
1724	Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. 2002 , 20, 1248-59	1585
1723	Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. 2002 , 63, 16-22	24
1722	Preoperative findings in non-gynecologic carcinomas metastasizing to the ovaries. 2002 , 54, 221-7	16
1721	Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium. 2002 , 20, 485-97	16
1720	Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. 2002 , 62, 2089-126	77
1719	Overcoming Resistance to Platinum Therapy in Patients with Advanced Cancer. 2002 , 1, 247-255	10
1718	Spotlight on Paclitaxel in Ovarian Cancer. 2002 , 10, 259-262	
1717	Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. 2002 , 2, 97-105	18
1716	Treatment of ovarian cancer continues to evolve. 2002 , 18, 13-16	
1715	Tumour necrosis factor- α blockers: increasing the options for managing rheumatoid arthritis. 2002 , 18, 16-20	
1714	Paclitaxel in cancer therapy. 2002 , 3, 755-66	237
1713	Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. 2002 , 360, 505-15	429
1712	Ovarian cancer chemotherapy: carboplatin as standard. 2002 , 360, 500-1	11
1711	ICON3 and chemotherapy for ovarian cancer. 2002 , 360, 2086-7; author reply 2088	14

1710	ICON3 and chemotherapy for ovarian cancer. 2002 , 360, 2087; author reply 2088		1
1709	Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. 2002 , 100, 59-64		88
1708	Mutational analysis of the beta-tubulin gene in lung cancer. 2002 , 35, 11-6		52
1707	Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. <i>Lancet Oncology, The</i> , 2002 , 3, 529-36	21.7	122
1706	The role of topoisomerase inhibitors in gynaecological oncology. 2002 , 2, 29-34		2
1705	Of mice and women. 2002 , 1, 11-2		4
1704	Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. 2002 , 38, 1653-60		19
1703	Mutations of TP53 do not correlate with the sensitivity to paclitaxel--a study using 27 gynaecological cancer cell lines. 2002 , 38, 1783-91		11
1702	Ovarian cancer: progress and continuing controversies in management. 2002 , 38, 1701-7		62
1701	Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. 2002 , 38, 2005-13		32
1700	Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. 2002 , 38, 2435-45		105
1699	Ovarian cancer: patterns of care in Victoria during 1993-1995. 2002 , 177, 11-6		32
1698	The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer. 2002 , 12, 435-437		1
1697	Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: A phase II study. 2002 , 12, 710-714		5
1696	Ovarian Cancer: Diagnosis and Treatment. 2002 , 353-360		
1695	Polychemotherapy in Ovarian Cancer in Patients over Seventy Years of Age. 2002 , 88, S120-S121		
1694	Combination Antiretroviral Chemotherapy. 2002 , 1-31		
1693	Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. 2002 , 20, 694-8		89

1692	Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?. 2002 , 20, 1158-60	53
1691	Recurrent ovarian cancer: evidence-based treatment. 2002 , 20, 1161-3	93
1690	Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come!. 2002 , 20, 3944-6	56
1689	Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. 2002 , 20, 173-8	103
1688	Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. 2002 , 20, 1238-47	83
1687	Paradigms for primary prevention of ovarian carcinoma. 2002 , 52, 216-25	29
1686	Second-line treatment of ovarian cancer with single-agent gemcitabine. 2002 , 29, 9-10	23
1685	The role of gemcitabine-based doublets in the management of ovarian carcinoma. 2002 , 29, 11-6	13
1684	Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). 2002 , 29, 20-31	42
1683	Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. 2002 , 29, 17-9	25
1682	Pegylated liposomal doxorubicin prolongs survival compared to topotecan as second-line treatment in women with platinum-sensitive ovarian cancer. 2002 , 3, 21-23	
1681	Paclitaxel may be as effective as platinum-based regimens for women with recurrent ovarian cancer after treatment with platinum-based regimens. 2002 , 3, 179-181	
1680	Current clinical practices for ovarian cancers. 2002 , 29, 3-6	1
1679	Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. 2002 , 63, 1699-707	29
1678	The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. 2002 , 64, 1267-77	26
1677	Chemotherapy for advanced epithelial ovarian carcinoma. 2002 , 16, 553-71	12
1676	Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma. 2002 , 95, 2044-50	9
1675	Epithelial ovarian cancer. 2002 , 3, 131-41	23

1674	Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies. 2002 , 4, 165-74	13
1673	The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. 2002 , 128, 153-60	36
1672	Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy. 2002 , 7, 45-50	2
1671	Complete remission of uterine endometrial cancer with multiple lung metastases treated by paclitaxel and carboplatin. 2002 , 7, 197-200	4
1670	Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patients. 2002 , 7, 330-3	15
1669	Therapie des Ovarialkarzinoms. 2002 , 8, s38-s40	
1668	Primäre Chemotherapie beim fortgeschrittenen Ovarialkarzinom. 2002 , 8, 1171-1177	
1667	Hochdosischemotherapie des fortgeschrittenen Ovarialkarzinoms. 2002 , 8, 1178-1186	
1666	Medikamentöse Rezidivtherapie des Ovarialkarzinoms. 2002 , 8, 1222-1225	
1665	Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland. 2002 , 8, 1201-1215	
1664	Relapsed, poor-prognosis ovarian cancer, individualized, interdisciplinary treatment approach, and quality of life: a case report. 2002 , 10, 81-3	1
1663	Secondary cytoreductive surgery in the patient with recurrent ovarian cancer is often beneficial. 2002 , 41, 335-41	4
1662	Role of weekly paclitaxel in the treatment of advanced ovarian cancer. 2002 , 44 Suppl, S43-51	22
1661	Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer. 2002 , 12, 66-73	14
1660	Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines. 2002 , 12, 202-7	5
1659	Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy. 2002 , 12, 250-6	28
1658	Docetaxel in combination with carboplatin for chemo-naïve patients with epithelial ovarian cancer. 2002 , 12, 704-9	8
1657	The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer. 2002 , 12, 435-7	9

1656	Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: a phase II study. 2002 , 12, 710-4		9
1655	Radiation therapy for gynecologic cancer. 2002 , 28, 123-40		9
1654	Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. 2000 , 87, 1006-15		81
1653	Adjuvant whole abdominal radiotherapy in epithelial cancer of the ovary. 2002 , 53, 360-5		9
1652	Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. 2002 , 11, 142-53		210
1651	Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. 2002 , 30, 95-102		62
1650	Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study. 2002 , 30, 879-84		4
1649	A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer. 2002 , 86, 1379-84		34
1648	A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer. 2002 , 86, 1385-90		8
1647	Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. 2002 , 86, 1858-63		38
1646	First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. 2002 , 87, 815-24		99
1645	First-line chemotherapy for ovarian cancer - the controversy continues. 2002 , 87, 813-4		2
1644	IMRT of large fields: whole-abdomen irradiation. 2002 , 54, 278-89		86
1643	Anthracyclines in the treatment of gynecologic malignancies. <i>Gynecologic Oncology</i> , 2002 , 85, 18-31	4.9	49
1642	Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2002 , 84, 32-5	4.9	13
1641	Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen. <i>Gynecologic Oncology</i> , 2002 , 84, 368-73	4.9	19
1640	Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin. <i>Gynecologic Oncology</i> , 2002 , 84, 404-12	4.9	24
1639	A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. <i>Gynecologic Oncology</i> , 2002 , 84, 420-5	4.9	54

1638	Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2002 , 85, 71-80	4.9	117
1637	Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2002 , 85, 129-35	4.9	10
1636	Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2002 , 85, 278-84	4.9	13
1635	Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. <i>Gynecologic Oncology</i> , 2002 , 85, 53-8	4.9	105
1634	First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study. <i>Gynecologic Oncology</i> , 2002 , 85, 321-6	4.9	23
1633	Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary. <i>Gynecologic Oncology</i> , 2002 , 85, 459-63	4.9	80
1632	Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer. <i>Gynecologic Oncology</i> , 2002 , 85, 517-23	4.9	16
1631	Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. <i>Gynecologic Oncology</i> , 2002 , 86, 239-43	4.9	16
1630	Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2002 , 86, 171-6	4.9	97
1629	The prophylactic administration of recombinant erythropoietin in the management of ovarian cancer: time for a definitive phase 3 randomized trial. <i>Gynecologic Oncology</i> , 2002 , 86, 237-8	4.9	3
1628	Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. <i>Gynecologic Oncology</i> , 2002 , 87, 8-16	4.9	78
1627	A phase I study of weekly topotecan and Paclitaxel in previously treated epithelial ovarian carcinoma patients. <i>Gynecologic Oncology</i> , 2002 , 87, 171-7	4.9	16
1626	Medikamentöse Primärtherapie beim fortgeschrittenen epithelialen Ovarialkarzinom. <i>Der Gynakologe</i> , 2002 , 35, 458-464	0.1	
1625	Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies. 2002 , 20, 55-61		14
1624	Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group study. 2002 , 20, 383-7		2
1623	Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma. 2002 , 19, 25-33		5
1622	A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study. 2003 , 21, 373-7		15
1621	Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. <i>Gynecologic Oncology</i> , 2003 , 88, 9-16	4.9	87

1620	Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2003 , 88, 3-8	4.9	29
1619	Managing taxane toxicities. 2003 , 11, 144-7		103
1618	Consolidation/maintenance chemotherapy for ovarian cancer. 2003 , 5, 454-8		5
1617	The role of interval debulking surgery in ovarian cancer. 2003 , 5, 473-81		40
1616	Pflanzliche Zytostatika. 2003 , 46, 1050-1054		
1615	Paclitaxel nicht mehr erste Wahl beim Ovarialkarzinom?. <i>Der Gynakologe</i> , 2003 , 36, 362-365	0.1	
1614	Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. 2003 , 8, 156-61		63
1613	Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. 2003 , 3, 377-86		250
1612	Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. 2003 , 189, 28-36		52
1611	Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. 2003 , 3, 19		56
1610	Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. <i>Gynecologic Oncology</i> , 2003 , 91, 573-6	4.9	31
1609	Distinct subtypes of serous ovarian carcinoma identified by p53 determination. <i>Gynecologic Oncology</i> , 2003 , 91, 504-12	4.9	60
1608	Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial. <i>Gynecologic Oncology</i> , 2003 , 88, 282-8	4.9	9
1607	Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. <i>Gynecologic Oncology</i> , 2003 , 88, 118-22	4.9	30
1606	Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens. <i>Gynecologic Oncology</i> , 2003 , 88, 351-7	4.9	5
1605	Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. <i>Gynecologic Oncology</i> , 2003 , 88, 394-9	4.9	46
1604	Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2003 , 89, 148-54	4.9	63
1603	Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. <i>Gynecologic Oncology</i> , 2003 , 88, 429-33	4.9	49

1602	First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients. <i>Gynecologic Oncology</i> , 2003 , 89, 354-9	4.9	16
1601	Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin. <i>Gynecologic Oncology</i> , 2003 , 89, 486-93	4.9	4
1600	A case of chronic paclitaxel administration in ovarian cancer. <i>Gynecologic Oncology</i> , 2003 , 89, 532-5	4.9	12
1599	Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2003 , 90, 3-9	4.9	34
1598	Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. <i>Gynecologic Oncology</i> , 2003 , 89, 429-33	4.9	69
1597	A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2003 , 90, 421-4	4.9	12
1596	Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2003 , 90, 581-6	4.9	4
1595	Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. <i>Gynecologic Oncology</i> , 2003 , 90, S1-7	4.9	46
1594	Neoadjuvant chemotherapy for advanced ovarian cancer: the role of cytology in pretreatment diagnosis. <i>Gynecologic Oncology</i> , 2003 , 90, 644-50	4.9	21
1593	Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. <i>Gynecologic Oncology</i> , 2003 , 90, 593-6	4.9	97
1592	Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study. <i>Gynecologic Oncology</i> , 2003 , 91, 32-8	4.9	18
1591	Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. <i>Gynecologic Oncology</i> , 2003 , 91, 123-9	4.9	35
1590	A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. <i>Gynecologic Oncology</i> , 2003 , 91, 293-8	4.9	12
1589	Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia. <i>Gynecologic Oncology</i> , 2003 , 91, 118-22	4.9	7
1588	Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel. <i>Gynecologic Oncology</i> , 2003 , 91, 423-5	4.9	13
1587	The follow-up of ovarian cancer. 2003 , 30, 401-12		46
1586	BGP-15, a hydroximic acid derivative, protects against cisplatin- or taxol-induced peripheral neuropathy in rats. 2003 , 190, 9-16		39
1585	High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. 2003 , 57, 201-7		36

1584	Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: Effect of the radionuclide. 2003 , 13, 607-13	23
1583	Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study. 2003 , 13, 130-7	15
1582	Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. 2003 , 13, 142-7	29
1581	Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy. 2003 , 13, 287-91	10
1580	Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study. 2003 , 13, 419-27	21
1579	A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC). 2003 , 13, 428-34	8
1578	A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum. 2003 , 29, 123-31	8
1577	Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. 2003 , 22, 2239-56	109
1576	Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132. 2003 , 13 Suppl 2, 156-62	14
1575	Consolidation therapy revisited: intravenous chemotherapy. 2003 , 13 Suppl 2, 204-7	31
1574	Cost-effectiveness studies in ovarian cancer. 2003 , 13 Suppl 2, 212-9	9
1573	Systemic treatment policies in ovarian cancer: the next 10 years. 2003 , 13 Suppl 2, 231-40	17
1572	Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. 2003 , 13 Suppl 2, 144-8	93
1571	Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5. 2003 , 13 Suppl 2, 149-55	14
1570	First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. 2003 , 13 Suppl 2, 172-7	39
1569	Ovarian cancer treatment: what is new. 2003 , 13 Suppl 2, 241-50	15
1568	Targeted therapy for epithelial ovarian cancer: current status and future prospects. 2003 , 13, 701-34	39
1567	Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. 2003 , 13, 735-40	68

1566	Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. 2003 , 13, 741-8	197
1565	Improving first-line therapy of advanced ovarian cancer - the AGO Ovarian Cancer Study Group perspective. 2003 , 13 Suppl 2, 169-71	5
1564	Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. 2003 , 89, 1002-7	30
1563	Primary ovarian cancer chemotherapy: current standards of care. 2003 , 89 Suppl 3, S3-8	117
1562	The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. 2003 , 89 Suppl 3, S16-22	58
1561	Ovarian cancer: strategies for overcoming resistance to chemotherapy. 2003 , 3, 502-16	883
1560	Management of peritoneal surface component of ovarian cancer. 2003 , 12, 561-83	26
1559	Optimizing primary chemotherapy in ovarian cancer. 2003 , 17, 957-68, viii	24
1558	Salvage therapy for recurrent epithelial ovarian cancer. 2003 , 17, 977-88	14
1557	International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma. 2003 , 95, 105-112	313
1556	Progress in ovarian cancer. 2003 , 1, 43-55	7
1555	From clinical trials to evidence-based medicine: how to build the evidence!. 2003 , 1, 55-65	2
1554	Controversies in chemotherapy - what is standard treatment?. 2003 , 1, 107-114	
1553	Quality of life in patients receiving treatment for gynecologic malignancies: special considerations for patient care. 2003 , 83 Suppl 1, 211-29	24
1552	Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. 2003 , 361, 2099-106	922
1551	Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer. 2003 , 102, 1200-1202	58
1550	Influence of surgery and postoperative therapy and tumor characteristics on patient prognosis in advanced ovarian carcinomas. 2003 , 111, 189-96	16
1549	Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer. 2003 , 198, 89-97	43

1548	Chemotherapy for newly diagnosed and relapsed advanced ovarian cancer. 2003 , 19, 25-35	7
1547	An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. 2003 , 39, 1402-8	148
1546	Chemotherapeutic management of advanced ovarian cancer. 2003 , 19, 3-18	1
1545	Pharmacological factors influencing anticancer drug selection in the elderly. 2003 , 20, 737-59	31
1544	Platinum-Resistant and Refractory Ovarian Cancer. 2003 , 2, 1-13	4
1543	Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. 2003 , 21, 4207-13	69
1542	Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer. 2003 , 21, 1682-7	11
1541	New chemotherapy treatments in advanced cancer patients: an easily applicable evaluation of clinical efficacy and cost-effectiveness. 2003 , 42, 895-902	10
1540	Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. 2003 , 21, 3194-200	1612
1539	Developmental chemotherapy and management of recurrent ovarian cancer. 2003 , 21, 149s-167s	54
1538	Current status of taxane and platinum-based chemotherapy in ovarian cancer. 2003 , 21, 133s-135s	28
1537	Regarding "Sweet time unafflicted". 2003 , 21, 958	1
1536	Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. 2003 , 21, 1313-9	47
1535	Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. 2003 , 14, 74-7	56
1534	Early-stage ovarian cancer: to treat or not to treat. 2003 , 95, 94-5	30
1533	Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. 2003 , 21, 2843-8	84
1532	CORRESPONDENCE. 2003 , 21, 957-958	
1531	Management of toxicities associated with the administration of taxanes. 2003 , 2, 141-6	49

1530	Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. 2003 , 21, 2460-5	386
1529	Weekly paclitaxel infusion as salvage therapy in ovarian cancer. 2003 , 21, 675-81	12
1528	Current therapies in ovarian cancer. 2003 , 21, 148-56	23
1527	Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. 2003 , 89 Suppl 3, S23-8	94
1526	Docetaxel: an alternative taxane in ovarian cancer. 2003 , 89 Suppl 3, S9-S15	63
1525	Second-line chemotherapy of epithelial ovarian cancer. 2003 , 3, 31-6	2
1524	Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. 2003 , 21, 136s-144s	30
1523	Carboplatin equals cisplatin: but how do I prescribe it?. 2003 , 21, 3183-5	14
1522	Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. 2003 , 21, 3488-94	126
1521	Intraperitoneal chemotherapy for stage III ovarian cancer. 2003 , 21, 957; author reply 957-8	4
1520	Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. 2003 , 21, 2856-9	41
1519	Adnexal masses in pregnancy. 2003 , 26, 167-72	27
1518	An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer. 2003 , 14, 1406-11	10
1517	Maybe more is better. 2003 , 21, 2454-6	9
1516	Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma. 2003 , 14, 638-42	6
1515	Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. 2003 , 23, 837	3
1514	Suppression of cell migration in ovarian cancer cells mediated by PTEN overexpression. 2003 , 23, 1109	4
1513	["IMO"--intraoperative mapping of ovarian cancer]. 2003 , 125, 129-35	57

1512 Klinik, Histopathologie und Molekularbiologie des Tubenkarzinoms. **2003**, 63, 853-859

1511 Progress in the management of gynecologic cancer: consensus summary statement. **2003**, 21, 129s-132s 45

1510 Paclitaxel and Carboplatin Chemotherapy Administered During Pregnancy for Advanced Epithelial Ovarian Cancer. **2003**, 102, 1200-1202 3

1509 The effect of granisetron on in vitro metabolism of paclitaxel and docetaxel. **2003**, 9, 67-70 5

1508 Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer. **2003**, 14, 633-8 13

1507 Long-term results of paclitaxel in FIGO stage III ovarian carcinoma. **2003**, 14, 347-52 2

1506 Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study. **2003**, 14, 359-64 4

1505 Peritoneal carcinoma in a male patient. **2003**, 64, 468-72 6

1504 Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture. **2003**, 65, 29-36 54

1503 Emerging treatments for ovarian cancer. **2003**, 8, 203-16 8

1502 Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. **2003**, 13, 741-748 171

1501 Gynecologic Cancers. **2003**, 469-485

1500 . **2003**, 19

1499 A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer. **2003**, 10, 951 2

1498 Ovarian and Fallopian Tube Cancers. 377-393 3

1497 Ovarian Cancer. **2003**, 514-525

1496 State-of-the-art first-line treatment of ovarian cancer. **2003**, 26, 446-50 2

1495 Intraperitoneal Chemotherapy. **2003**, 505-513

1494 Neue Aspekte in der gynkologischen Onkologie. **2003**, 43, 266-267

1493 Paclitaxel inhibits expression of heat shock protein 27 in ovarian and uterine cancer cells. **2004**, 14, 616-620 7

1492 Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. **2004**, 14, 224-228 2

1491 The Role of Cancer Cooperative Groups within the Spectrum of Cancer Care. **2004**, 11, 55-63 6

1490 [Advances in the treatment of ovarian carcinoma]. **2004**, 129, 379-84

1489 Novel therapies for recurrent ovarian cancer management. **2004**, 4, 437-48 12

1488 [First-line therapy in ovarian cancer]. **2004**, 126, 312-4

1487 Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. **2004**, 233, 433-40 141

1486 Estrogen inhibits paclitaxel-induced apoptosis via the phosphorylation of apoptosis signal-regulating kinase 1 in human ovarian cancer cell lines. **2004**, 145, 49-58 43

1485 The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma. *Japanese Journal of Clinical Oncology*, **2004**, 34, 499-504 2.8 15

1484 Gene expression signature with independent prognostic significance in epithelial ovarian cancer. **2004**, 22, 4700-10 217

1483 Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. **2004**, 64, 2502-8 223

1482 Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. **2004**, 182, 227-33 127

1481 Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. **2004**, 22, 4595-603 45

1480 trans-3,4,5'-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. **2004**, 10, 5253-63 158

1479 Cisplatin, paclitaxel and escalating doses of doxorubicin (TAP) in advanced ovarian cancer: a phase I trial. *Japanese Journal of Clinical Oncology*, **2004**, 34, 540-6 2.8 5

1478 Secondary surgical cytoreduction for advanced ovarian carcinoma. *New England Journal of Medicine*, **2004**, 351, 2489-97 59.2 309

1477 Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study. **2004**, 31, 615-23 53

1476	Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. 2004 , 57, 153-6	39
1475	Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. 2004 , 10, 7645-54	106
1474	Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. 2004 , 66, 112-7	108
1473	Aggressive management of recurrent ovarian cancer--the challenge of individualizing cancer therapy illustrated by a case report. 2004 , 27, 393-7	
1472	Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum. 2004 , 66, 343-6	13
1471	Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer. 2004 , 22 Suppl 2, 11-20	16
1470	First-line therapy for ovarian carcinoma: what's next?. 2004 , 22 Suppl 2, 21-8	22
1469	Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. 2004 , 22, 4523-31	110
1468	Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. 2004 , 10, 6080-5	15
1467	Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. 2004 , 22, 120-6	14
1466	Ethical conflict in providing informed consent for clinical trials: a problematic example from the gynecologic cancer research community. 2004 , 9, 3-7	309
1465	Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. 2004 , 10, 3919-26	106
1464	Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. 2004 , 22, 3507-16	155
1463	Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. 2004 , 10, 2962-7	37
1462	Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells. 2004 , 279, 3941-8	46
1461	Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. 2004 , 22, 1040-4	245
1460	Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data. 2004 , 19, 216-28	18
1459	Vaccination of patients with advanced ovarian carcinoma with the anti-idiotypic ACA125: immunological response and survival (phase Ib/II). 2004 , 10, 1580-7	128

1458	Recurrent ovarian cancer: how important is it to treat to disease progression?. 2004 , 10, 7439-49	116
1457	Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. 2004 , 96, 1682-91	497
1456	EphA2 expression is associated with aggressive features in ovarian carcinoma. 2004 , 10, 5145-50	181
1455	A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131. 2004 , 15, 1115-22	17
1454	Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. 2004 , 22, 2635-42	130
1453	Targeting the platelet-derived growth factor receptor in antivasular therapy for human ovarian carcinoma. 2004 , 10, 897-908	84
1452	Correlation between MIB1-determined tumor growth fraction and incidence of tumor recurrence in early ovarian carcinomas. 2004 , 22, 185-94	20
1451	Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. 2004 , 14, 224-8	20
1450	Remaining controversies in the upfront management of advanced ovarian cancer. 2004 , 14, 707-20	18
1449	Prognostic importance of the time interval from surgery to chemotherapy in treatment of ovarian carcinoma. 2004 , 14, 788-93	16
1448	Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. 2004 , 14, 804-14	12
1447	Paclitaxel inhibits expression of heat shock protein 27 in ovarian and uterine cancer cells. 2004 , 14, 616-20	35
1446	The European Canadian Intergroup trial (OV10 trial) and the US Gynaecologic Oncology Group trial (GOG 111). 2004 , 14, 697; author reply 698	
1445	Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. 2004 , 11, 547-54	21
1444	Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer. 2004 , 90, 1318-22	5
1443	A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. 2004 , 91, 627-32	18
1442	Focus on epithelial ovarian cancer. 2004 , 5, 19-24	241
1441	Liposomal anthracycline treatment for ovarian cancer. 2004 , 31, 91-105	50

1440	Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. 2004 , 31, 17-24		32
1439	Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer. 2004 , 31, 19-24		20
1438	[Management of malignant epithelial tumors of the ovary]. 2004 , 141, 277-84		15
1437	Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. <i>Gynecologic Oncology</i> , 2004 , 92, 152-9	4.9	31
1436	In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 92, 160-6	4.9	47
1435	Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers. <i>Gynecologic Oncology</i> , 2004 , 92, 192-6	4.9	10
1434	Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study. <i>Gynecologic Oncology</i> , 2004 , 92, 293-9	4.9	18
1433	Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy. <i>Gynecologic Oncology</i> , 2004 , 92, 592-5	4.9	9
1432	Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. <i>Gynecologic Oncology</i> , 2004 , 93, 98-106	4.9	132
1431	Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. <i>Gynecologic Oncology</i> , 2004 , 92, 949-56	4.9	20
1430	Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. <i>Gynecologic Oncology</i> , 2004 , 93, 78-86	4.9	72
1429	The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , 2004 , 93, 131-6	4.9	37
1428	Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 93, 223-8	4.9	6
1427	Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 93, 474-8	4.9	10
1426	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 93, 417-21	4.9	20
1425	Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 93, 493-8	4.9	28
1424	Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. <i>Gynecologic Oncology</i> , 2004 , 94, 98-106	4.9	14
1423	Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 93, 647-52	4.9	20

1422	Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. <i>Gynecologic Oncology</i> , 2004 , 93, 699-701	4.9	49
1421	The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 94, 74-9	4.9	24
1420	The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. <i>Gynecologic Oncology</i> , 2004 , 94, 67-73	4.9	37
1419	Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. <i>Gynecologic Oncology</i> , 2004 , 94, 197-203	4.9	81
1418	Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 94, 540-9	4.9	56
1417	Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. <i>Gynecologic Oncology</i> , 2004 , 94, 404-8	4.9	17
1416	Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 94, 533-9	4.9	11
1415	Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. <i>Gynecologic Oncology</i> , 2004 , 94, 267-76	4.9	27
1414	An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2004 , 94, 368-74	4.9	42
1413	A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 94, 442-8	4.9	58
1412	Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers. <i>Gynecologic Oncology</i> , 2004 , 94, 796-802	4.9	10
1411	Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 95, 157-64	4.9	23
1410	Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. <i>Gynecologic Oncology</i> , 2004 , 95, 109-13	4.9	7
1409	Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. <i>Gynecologic Oncology</i> , 2004 , 95, 370-6	4.9	122
1408	Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. <i>Gynecologic Oncology</i> , 2004 , 95, 506-12	4.9	22
1407	Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 95, 686-90	4.9	51
1406	Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. 2004 , 190, 910-25		69
1405	In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo. 2004 , 130, 178-86		12

1404	Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma. 2004 , 9, 403-5	10
1403	The importance of angiogenesis in ovarian cancer. 2004 , 6, 462-467	0
1402	A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. 2004 , 53, 809-16	35
1401	Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. 2004 , 28, 1040-5	94
1400	A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study. 2004 , 53, 489-95	10
1399	Standards in der Therapie des Ovarialkarzinoms. <i>Der Gynakologe</i> , 2004 , 37, 662-668	0.1
1398	Laparoscopic fluorescence detection of ovarian carcinoma metastases using 5-aminolevulinic acid-induced protoporphyrin IX. 2004 , 100, 1650-6	92
1397	Systematic review of adjuvant care for women with Stage I ovarian carcinoma. 2004 , 101, 1926-35	32
1396	Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. 2004 , 109, 926-32	141
1395	The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence Guidance 2001: the Nottingham experience. 2004 , 16, 543-8	2
1394	Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer. 2004 , 22, 375-87	15
1393	From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer. 2004 , 22, 633-41	13
1392	Les m?tastases ganglionnaires du cancer ovarien sont-elles chimiosensiblesB? ttude comparative de la lymphad?nectomie premi?re ou apr?s chimioth?rapie. 2004 ,	
1391	Betabloqueantes e insuficiencia card?ca. 2004 , 30, 470-473	
1390	The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. <i>Gynecologic Oncology</i> , 2004 ,	4.9
1389	Molecular cloning and characterization of a cytochrome P450 taxoid 2?hydroxylase involved in Taxol biosynthesis. 2004 , 427, 48-48	
1388	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-2004. A 52-year-old woman with postmenopausal bleeding and a cystic ovarian mass. <i>New England Journal of Medicine</i> , 2004 , 351, 2531-8	59.2 1
1387	Role of primary surgery in advanced ovarian cancer. 2004 , 2, 32	19

1386	Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. <i>Gynecologic Oncology</i> , 2004 ,	4.9	0
1385	Cancer of the ovary. <i>New England Journal of Medicine</i> , 2004 , 351, 2519-29	59.2	1419
1384	MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines. 2004 , 340, 53-9		12
1383	[Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer]. 2004 , 32, 391-7		6
1382	[Are nodal metastases in ovarian cancer chemoresistant lesions? Comparative study of initial lymphadenectomy or after chemotherapy]. 2004 , 32, 502-7		8
1381	Antioxidant protection in a new animal model of cisplatin-induced ototoxicity. 2004 , 198, 137-43		56
1380	Molecular cloning and characterization of a cytochrome P450 taxoid 2alpha-hydroxylase involved in Taxol biosynthesis. 2004 , 427, 48-57		68
1379	Changing Practice of Gynecologic Oncology based on Current Evidence. 2004 , 60, 102-6		
1378	Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. 2004 , 27, 14-8		26
1377	Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study. 2004 , 27, 229-31		5
1376	Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer. 2004 , 27, 461-4		8
1375	Paclitaxel and carboplatin as second-line therapy in women with platinum-sensitive ovarian carcinoma treated with platinum and paclitaxel as first-line therapy. 2004 , 27, 46-50		4
1374	Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. 2004 , 27, 211-9		34
1373	Modification of p53 Immunoexpression Associated with Chemotherapy Regimens in Advanced and Refractory Ovarian Cancers. 2004 , 37, 15-20		1
1372	Carboxyamidotriazole, an Inhibitor of Nonvoltage-Operated Calcium Entry. 2005 , 89-105		1
1371	1 Ovarian Carcinoma: An Introduction. 2005 , 4, 287-306		
1370	5 Role of BRCA1/BRCA2 in Ovarian, Fallopian Tube, and Peritoneal Papillary Serous Carcinoma. 2005 , 347-356		
1369	The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. 2005 , 17, 505-14		56

1368 Current management of ovarian carcinoma. **2005**, 2, 275-286

1367 High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. **2005**, 816, 183-92 20

1366 Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. **2005**, 62, 104-10 33

1365 Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. **2005**, 63, 839-44 32

1364 Nuclear localisation of glutathione S-transferase pi is an evaluation factor for drug resistance in gynaecological cancers. **2005**, 17, 264-70 22

1363 Epithelial ovarian cancer: a review of current management. **2005**, 17, 399-411 74

1362 Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. **2005**, 55, 153-66 46

1361 Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. **2005**, 15, 785-92 196

1360 Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. **2005**, 12, 765-77 110

1359 Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. **2005**, 192, 1365-7 54

1358 Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer. **2005**, 15, 770-5 20

1357 Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review. **2005**, 15, 793-8 5

1356 Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives. **2005**, 15, 1002-13 18

1355 What is the role of dose-dense therapy?. **2005**, 15 Suppl 3, 233-40 27

1354 "Dose dense" chemotherapy in ovarian cancer. **2005**, 15 Suppl 3, 226-32 9

1353 Standard treatment in advanced ovarian cancer in 2005: the state of the art. **2005**, 15 Suppl 3, 212-20 53

1352 Clear-cell cancer of the ovary-is it chemosensitive?. **2005**, 15, 432-7 39

1351 Treatment goals in ovarian cancer. **2005**, 15 Suppl 1, 3-11 199

1350	Review of gemcitabine-based combinations for platinum-resistant ovarian cancer. 2005 , 15 Suppl 1, 23-30	13
1349	Future options for first-line therapy of advanced ovarian cancer. 2005 , 15 Suppl 1, 42-50	40
1348	Surgical indications for combined partial resectosigmoidectomy in ovarian cancer. 2005 , 31, 556-61	8
1347	Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. 2005 , 93, 647-51	41
1346	Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy. 2005 , 15, 45-9	16
1345	A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2005 , 96, 296-300	4.9 34
1344	Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer. <i>Gynecologic Oncology</i> , 2005 , 96, 323-9	4.9 29
1343	A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). <i>Gynecologic Oncology</i> , 2005 , 96, 444-51	4.9 23
1342	Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. <i>Gynecologic Oncology</i> , 2005 , 96, 287-95	4.9 131
1341	Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2005 , 96, 701-4	4.9 25
1340	Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2005 , 96, 810-7	4.9 15
1339	The role of secondary cytoreductive surgery for recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2005 , 97, 74-9	4.9 56
1338	Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial. <i>Gynecologic Oncology</i> , 2005 , 97, 200-5	4.9 4
1337	Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. <i>Gynecologic Oncology</i> , 2005 , 97, 436-41	4.9 93
1336	Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m ²) in the treatment of gynecologic cancers. <i>Gynecologic Oncology</i> , 2005 , 97, 374-8	4.9 44
1335	Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma. <i>Gynecologic Oncology</i> , 2005 , 97, 893-7	4.9 28
1334	A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2005 , 98, 134-40	4.9 6
1333	Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: an extended follow-up. <i>Gynecologic Oncology</i> , 2005 , 98, 59-62	4.9 11

1332	Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2005 , 98, 360-8	4.9	25
1331	Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent. <i>Gynecologic Oncology</i> , 2005 , 98, 376-82	4.9	12
1330	Difference of carboplatin clearance estimated by the Cockcroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula. <i>Gynecologic Oncology</i> , 2005 , 99, 327-33	4.9	28
1329	Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). 2005 , 114, 224-9		42
1328	A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. 2005 , 104, 1204-12		10
1327	Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. 2005 , 55, 277-85		64
1326	A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers. 2005 , 131, 26-30		11
1325	A "snapshot" of an ovarian cancer clinical practice: evidence for viewing the malignancy as a "chronic disease". 2005 , 7, 393-4		1
1324	Secondary cytoreduction for patients with recurrent ovarian cancer. 2005 , 7, 451-8		31
1323	[The action and toxicity of taxanes]. 2005 , 34, 128-37		2
1322	Consolidation therapy for ovarian cancer. 2005 , 5, 3-8		
1321	Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy. 2005 , 15, 45-49		13
1320	Cooperative Cancer Trials. 2005 ,		
1319	Bibliography. 2005 , 649-682		
1318	The Gynecologic Cancer Intergroup (GCIg): history and current status. 2005 , 16 Suppl 8, viii39-viii42		7
1317	Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215. 2005 , 11, 2408-15		21
1316	Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. 2005 , 16, 1795-800		259
1315	Retinoid receptors in ovarian cancer: expression and prognosis. 2005 , 16, 1477-87		17

1314	Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. 2005 , 23, 751-8	44
1313	Molecular basis of restenosis and drug-eluting stents. 2005 , 111, 2257-73	393
1312	Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. 2005 , 11, 8829-36	84
1311	Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. 2005 , 16, 1116-22	17
1310	3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. 2005 , 16 Suppl 8, viii36-viii38	7
1309	Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. 2005 , 23, 5605-12	96
1308	Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. 2005 , 11, 4923-33	74
1307	Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. 2005 , 16 Suppl 8, viii13-viii19	34
1306	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma. 2005 , 16 Suppl 1, i13-5	19
1305	Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. 2005 , 11, 6030-9	302
1304	Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. 2005 , 11, 2149-55	129
1303	Camptothecins in Cancer Therapy. 2005 ,	4
1302	Intraperitoneal chemotherapy for epithelial ovarian carcinoma. <i>Future Oncology</i> , 2005 , 1, 289-92	3.6
1301	Paclitaxel: cost-effectiveness in ovarian cancer. 2005 , 5, 235-43	2
1300	Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. 2005 , 10, 602-12	48
1299	Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. 2005 , 14, 1717-23	53
1298	Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. 2005 , 92, 1636-43	14
1297	Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. 2005 , 11, 3686-96	218

1296	Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. 2005 , 11, 8837-44	75
1295	Clinical trials in ovarian carcinoma: study methodology. 2005 , 16 Suppl 8, viii20-viii29	18
1294	Role of Integrated 18-F FDG PET/CT in Recurrent Ovarian Cancer. 2005 , 1, 1-4	72
1293	Topotecan in platinum-resistant epithelial ovarian cancer. 2005 , 51, 347-51	8
1292	Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. 2005 , 16, 300-6	22
1291	Advances in the understanding and treatment of ovarian cancer. 2005 , 11, 66-71	8
1290	Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. 2005 , 4, 716-9	16
1289	Efficient gene transfer of CD40 ligand into ovarian carcinoma cells with a recombinant adeno-associated virus vector. 2005 , 26, 95	1
1288	Current concepts of treatment strategies in advanced or recurrent ovarian cancer. 2005 , 68, 293-8	57
1287	Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial. 2005 , 69, 348-53	10
1286	Role of chemotherapy in the management of epithelial ovarian cancer. 2005 , 5, 139-47	6
1285	Investigational agents for epithelial ovarian cancer. 2005 , 5, 855-68	7
1284	C?ncer de ovario. 2005 , 9, 1667-1674	
1283	Emerging drugs for ovarian cancer. 2005 , 10, 413-24	34
1282	Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice. 2005 , 59 Suppl 2, S306-10	24
1281	Place de la chimioth?rapie de premi?re ligne dans le cancer de l'ovaire. 2005 , 1, 13-24	
1280	A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. 2005 , 118, 23-34	88
1279	Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004. 2005 , 6, 1269-75	

1278	Treatment of elderly cancer patients with chemotherapy. 2005 , 23, 537-47	9
1277	A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. 2005 , 41, 539-48	13
1276	[Treatment of cancer and hematological malignancy in elderly people (Part II)]. 2005 , 26, 304-14	2
1275	Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. 2005 , 97, 1407-27	778
1274	Front-line treatment of epithelial ovarian cancer. 2005 , 4, 221-231	1
1273	Management Strategies for Partially Platinum-Sensitive Ovarian Cancer. 2006 , 5, 341-354	4
1272	Intraperitoneal cisplatin and paclitaxel in ovarian cancer. <i>New England Journal of Medicine</i> , 2006 , 354, 34-43	59.2 2065
1271	Staging, cytoreduction and chemotherapy improve long-term outcomes in patients with ovarian cancer. 2006 , 22, 10-13	
1270	Ovarian cancer. 2006 , 16, 161-167	5
1269	Quality of life considerations in gynecologic cancer. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. 2006 , 95 Suppl 1, S247-57	45
1268	Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. 2006 , 4, 16	11
1267	Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. 2006 , 4, 17	20
1266	Comparison of hormone responses following light resistance exercise with partial vascular occlusion and moderately difficult resistance exercise without occlusion. 2006 , 101, 1616-22	108
1265	A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG). 2006 , 42, 179-85	12
1264	Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. 2006 , 42, 2296-302	49
1263	The role of gene expression profiling in the clinical management of ovarian cancer. 2006 , 42, 2930-8	18
1262	Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. 2006 , 32, 671-5	82
1261	Key clinical trials in gynaecological oncology. 2006 , 32, 887-91	1

1260	An unadjusted NNT was a moderately good predictor of health benefit. 2006 , 59, 224-33	15
1259	Systemic therapy for gynecological neoplasms: Ovary, cervix and endometrium. 2006 , 1, 515-538	1
1258	An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. 2006 , 68, 386-91	48
1257	Medical Treatment of Ovarian Carcinoma. 82-93	
1256	Extra-ovarian Primary Peritoneal Carcinomas. 2006 , 437-446	
1255	Ovarian Cancer. 2006 ,	
1254	Facteurs pronostiques et chimiothérapie de première ligne des adénocarcinomes ovariens. 2006 , 1, 1-8	
1253	Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients. 2006 , 29, 399-404	5
1252	Intraperitoneal chemotherapy for ovarian cancer. 2006 , 18, 507-15	13
1251	Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. 2006 , 29, 919	3
1250	Consolidation therapy in ovarian cancer: where do we stand?. 2006 , 18, 3-7	10
1249	Diagnosis and management of epithelial ovarian cancer. 2006 , 107, 1399-410	150
1248	Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer. 2006 , 15, 237	
1247	Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. 2006 , 16, 1301	
1246	Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. 2006 , 15, 1265	2
1245	Treatment strategy for recurrent and refractory epithelial ovarian cancer: efficacy of high-dose chemotherapy with hematopoietic stem cell transplantation. 2006 , 39, 61-7	2
1244	Variation in chemotherapy utilization in ovarian cancer: the relative contribution of geography. 2006 , 41, 2201-18	42
1243	First-line gemcitabine and carboplatin in advanced ovarian carcinoma: a phase II study. 2006 , 113, 1388-92	6

1242	Malignant transformation of ovarian mature cystic teratoma. 2006 , 16, 140-4	98
1241	Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. 2006 , 16, 52-6	53
1240	Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. 2006 , 16, 65-70	29
1239	Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. 2006 , 16, 210-8	53
1238	Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. 2006 , 16, 194-201	58
1237	Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients. 2006 , 16 Suppl 1, 60-7	10
1236	A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. 2006 , 16 Suppl 1, 79-85	13
1235	Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. 2006 , 16 Suppl 1, 267-72	29
1234	Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important?. 2006 , 16 Suppl 1, 68-73	5
1233	Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer. 2006 , 16 Suppl 1, 236-40	16
1232	Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix. 2006 , 16, 1157-64	22
1231	Arsenic trioxide-loaded, microemulsion-enhanced cytotoxicity on MDAH 2774 ovarian carcinoma cell line. 2006 , 16, 532-7	6
1230	The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. 2006 , 16, 496-500	37
1229	Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. 2006 , 16, 1777-82	27
1228	Survival in ovarian cancer in Wales: Prior to introduction of all Wales guidelines. 2006 , 16, 1770-6	18
1227	HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. 2006 , 16, 1897-902	102
1226	Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin. 2000 , 922, 178-87	4
1225	SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. 2006 , 94, 55-61	7

1224	Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study. 2006 , 37, 651-9	4
1223	Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol. 2006 , 37, 669-75	5
1222	Ovarian cancer. 2006 , 60, 159-79	159
1221	The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. 2006 , 194, 49-56	40
1220	Historical control study of paclitaxel-carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer. 2006 , 11, 221-8	2
1219	Primary chemotherapy-associated effect of second-line chemotherapy on survival of patients with advanced ovarian cancer. 2006 , 11, 236-42	
1218	Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with platinum/doxorubicin/cyclophosphamide?. 2006 , 11, 163	
1217	Medikamentöse Primärtherapie des fortgeschrittenen Ovarialkarzinoms. <i>Der Gynakologe</i> , 2006 , 39, 768-773.1	
1216	GBP1 overexpression is associated with a paclitaxel resistance phenotype. 2006 , 57, 25-33	42
1215	The tumor specific cytotoxicity of dihydronitidine from <i>Toddalia asiatica</i> Lam. 2006 , 58, 451-9	26
1214	Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy. 2006 , 8, 455-64	1
1213	A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2006 , 100, 111-5	4.9 3
1212	Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. <i>Gynecologic Oncology</i> , 2006 , 100, 133-8	4.9 51
1211	Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2006 , 100, 116-27	4.9 49
1210	Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). <i>Gynecologic Oncology</i> , 2006 , 100, 300-7	4.9 44
1209	Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study. <i>Gynecologic Oncology</i> , 2006 , 100, 324-9	4.9 10
1208	B7-H4 overexpression in ovarian tumors. <i>Gynecologic Oncology</i> , 2006 , 100, 44-52	4.9 119
1207	Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study. <i>Gynecologic Oncology</i> , 2006 , 101, 114-9	4.9 4

1206	The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 100, 412-6	4.9	43
1205	Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. <i>Gynecologic Oncology</i> , 2006 , 101, 423-8	4.9	68
1204	Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 100, 417-21	4.9	11
1203	Phase II trial of weekly paclitaxel (80 mg/m ²) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2006 , 101, 436-40	4.9	176
1202	Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 101, 495-8	4.9	8
1201	The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , 2006 , 102, 15-21	4.9	33
1200	Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 102, 204-9	4.9	25
1199	A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. <i>Gynecologic Oncology</i> , 2006 , 102, 388-8	4.9	116
1198	Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. <i>Gynecologic Oncology</i> , 2006 , 102, 285-91	4.9	112
1197	A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. <i>Gynecologic Oncology</i> , 2006 , 102, 468-74	4.9	9
1196	Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. <i>Gynecologic Oncology</i> , 2006 , 102, 270-7	4.9	29
1195	Clinical characteristics and prognosis of mucinous tumors of the ovary. <i>Gynecologic Oncology</i> , 2006 , 103, 171-5	4.9	24
1194	A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2006 , 103, 391-6	4.9	59
1193	Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , 2006 , 103, 473-8	4.9	12
1192	Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study. <i>Gynecologic Oncology</i> , 2006 , 103, 439-45	4.9	10
1191	Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. <i>Gynecologic Oncology</i> , 2006 , 103, 451-7	4.9	52
1190	Outcomes for systemic therapy in women with ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 103, 554-8	4.9	14
1189	The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. <i>Gynecologic Oncology</i> , 2006 , 102, 425-8	4.9	104

1188	Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2006 , 102, 432-9	4.9	221
1187	Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. <i>Gynecologic Oncology</i> , 2006 , 103, 1070-6	4.9	290
1186	Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. <i>Gynecologic Oncology</i> , 2006 , 103, 1-6	4.9	47
1185	Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 103, 783-92	4.9	28
1184	Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. 2006 , 203, 527-32		49
1183	Treatments for gynaecological cancers. 2006 , 20, 985-1000		30
1182	Optimizing gemcitabine regimens in ovarian cancer. 2006 , 33, S17-25		10
1181	The role of gemcitabine in first-line treatment of advanced ovarian carcinoma. 2006 , 33, S26-32		72
1180	Clinical efficacy supporting the role of intraperitoneal drug delivery in the primary chemotherapeutic management of small-volume residual advanced ovarian cancer. 2006 , 33, S3-7		78
1179	Introduction. 2006 , 33, 1-2		36
1178	Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. 2006 , 6, 202		18
1177	Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. 2006 , 6, 228		11
1176	Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. 2006 , 106, 375-82		93
1175	Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. 2006 , 107, 299-308		84
1174	Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis. 2006 , 107, 536-43		48
1173	Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival. 2006 , 107, 1511-9		33
1172	Fluorescence staining of human ovarian cancer tissue following application of 5-aminolevulinic acid: fluorescence microscopy studies. 2006 , 38, 549-54		20
1171	Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. 2006 , 94, 138-43		73

1170	Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. 2006 , 108, 361-8		198
1169	Maintenance or consolidation therapy in advanced ovarian cancer. 2006 , 70, 315-24		16
1168	Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma. 2006 , 71, 49-53		13
1167	Optimizing management of recurrent epithelial ovarian cancer: a critical need for evidence-based data. 2006 , 71, 309-11		2
1166	Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?. 2006 , 7, 975-87		11
1165	Stimulation of erythrocyte phosphatidylserine exposure by paclitaxel. 2006 , 18, 151-64		88
1164	Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis. <i>New England Journal of Medicine</i> , 2006 , 354, 1615-25	59.2	4
1163	Potential of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice. 2006 , 12, 298-304		72
1162	Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 767-75	6.1	22
1161	Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients. 2006 , 45, 463-8		12
1160	A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. 2006 , 17, 429-36		25
1159	Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. 2006 , 98, 1036-45		165
1158	Pegylated liposomal doxorubicin consolidation therapy. 2006 , 11, 855; author reply 855-6		
1157	The role of surgery in advanced and recurrent ovarian cancer. 2006 , 17 Suppl 10, x235-40		14
1156	Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. 2006 , 12, 4916-24		260
1155	Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients. 2006 , 11, 336-41		14
1154	Treatment issues in clear cell carcinoma of the ovary: a different entity?. 2006 , 11, 1089-94		74
1153	Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. 2006 , 21, 1127-35		168

1152	Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. 2006 , 71, 320-6	29
1151	Is it time for some new approaches for treating advanced ovarian cancer?. 2006 , 98, 1024-6	5
1150	Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. 2006 , 24, 579-86	73
1149	Challenges for chemotherapy in ovarian cancer. 2006 , 17 Suppl 5, v181-7	78
1148	Role of gemcitabine in ovarian cancer treatment. 2006 , 17 Suppl 5, v188-94	56
1147	Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. 2006 , 4, 165-72	185
1146	Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy. 2006 , 6, 207-27	11
1145	Topotecan in the treatment of ovarian cancer. 2006 , 1, 149-158	1
1144	Ovarian cancer: a focus on management of recurrent disease. 2006 , 3, 604-11	84
1143	Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging. 2006 , 66, 9178-85	22
1142	Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. 2006 , 98, 1655-63	133
1141	Les cancers ovariens. 2006 ,	
1140	Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. 2006 , 103, 10403-10407	35
1139	Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. 2006 , 24, 988-94	151
1138	Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. 2007 , 25, 384-9	193
1137	Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 1379-86	6.1 71
1136	ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. 2007 , 25, 5172-9	85
1135	Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer. 2007 , 11, 211-6	7

1134	Ovarian cancer: an overview of treatment options. 2007 , 11, 201-7	9
1133	Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2007 , 18 Suppl 2, ii12-4	3
1132	Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic. 2007 , 2, 225-238	1
1131	Peritoneal Carcinomatosis. 2007 ,	3
1130	Progress in the Management of Gynecologic Cancer. 2007 , 25, 2865-2866	2
1129	Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy. 2007 , 73, 177-84	13
1128	Intraperitoneal chemotherapy of ovarian cancer. 2007 , 3, 433-40	
1127	Aktuelle Aspekte der Therapie des platinresistenten Ovarialkarzinoms. 2007 , 67, 823-830	
1126	Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. 2007 , 25, 2281-7	118
1125	Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. 2007 , 18, 263-8	88
1124	Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. 2007 , 18, 1943-50	98
1123	Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. 2007 , 25, 437-43	157
1122	A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. 2007 , 67, 4474-81	34
1121	Experience with bevacizumab in the management of epithelial ovarian cancer. 2007 , 25, 2902-8	101
1120	New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. 2007 , 12, 186-90	21
1119	Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. 2007 , 25, 4187-93	61
1118	Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapy. 2007 , 63, 1-6	8
1117	Use of the collagen gel droplet embedded drug sensitivity test to determine drug sensitivity against ovarian mature cystic teratoma with malignant transformation to adenocarcinoma: a case report. 2007 , 53, 137-41	5

1116	Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?. 2007 , 25, 1169-75	66
1115	Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. 2007 , 25, 4466-71	45
1114	Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. 2007 , 67, 10976-83	177
1113	Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. 2007 , 13, 3617-22	138
1112	Peroxisome proliferator-activated receptor α and β ligands inhibit the growth of human ovarian cancer. 2007 , 18, 833	3
1111	Neoadjuvant chemotherapy for ovarian cancer: pro versus con. 2007 , 6, 27-35	
1110	Multidisciplinary Team Management of Gynaecological Cancers. 2007 ,	
1109	Current and Future Directions of Clinical Trials for Ovarian Cancer. 2007 , 14, 44-51	
1108	Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer. 2007 , 26, 334-40	16
1107	Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action. 2007 , 25, 4168-70	34
1106	Current Management Strategies for Ovarian Cancer. 2007 , 82, 751-770	112
1105	Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience. 2007 , 19, 577-81	12
1104	Neoadjuvant chemotherapy in the management of advanced epithelial ovarian cancer. 2007 , 2, 321-329	
1103	A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. 2007 , 33, 688-703	113
1102	Time to reevaluate clinical trials for mucinous ovarian cancer. 2007 , 5, 243-246	
1101	Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: a retrospective university experience. 2007 , 17, 998-1002	4
1100	Microtubule Protocols. 2007 ,	3
1099	Novel agents in ovarian cancer. 2007 , 16, 1227-39	9

1098	An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. 2007 , 25, 517-25	222
1097	GYNECOLOGICAL CANCERS. 2007 , 25, 24-31	1
1096	Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. 2007 , 25, 3621-7	640
1095	Current management strategies for ovarian cancer. 2007 , 82, 751-70	137
1094	Ido serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. 2007 , 1304, 262-273	
1093	Carcinomatous lymphangitis as the initial manifestation of ovarian adenocarcinoma. 2007 , 33, 609-11	1
1092	Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. 2007 ,	
1091	Cytoreductive surgery in ovarian cancer. 2007 , 7, 210-5	22
1090	Ovarian Cancer. 2007 , 1-4	
1089	The use of cytoprotectants in the treatment of gynecological malignancies. 2007 , 6, 7-14	
1088	[Epithelial ovarian cancer]. 2007 , 64, 375-80	4
1087	Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma. 2007 ,	
1086	Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. 2007 , 120, 278-84	24
1085	Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo. 2007 , 120, 2243-50	38
1084	Prosurvival function of the granulin-epithelin precursor is important in tumor progression and chemoresponse. 2007 , 120, 2339-43	44
1083	Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease. 2007 , 46, 1-9	62
1082	The dangers of "cross-trial" and "cross-retrospective experience" comparisons: examples employing data in the peer-reviewed ovarian cancer literature. 2007 , 109, 1929-32	7
1081	Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. 2007 , 110, 791-800	53

1080	Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of caution. 2007 , 110, 1644-7	1
1079	The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma. 2007 , 19, 125-8	1
1078	Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group. 2007 , 97, 1200-5	13
1077	Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. 2007 , 16, 231-7	40
1076	Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma. <i>Cancer Science</i> , 2007 , 98, 2002-8	13
1075	Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis. 2007 , 17, 159-63	14
1074	Four-dimensional computed tomography-based respiratory-gated whole-abdominal intensity-modulated radiation therapy for ovarian cancer: a feasibility study. 2007 , 17, 55-60	10
1073	Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. 2007 , 17, 387-93	134
1072	Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. 2007 , 17, 350-8	11
1071	Principles and practice of intraperitoneal chemotherapy for ovarian cancer. 2007 , 17, 1-20	64
1070	Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy. 2007 , 17, 589-94	11
1069	Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. 2007 , 17, 21-31	94
1068	Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. 2007 , 17, 739-63	38
1067	Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study. 2007 , 17, 777-83	28
1066	Survival and prognostic factors in early-stage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy. 2007 , 17, 1231-7	7
1065	Topotecan in cervical cancer. 2007 , 17, 1215-23	17
1064	Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum. 2007 , 7, 155	9
1063	The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. 2007 , 12, 514-27	171

1062	CHFR gene is neither mutated nor hypermethylated in ovarian cancer. 2007 , 31, 257-61		4
1061	Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , 2007 , 104, 114-9	4.9	7
1060	Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?. <i>Gynecologic Oncology</i> , 2007 , 104, 212-6	4.9	39
1059	A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. <i>Gynecologic Oncology</i> , 2007 , 104, 591-5	4.9	23
1058	Participation of patients with gynecological cancer in phase I clinical trials: two years experience in a major cancer center. <i>Gynecologic Oncology</i> , 2007 , 104, 551-6	4.9	6
1057	Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). <i>Gynecologic Oncology</i> , 2007 , 105, 113-21	4.9	30
1056	Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. <i>Gynecologic Oncology</i> , 2007 , 104, 480-90	4.9	154
1055	Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. <i>Gynecologic Oncology</i> , 2007 , 105, 211-7	4.9	139
1054	Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. <i>Gynecologic Oncology</i> , 2007 , 105, 312-20	4.9	20
1053	Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. <i>Gynecologic Oncology</i> , 2007 , 105, 358-64	4.9	21
1052	Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. <i>Gynecologic Oncology</i> , 2007 , 105, 291-8	4.9	37
1051	Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. <i>Gynecologic Oncology</i> , 2007 , 105, 657-61	4.9	52
1050	A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2007 , 105, 667-71	4.9	12
1049	Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). <i>Gynecologic Oncology</i> , 2007 , 106, 63-74	4.9	140
1048	A relevant historical perspective on the current toxicity of IP chemotherapy: implications for the future. <i>Gynecologic Oncology</i> , 2007 , 105, 561-2	4.9	1
1047	Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. <i>Gynecologic Oncology</i> , 2007 , 106, 381-7	4.9	61
1046	Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials. <i>Gynecologic Oncology</i> , 2007 , 106, 279-81	4.9	12
1045	Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis. <i>Gynecologic Oncology</i> , 2007 , 107, 344-9	4.9	24

1044	The management of recurrent ovarian cancer. 2007 , 34, S1-15	71
1043	Current practice and new developments in ovarian cancer chemotherapy. 2007 , 9, 265-269	1
1042	[Systemic treatment of peritoneal metastases]. 2007 , 78, 1117-22	3
1041	A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer. 2007 , 59, 631-6	3
1040	Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. 2007 , 60, 123-8	10
1039	Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. 2008 , 61, 243-50	29
1038	[Therapeutic standards for ovarian cancer]. 2007 , 28, 222-8	2
1037	Paclitaxel-2'-Ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity. 2007 , 24, 555-65	19
1036	A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer. 2007 , 12, 205-11	14
1035	Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. 2007 , 12, 256-60	30
1034	Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma. 2007 , 133, 619-25	3
1033	Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients. 2007 , 1, 283-91	68
1032	Current status of signal transduction modulators in the treatment of gynecologic malignancies. 2007 , 8, 383-92	5
1031	Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer. 2007 , 9, 469-71	1
1030	Operative management of primary epithelial ovarian cancer. 2007 , 9, 478-84	8
1029	Treatment guidelines in ovarian cancer. 2007 , 9, 308-16	10
1028	Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: a new standard in patient care?. 2007 , 9, 409-11	3
1027	Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?. 2007 , 62, 137-47	17

1026	Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE). 2007 , 64, 106-14	3
1025	A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. 2008 , 66, 229-36	59
1024	Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest. 2008 , 25, 2272-82	6
1023	Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. 2008 , 35, 1439-48	79
1022	Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. 2008 , 35, 1912-20	134
1021	Predictive value of neoadjuvant chemotherapy for the clinical utility of subsequently performed major cancer surgery. 2008 , 10, 447-8	3
1020	Primary chemotherapy and maintenance therapy in epithelial ovarian cancer. 2008 , 1, 99-102	1
1019	Oral premedication for the prevention of hypersensitivity reactions to paclitaxel. 2008 , 25, 274-8	13
1018	Chimiothérapie néoadjuvante dans les cancers ovariens avancés: impact sur la qualité de la chirurgie d'intervalle et sur la survie sans rechute. 2008 , 10, 216-225	
1017	The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus. 2008 , 98, 258-62	25
1016	Prohibition against competing cancer clinical trials: a counter argument. 2008 , 112, 455-7	
1015	Enzymatic stability of 2'-ethylcarbonate-linked paclitaxel in serum and conversion to paclitaxel by rabbit liver carboxylesterase for use in prodrug/enzyme therapy. 2008 , 29, 259-69	4
1014	Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up. 2008 , 87, 1343-52	12
1013	A new model of ovarian carcinogenesis may influence early detection strategies. 2008 , 198, 349-50	8
1012	Utilization of a uniform grading system for interpreting serous ovarian cancer. 2008 , 199, 189.e1-6	6
1011	Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. 2008 , 98, 1197-203	65
1010	Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients. 2008 , 98, 1910-5	15
1009	Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cell-cycle regression in ovarian cancer cells. 2008 , 99, 1823-31	12

1008	High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial. 2008 , 41, 547-54		8
1007	Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients. 2008 , 18, 8-13		3
1006	A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum. 2008 , 18, 249-54		10
1005	Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma. 2008 , 18, 652-9		41
1004	Maintenance chemotherapy in advanced ovarian cancer: the US experience. 2008 , 18 Suppl 1, 40-3		2
1003	First-line randomized trials: revisiting the Ptolemaic universe. 2008 , 18 Suppl 1, 47-52		5
1002	The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. 2008 , 18, 879-90		34
1001	Human monoclonal antibody for ovarian clear cell carcinoma-2, a human monoclonal antibody with antitumor activity against ovarian cancer cells that recognizes CA125-like antigen. 2008 , 18, 996-1006		3
1000	Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. 2008 , 18, 937-42		55
999	Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. 2008 , 18, 1194-9		9
998	Involvement of thioredoxin-binding protein 2 in the antitumor activity of CD437. <i>Cancer Science</i> , 2008 , 99, 2485-90	6.9	17
997	The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2008 , 108, 287-92	4.9	91
996	Expression and activity of taxane-metabolizing enzymes in ovarian tumors. <i>Gynecologic Oncology</i> , 2008 , 108, 355-60	4.9	16
995	Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2008 , 109, 359-63	4.9	16
994	Evidence-based chemotherapy administration in advanced ovarian cancer: an impressive past, a disquieting present and an uncertain future. <i>Gynecologic Oncology</i> , 2008 , 109, 4-7	4.9	25
993	Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion. <i>Gynecologic Oncology</i> , 2008 , 109, 226-33	4.9	19
992	Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2008 , 109, 27-32	4.9	21
991	Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2008 , 109, 187-93	4.9	16

990	Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2008 , 109, 353-8	4.9	47
989	Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. <i>Gynecologic Oncology</i> , 2008 , 110, 87-92	4.9	12
988	A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. <i>Gynecologic Oncology</i> , 2008 , 110, 140-5	4.9	72
987	Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. <i>Gynecologic Oncology</i> , 2008 , 110, 345-53	4.9	108
986	The remarkable "paclitaxel story": how many chapters remain to be written?. <i>Gynecologic Oncology</i> , 2008 , 111, 7-8	4.9	2
985	Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2008 , 111, 487-95	4.9	42
984	TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. 2008 , 8, 27		18
983	Progress in gynecologic cancer research: the Gynecologic Oncology Group experience. 2008 , 35, 507-21		17
982	Ovarian cancer in older women. 2008 , 35, 582-9		18
981	Pharmaceutical management of ovarian cancer : current status. 2008 , 68, 771-89		83
980	Maintenance Therapy in Epithelial Ovarian Cancer: Rationale and Results. 2008 , 1, 40-43		
979	Bevacizumab in the Management of Epithelial Ovarian Cancer. 2008 , 1, 116-119		
978	Ovarian Cancer. 2008 ,		2
977	Targeted Cancer Therapy. 2008 ,		6
976	Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. 2008 , 29, 515-9		45
975	Reversal of the malignant phenotype of ovarian cancer A2780 cells through transfection with wild-type PTEN gene. 2008 , 271, 205-14		18
974	Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. 2008 , 44, 2169-77		16
973	Progression-free versus overall survival and adequate powering in randomised studies. 2008 , 44, 2092-4		0

972	Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. 2008 , 44, 2608-14	81
971	CD437 induces apoptosis in ovarian adenocarcinoma cells via ER stress signaling. 2008 , 366, 840-7	24
970	Neoadjuvant chemotherapy prior to intraperitoneal chemotherapy in women with advanced ovarian cancer. 2008 , 5, 376-380	
969	Ovarian cancer: can we reverse drug resistance?. 2008 , 622, 153-67	8
968	Lipoxygenase pathway receptor expression in ovarian cancer. 2008 , 15, 321-6	38
967	Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. 2008 , 26, 76-82	462
966	Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. 2008 , 26, 83-9	271
965	Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. 2008 , 26, 4144-50	37
964	Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. 2008 , 68, 5849-58	79
963	Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2008 , 19 Suppl 2, ii14-6	41
962	Carcinoma of Unknown Primary - an Orphan Disease?. 2008 , 3, 164-170	12
961	The promise and perils of 'targeted therapy' of advanced ovarian cancer. 2008 , 74, 1-6	17
960	Paclitaxel- and platinum-based postoperative chemotherapy for primary fallopian tube carcinoma: a single institution experience. 2008 , 75, 42-8	8
959	Targeting signaling pathways in ovarian cancer. 2008 , 12, 353-65	20
958	Gene-expression profiling in epithelial ovarian cancer. 2008 , 5, 577-87	85
957	Paclitaxel in the management of ovarian cancer. 2008 , 3, 287-299	
956	The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers. 2008 , 98, 1068-75	51
955	A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis. 2008 , 98, 720-7	6

954	Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?. 2008 , 8, 1135-47		11
953	Taxanes in the management of gynecologic malignancies. 2008 , 8, 219-26		5
952	Ovarian Cancer. 2008 , 712-718		
951	Ovarian cancer: front-line standard treatment in 2008. 2008 , 19 Suppl 7, vii61-6		10
950	Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review. 2008 , 19, 688-95		19
949	Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 704-11	6.1	26
948	Intraperitoneal chemotherapy for women with ovarian cancer: nursing care and considerations. 2008 , 12, 265-71		4
947	Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer: a review of contributing factors. 2008 , 12, 445-54		20
946	Hereditary Gynecologic Cancer. 2008 ,		2
945	Development of antiangiogenic agents for ovarian cancer. 2008 , 8, 21-32		4
944	Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. 2008 , 26, 890-6		221
943	Emerging drugs for ovarian cancer. 2008 , 13, 523-36		7
942	Anti-idiotypic antibody abagovomab in advanced ovarian cancer. <i>Future Oncology</i> , 2008 , 4, 769-73	3.6	1
941	Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. 2008 , 26, 822-9		19
940	Survival analysis of ovarian clear cell carcinoma confined to the ovary with or without comprehensive surgical staging. 2008 ,		2
939	The role of cytoreductive/debulking surgery in ovarian cancer. 2008 , 6, 803-10; quiz 811		28
938	Intraperitoneal chemotherapy in ovarian cancer: an update. 2008 , 14, 7-9		3
937	Ovary. 257-266		

936	Apoptotic and chemotherapeutic properties of iron (III)-salophene in an ovarian cancer animal model. 2009 , 3, 17-26	8
935	Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. 2008 , 19, 223-8	48
934	A Menu-Driven Facility for Sample-Size Calculation in Novel Multiarm, Multistage Randomized Controlled Trials with a Time-to-Event Outcome. 2009 , 9, 505-523	17
933	Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. 2009 , 24, 945-50	2
932	[First line chemotherapy of advanced epithelial ovarian cancer]. 2009 , 96, 1207-13	1
931	Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?. 2009 , 19, 343-7	4
930	Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer in Women who are Refractory to Both Platinum- and Paclitaxel-Based Chemotherapy Regimens. 2009 , 1, CMT.S2219	
929	Ovarian cancer: pathology, biology, and disease models. 2009 , 14, 2089-102	71
928	Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women. 2009 , 50, 266-72	11
927	Overview of epithelial ovarian cancer and updates in management strategies. 2009 , 4, 383-399	1
926	Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. 2009 , 13, 345-54	65
925	Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2009 , 20 Suppl 4, 21-3	37
924	Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. 2009 , 27, 418-25	145
923	Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. 2009 , 27, 1419-25	547
922	Role of cytoreductive surgery in recurrent ovarian cancer. 2009 , 9, 917-22	12
921	Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy. 2009 , 101, 1321-8	16
920	Influence of paclitaxel on parasitemia and survival of Plasmodium berghei infected mice. 2009 , 23, 191-8	74
919	Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. 2009 , 15, 1473-80	48

918	Tissue transglutaminase expression and drug resistance in ovarian cancer. 2009 , 4, 105-110		
917	Considering usual medical care in clinical trial design. 2009 , 6, e1000111		41
916	Study of 'patterns of care' of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India. 2009 , 46, 28-33		36
915	Therapeutic Targeting of ATP7B in Ovarian Carcinoma. 2009 , 15, 3770-80		103
914	Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy. 2009 , 27, 1355-8		9
913	Yin yang 1 modulates taxane response in epithelial ovarian cancer. 2009 , 7, 210-20		45
912	Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. 2009 , 27, 4642-8		93
911	Where is the future of endometrial cancer therapy?. 2009 , 20, 1757-61		6
910	Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. 2009 , 61, 554-63		127
909	TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. <i>Gynecologic Oncology</i> , 2009 , 112, 179-84	4.9	18
908	Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum. <i>Gynecologic Oncology</i> , 2009 , 112, 35-9	4.9	15
907	Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. <i>Gynecologic Oncology</i> , 2009 , 112, 444-9	4.9	32
906	BRCA1 and implications for response to chemotherapy in ovarian cancer. <i>Gynecologic Oncology</i> , 2009 , 113, 134-42	4.9	70
905	Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. <i>Gynecologic Oncology</i> , 2009 , 113, 57-62	4.9	46
904	An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2009 , 113, 63-7	4.9	18
903	Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2009 , 113, 384-90	4.9	28
902	A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2009 , 113, 205-9	4.9	66
901	Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2009 , 113, 341-7	4.9	35

900	Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). <i>Gynecologic Oncology</i> , 2009 , 114, 199-205	4.9	48
899	Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2009 , 114, 472-9	4.9	31
898	The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland. <i>Gynecologic Oncology</i> , 2009 , 115, 199-203	4.9	25
897	The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2009 , 115, 377-81	4.9	25
896	Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study. <i>Gynecologic Oncology</i> , 2009 , 115, 382-8	4.9	5
895	Antioxidants in cardiovascular disease: randomized trials. 1996 , 54, 175-7		16
894	beta-Carotene and the carotenoids: beyond the intervention trials. 1996 , 54, 185-8		24
893	Fruits and vegetables: protective or just fellow travelers?. 1996 , 54, 255-7		13
892	Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma. 2009 , 190, 66-70		13
891	Treatment for patients with unknown primary cancer and favorable prognostic factors. 2009 , 36, 44-51		60
890	Management of women with newly diagnosed ovarian cancer. 2009 , 36, 91-105		5
889	IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. 2009 , 124, 1440-8		14
888	Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. 2009 , 125, 2721-7		28
887	The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. 2009 , 115, 1028-35		68
886	CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. 2009 , 115, 1395-403		54
885	Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. 2009 , 115, 4210-7		41
884	Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future. 2009 , 100, 335-44		26
883	Exact, distribution free confidence intervals for late effects in censored matched pairs. 2009 , 51, 31-44		

882	Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. 2009 , 71, 233-41	27
881	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: overview and rationale. 2009 , 33, 125-41	19
880	Gonadotropin and steroid receptors as prognostic factors in advanced ovarian cancer: a retrospective study. 2009 , 11, 748-52	9
879	Meta-analysis of trials comparing gemcitabine and pegylated liposomal doxorubicin for treatment in women with progressive or recurrent ovarian cancer. 2009 , 6, 412-417	
878	Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer. 2009 , 11, 457-65	23
877	Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. 2009 , 2, 34	165
876	Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. 2009 , 2, 13	131
875	Cyclophosphamide and cancer: golden anniversary. 2009 , 6, 638-47	457
874	High-dose vitamin supplements for cigarette smokers: caution is indicated. 1997 , 55, 369-70	8
873	Prooxidant actions of carotenoids in biologic systems. 1998 , 56, 257-65	230
872	Plasma homocysteine as a cardiovascular risk factor: causal, consequential, or of no consequence?. 1999 , 57, 299-305	16
871	Effect of vitamin E, vitamin C, and beta-carotene on stroke risk. 2000 , 58, 184-7	11
870	Herbal medicine Shakuyaku-kanzo-to reduces paclitaxel-induced painful peripheral neuropathy in mice. 2009 , 13, 22-7	47
869	Fluorescence diagnosis and photodynamic therapy in intra-abdominal gynecologic diseases and breast cancer [A review. 2009 , 24, 18-26	3
868	Tailoring cancer treatment using germline cancer genetics - are we almost there?. 2009 , 21, 441-3	1
867	Chemotherapy for gynecologic cancers. 2009 , 76, 577-88	5
866	Carboplatin and paclitaxel adjuvant chemotherapy in primitive neuroectodermal tumor of the uterine corpus. 2009 , 200, e6-9	15
865	Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. 2009 , 27, 6243-50	69

864	Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. 2009 , 27, 5601-6	250
863	Novel strategies for reversing platinum resistance. 2009 , 12, 148-52	53
862	Aurora kinases as prognostic biomarkers in ovarian carcinoma. <i>Human Pathology</i> , 2009 , 40, 631-8	3.7 30
861	CON: Patients with Recurrent Ovarian Carcinoma Should Not Be Treated with Antiangiogenic Agents in Combination with Chemotherapy. 2009 , 2, 16-18	
860	Trial Design Strategies for Vascular-Targeted Therapy of Patients with Ovarian Cancer. 2009 , 2, 3-9	
859	Trial Design Strategies for Vascular-Targeted Therapy of Patients with Ovarian Cancer. 2009 , 2, 24-30	1
858	Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. 2009 , 7, 14	26
857	Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. 2009 , CD004706	12
856	Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. 2009 ,	15
855	Surrogate Efficacy Endpoints in Oncology Trials. 2009 , 23, 283-287	1
854	Ovarian cancer. 2009 , 374, 1371-82	477
853	Cáncer de ovario. 2009 , 10, 1591-1598	
852	Carcinoma de ovario: enfermedad tras citorreducción y quimioterapia adyuvante. Importancia e implicaciones terapéuticas. 2009 , 52, 393-401	
851	An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer. 2009 , 15, 105-9	11
850	Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. 2009 , CD004706	27
849	Primary Adrenal Malignancy. 2009 , 290-308	1
848	Clinical trial participation is associated with improved outcome in women with ovarian cancer. 2009 , 19, 124-8	17
847	Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. 2009 , 19, 992-7	51

- 846 Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2). **2009**, 19, 615-9 12
- 845 The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment. **2009**, 15, 1373-84 30
- 844 First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions. **2010**, 22, 513-20 17
- 843 Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay. **2010**, 33, 358-63 13
- 842 Ramirez's abdominoplasty technique combined with intraperitoneal chemohyperthermia after surgical cytoreductive procedures for the treatment of advanced intraperitoneal cancer in patients with ventral hernia. **2010**, 64, 187-92 2
- 841 Pure primary squamous cell carcinoma of the ovary: a report of two cases and review of the literature. **2010**, 29, 328-34 15
- 840 Patient-specific tumor biology-based selection of ovarian cancer therapy. **2010**, 7, 213-216 1
- 839 Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells. **2010**, 37, 419-28 6
- 838 Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. **2010**, 20, 704-16 22
- 837 Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killer cell function and angiogenesis promotion. **2010**, 38, 2
- 836 Taxane monotherapy for the treatment of platinum pre-treated epithelial ovarian cancer. *The Cochrane Library*, **2010**, 5.2 1
- 835 Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. **2010**, 20, 240-7 49
- 834 Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?. **2010**, 89, 623-8 17
- 833 Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?. **2010**, 37, 1259-69 35
- 832 Whole abdominal radiotherapy in ovarian cancer. **2010**, 15, 27-30 7
- 831 Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas. **2010**, 281, 325-8 26
- 830 Efficacy of a methyl ester of 5-aminolevulinic acid in photodynamic therapy for ovarian cancers. **2010**, 136, 1143-50 27
- 829 Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer. **2010**, 15, 468-71 23

828	Combination of docetaxel-carboplatin for adjuvant chemotherapy of epithelial ovarian, primary peritoneal and fallopian tube cancers: a meta-analysis. 2010 , 9, 475-481		
827	Pharmacoeconomy in cancer therapy. 2010 , 3, 99-102		0
826	Drug delivery systems for intraperitoneal therapy. 2010 , 27, 735-8		73
825	F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies. 2010 , 28, 132-8		11
824	Effect of a vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model. 2010 , 28, 543-53		15
823	Mucinous adenocarcinoma of the ovary. 2010 , 37, 314-20		3
822	Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells. 2010 , 10, 72		12
821	SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. 2010 , 18, 109-21		101
820	Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2010 , 116, 57-60	4.9	18
819	Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. <i>Gynecologic Oncology</i> , 2010 , 116, 340-4	4.9	15
818	A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2010 , 116, 332-4	4.9	23
817	Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. <i>Gynecologic Oncology</i> , 2010 , 117, 177-82	4.9	62
816	Achievements and unmet needs in the management of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2010 , 117, 152-8	4.9	68
815	FGFR2 mutations are rare across histologic subtypes of ovarian cancer. <i>Gynecologic Oncology</i> , 2010 , 117, 125-9	4.9	38
814	Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. <i>Gynecologic Oncology</i> , 2010 , 117, 429-39	4.9	30
813	Unmasking the complexities of mucinous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2010 , 117, 491-6	4.9	72
812	A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). <i>Gynecologic Oncology</i> , 2010 , 118, 308-12	4.9	50
811	Heat shock proteins in ovarian cancer: a potential target for therapy. <i>Gynecologic Oncology</i> , 2010 , 119, 164-6	4.9	24

810	Cognitive functions in long-term survivors of ovarian cancer. <i>Gynecologic Oncology</i> , 2010 , 119, 366-9	4.9	29
809	CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. <i>Gynecologic Oncology</i> , 2010 , 119, 265-9	4.9	30
808	Immunization with synthetic VEGF peptides in ovarian cancer. <i>Gynecologic Oncology</i> , 2010 , 119, 564-70	4.9	23
807	Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. <i>Gynecologic Oncology</i> , 2010 , 119, 451-6	4.9	49
806	Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer. 2010 , 116, 1476-84		22
805	Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. 2010 , 116, 1462-8		65
804	FEZ1/LZTS1 protein expression in ovarian cancer. 2010 , 222, 382-6		11
803	Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer. 2010 , 101, 418-24		14
802	Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. 2010 , 102, 663-70		53
801	Review role of topotecan in gynaecological cancers: current indications and perspectives. 2010 , 74, 163-74		42
800	Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc. 2010 , 10, 16		69
799	A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer. 2010 , 5, 84		11
798	Impact of bowel obstruction at the time of initial presentation in women with ovarian cancer. 2010 , 117, 32-8		4
797	Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy?. 2010 , 117, 1459-67		14
796	A call for prospective studies in early-stage ovarian cancer. 2010 , 117, 1441-3		3
795	Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo. <i>Cancer Science</i> , 2010 , 101, 143-8	6.9	14
794	Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer. <i>Cancer Science</i> , 2010 , 101, 2171-8	6.9	40
793	Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. <i>Oncogene</i> , 2010 , 29, 6051-63	9.2	44

792	Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model. 2010 , 103, 61-72		11
791	Management of ovarian and endometrial cancer in older adults. 201-218		1
790	A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma. 2010 , 20, 1132-6		9
789	Clinical trials and progress with paclitaxel in ovarian cancer. 2010 , 2, 411-27		74
788	Acute leukemia in women. 2010 , 6, 239-49		2
787	Personalizing therapy for ovarian cancer: BRCAness and beyond. 2010 , 28, 3545-8		52
786	Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 985-95	6.1	42
785	B19, a novel monocarbonyl analogue of curcumin, induces human ovarian cancer cell apoptosis via activation of endoplasmic reticulum stress and the autophagy signaling pathway. 2013 , 9, 766-77		47
784	A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer. 2013 , 24, 154-9		7
783	Biological Significance of Apoptosis in Ovarian Cancer: TRAIL Therapeutic Targeting. 2013 ,		
782	Ovarian cancer: the initial laparotomy. 405-414		
781	Chemotherapy of ovarian cancer. 415-424		1
780	Intra-peritoneal chemotherapy. 425-430		
779	Molecular profiling and commercial predication assays in ovarian cancer: still not ready for prime time?. 2014 , 139-47		1
778	Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System. 2014 , 4, 34		47
777	Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer. 2014 , 6, 351-8		16
776	Synergy of 1,25-dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV-3 cells. 2014 , 8, 1348-1354		20
775	PSY-1, a <i>Taxus chinensis</i> var. <i>mairei</i> Extract, Inhibits Cancer Cell Metastasis by Interfering with MMPs. 2014 , 9, 1934578X1400900		2

774 Cooperative Cancer Trials. **2014**,

773 Ovarian cancer and antiangiogenic therapy: caveat emptor. **2014**, 32, 3353-6

14

772 Successes and limitations of targeted cancer therapy in ovarian cancer. **2014**, 41, 89-97

8

771 The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer. **2014**, 14, 1105-13

2

770 Positron Emission Tomography (PET) in Oncology. *Cancers*, **2014**, 6, 1821-89

6.6 167

769 Pathology of the Ovary, Fallopian Tube and Peritoneum. **2014**,

768 Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy - a retrospective evaluation. **2014**, 44, 212-219

1

767 Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review. **2014**, 14, 649-65

11

766 nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer. **2014**, 52, 360-6

23

765 Dual-Pore Mesoporous Carbon@Silica Composite CoreShell Nanospheres for Multidrug Delivery. **2014**, 126, 5470-5474

44

764 Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. **2014**, 110, 575-84

39

763 Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. **2014**, 111, 17266-71

129

762 Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: a review. **2014**, 45, 609-19

57

761 Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. **2014**, 135, 308-18

50

760 A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age. **2014**, 19, 921-7

19

759 Cytoreductive surgery under aminolevulinic acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial. **2014**, 21, 4256-62

27

758 Taxanes: their impact on gynecologic malignancy. **2014**, 25, 522-35

14

757 Gynecologic Cancer InterGroup (GCIg) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. **2014**, 24, S9-13

50

756	Taxanes in combination with biologic agents for ovarian and breast cancers. 2014 , 25, 536-54	2
755	Prognosis and conditional disease-free survival among patients with ovarian cancer. 2014 , 32, 4102-12	48
754	Recurrent Ovarian Cancer: When to Treat and How to Assess. 2014 , 17-27	
753	The role of microRNAs in the regulation of apoptosis in lung cancer and its application in cancer treatment. 2014 , 2014, 318030	34
752	In vitro chemoresponse in metachronous pairs of gynecologic cancers. 2014 , 1, 7	1
751	Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study. 2014 , 39, 25-31	23
750	Sphingosine 1-phosphate: a potential molecular target for ovarian cancer therapy?. 2014 , 32, 71-80	23
749	Advances in Diagnosis and Management of Ovarian Cancer. 2014 ,	2
748	Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. <i>Gynecologic Oncology</i> , 2014 , 132, 203-10	4.9 30
747	Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. <i>Gynecologic Oncology</i> , 2014 , 132, 8-17	4.9 55
746	Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action. 2014 , 14, 61	32
745	Novel therapies, including enzastaurin, in the treatment of ovarian cancer. 2014 , 23, 579-98	5
744	L-shell x-ray fluorescence computed tomography (XFCT) imaging of Cisplatin. 2014 , 59, 219-32	21
743	Dual-pore mesoporous carbon@silica composite core-shell nanospheres for multidrug delivery. 2014 , 53, 5366-70	153
742	In vivo imaging as a pharmacodynamic marker. 2014 , 20, 2569-77	11
741	Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study. 2014 , 73, 61-8	2
740	Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. 2014 , 89, 207-16	124
739	Heat shock protein 27: a potential biomarker of peritoneal metastasis in epithelial ovarian cancer?. 2014 , 35, 1051-6	26

738	Expression and prognostic significance of APE1/Ref-1 and NPM1 proteins in high-grade ovarian serous cancer. 2014 , 141, 404-14	27
737	The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis. 2014 , 19, 528-35	36
736	Better therapeutic trials in ovarian cancer. 2014 , 106, dju029	27
735	Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. 2014 , 50, 2592-601	26
734	Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model. 2014 , 7, 368-76	6
733	Cisplatin in cancer therapy: molecular mechanisms of action. 2014 , 740, 364-78	2512
732	Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents. 2014 , 14, 1041-50	4
731	An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect. 2014 , 15, 314	22
730	Selective cytotoxicity of indirect nonequilibrium atmospheric pressure plasma against ovarian clear-cell carcinoma. 2014 , 3, 398	86
729	Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey. 2014 , 290, 425-34	5
728	Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients. 2014 , 140, 1681-7	8
727	Ovarian cancer: a brief historical overview of intraperitoneal trials. 2014 , 21, 1429-34	7
726	Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome. 2014 , 53, 242-50	7
725	Taxol, Taxoids, and Related Taxanes. 2014 , 127-180	2
724	Mucinous tumors of the ovary: current thoughts on diagnosis and management. 2014 , 16, 389	85
723	The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse. 2014 , 66, 109-13	8
722	First-line and maintenance therapy for ovarian cancer: current status and future directions. 2014 , 74, 879-89	17
721	Breast and ovarian cancer in the older woman. 2014 , 32, 2553-61	56

720	Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: the first step before intraperitoneal anti-vascular endothelial growth factor treatment?. 2014 , 50, 722-30		9
719	Inhibition of Wnt/ β -catenin pathway by niclosamide: a therapeutic target for ovarian cancer. <i>Gynecologic Oncology</i> , 2014 , 134, 112-20	4.9	118
718	Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer. <i>Human Pathology</i> , 2014 , 45, 1509-19	3.7	15
717	Perspective of strategic plasma therapy in patients with epithelial ovarian cancer: A short review of plasma in cancer treatment. 2014 , 53, 05FA05		22
716	Mean platelet volume could be a useful biomarker for monitoring epithelial ovarian cancer. 2014 , 34, 515-8		50
715	Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC-IV ovarian cancer. Critical analysis in elderly patients. 2014 , 179, 88-93		28
714	Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: a phase II trial. 2014 , 26, 139-45		6
713	The inhibition of constitutive androstane receptor-mediated pathway enhances the effects of anticancer agents in ovarian cancer cells. 2014 , 90, 356-66		10
712	The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2014 , 132, 560-5	4.9	39
711	Ovarian cancer. 2014 , 384, 1376-88		1123
710	Mucinous Epithelial Ovarian Cancer. 2014 , 64-69		1
709	Overexpression of goosecoid homeobox is associated with chemoresistance and poor prognosis in ovarian carcinoma. 2014 , 32, 189-98		25
708	Gynaecological cancer. 2014 , 321-354		
707	New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. 2014 , 20, 5150-6		97
706	Frontline treatment of epithelial ovarian cancer. 2015 , 11 Suppl 6, 1-16		11
705	HOTAIR is a potential target for the treatment of cisplatin-resistant ovarian cancer. 2015 , 12, 2211-6		46
704	Taxane platinum combination chemotherapy versus single agent platinum for the first line treatment of epithelial ovarian cancer. <i>The Cochrane Library</i> , 2015 ,	5.2	
703	The angiogenesis regulator vasohibin-1 inhibits ovarian cancer growth and peritoneal dissemination and prolongs host survival. 2015 , 47, 2057-63		15

702 Ovarian cancer. 790-812

701 Breast carcinoma. 679-690

700 Ovarian cancer standard of care: are there real alternatives?. **2015**, 34, 17-27 58

699 Low-grade epithelial ovarian cancer: a number of distinct clinical entities?. **2015**, 27, 412-9 15

698 Long-term primary culture of a clear cell ovarian carcinoma reveals an epithelial-mesenchymal cooperative interaction. **2015**, 15, 88 3

697 Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. *The Cochrane Library*, **2015**, CD004706 5.2 42

696 Increased Dose Single-agent Gemcitabine in Platinum-taxane Resistant Metastatic Ovarian Cancer. **2015**, 101, 36-40

695 Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study. **2015**, 25, 815-22 25

694 Trends in relative survival for ovarian cancer from 1975 to 2011. **2015**, 125, 1345-1352 75

693 Intact PTEN Expression by Immunohistochemistry is Associated With Decreased Survival in Advanced Stage Ovarian/Primary Peritoneal High-grade Serous Carcinoma. **2015**, 34, 497-506 9

692 Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?. **2015**, 114-21 34

691 Management of cancer of the ovary. 345-359

690 Annexin A3 Is a Potential Predictor of Platinum Resistance in Epithelial Ovarian Cancer Patients in a Prospective Cohort. **2015**, 6, 678-85 9

689 Hepatoma-derived growth factor predicts unfavorable prognosis of epithelial ovarian cancer. **2015**, 8, 2101-9 5

688 Two drugs are better than one. A short history of combined therapy of ovarian cancer. **2015**, 19, 350-3 10

687 Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. **2015**, 2015, 413076 143

686 A Rare Case of Paclitaxel and/or Trastuzumab Induced Acute Hepatic Necrosis. **2015**, 2015, 825603 4

685 Vernolepin regulates apoptosis and autophagy via microtubule formation in ovarian carcinoma cells. **2015**, 10, 1

684	Neoadjuvant and Adjuvant Chemotherapy for Advanced Ovarian Cancer, Including Biological Agents. 2015 , 441-453	
683	Comparative effectiveness research in gynecologic oncology. 2015 , 164, 237-59	
682	New perspectives on targeted therapy in ovarian cancer. 2015 , 7, 189-203	81
681	Tratamiento médico del cáncer epitelial de ovario. 2015 , 51, 1-5	
680	Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios. 2015 , 3, 317-321	21
679	Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells. 2015 , 47, 353-60	25
678	Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells. 2015 , 47, 2296-303	25
677	Paris saponin II inhibits human ovarian cancer cell-induced angiogenesis by modulating NF- κ B signaling. 2015 , 33, 2190-8	32
676	Inhibitory effect of carbonyl reductase 1 on ovarian cancer growth via tumor necrosis factor receptor signaling. 2015 , 47, 2173-80	5
675	Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer. 2015 , 34, 2683-91	16
674	Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells. 2015 , 46, 1405-11	64
673	Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways. 2015 , 72, 203-13	21
672	Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival. <i>Gynecologic Oncology</i> , 2015 , 136, 121-9	4.9 10
671	Preclinical and clinical development of siRNA-based therapeutics. 2015 , 87, 108-19	313
670	Current status of CPT and its analogues in the treatment of malignancies. 2015 , 14, 429-441	9
669	Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. 2015 , 41, 136-43	65
668	[Epidemiology of brain metastases]. 2015 , 19, 3-9	43
667	Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma. 2015 , 34, 5-10	9

666	Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma. 2015 , 31, 8-14		13
665	Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. <i>Scientific Reports</i> , 2014 , 4, 5810	4.9	30
664	Carcinosarcoma of the ovary successfully treated with paclitaxel and carboplatin therapy: two cases. 2015 , 4, 88-91		1
663	Cáncer de ovario: diagnóstico, evaluación y estrategia terapéutica. 2015 , 51, 1-10		1
662	Optimal follow-up of ovarian cancer patients. 2015 , 8, 57-61		
661	Enhancing the water dispersibility of paclitaxel by complexation with hydrophobic peptides. 2015 , 135, 408-415		10
660	Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015 , 137, 401-5	4.9	37
659	Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients. 2015 , 112, 1376-83		15
658	Tropical Hemato-Oncology. 2015 ,		2
657	Why have ovarian cancer mortality rates declined? Part II. Case-fatality. <i>Gynecologic Oncology</i> , 2015 , 138, 750-6	4.9	38
656	Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review. 2015 , 33, 1155-85		11
655	In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer. 2015 , 23, 4576-4582		15
654	Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. 2015 , 212, 468.e1-9		61
653	The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma. 2015 , 291, 1381-6		4
652	Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. <i>Future Oncology</i> , 2015 , 11, 747-57	3.6	40
651	The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction. 2015 , 22, 987-93		35
650	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1495-503	6.1	13
649	MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity. 2015 , 112, 504-13		24

648	Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 141-50	6.1	69
647	Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells. 2015 , 36, 6433-43		13
646	Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients. 2015 , 14, 1900-10		28
645	Cancer of the ovary, fallopian tube, and peritoneum. 2015 , 131 Suppl 2, S111-22		61
644	Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. 2015 , 76, 417-23		33
643	Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. 2015 , 5, 1137-54		436
642	Chemotherapy: Limited use of the intraperitoneal route for ovarian cancer-why?. 2015 , 12, 628-30		15
641	Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2015 , 139, 10-6	4.9	210
640	PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2015 , 139, 59-62	4.9	36
639	Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. 2015 , 220, 358-367		14
638	Prediction of advanced ovarian cancer recurrence by plasma metabolic profiling. 2015 , 11, 516-21		17
637	Gynecologic Oncology. 2015 ,		
636	Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer. 2015 , 21, 347-56		7
635	Mechanisms and Therapeutic Targets of microRNA-associated Chemoresistance in Epithelial Ovarian Cancer. 2016 , 16, 429-41		16
634	MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2. 2016 , 7, 53254-53268		48
633	Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice. 2016 , 7, 83451-83461		8
632	Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer. 2016 , 12, 23-36		
631	Chemotherapy for Elderly Ovarian Cancer Patients. 2016 , 6,		2

630	Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer. 2016 , 34, 4312-4314		1
629	A Rare Case of Intra-Endometrial Leiomyoma of Uterus Simulating Degenerated Submucosal Leiomyoma Accompanied by a Large Sertoli-Leydig Cell Tumor. 2016 , 57, 523-6		
628	Differential Cytotoxic Potential of Silver Nanoparticles in Human Ovarian Cancer Cells and Ovarian Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	26
627	Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?. 2016 , 11, e0147787		7
626	Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. 2016 , 26, 626-31		5
625	Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer. 2016 , 127, 985-991		18
624	Changing state of gynecologic oncologist specialty in Japan. 2016 , 42, 481-8		3
623	Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer. 2016 , 27, 547-59		5
622	The role of cediranib in ovarian cancer: current status and further investigation. 2016 , 4, 855-865		
621	Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells. 2016 , 49, 1211-20		13
620	Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database. 2016 , 9, 130-138		23
619	Mucinous ovarian cancer: A therapeutic review. 2016 , 102, 26-36		22
618	Opportunities in immunotherapy of ovarian cancer. 2016 , 27 Suppl 1, i11-i15		35
617	Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation. 2016 , 37, 14259-14269		22
616	Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study. 2016 , 11, 1859-1865		8
615	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. 2016 , 34, 3460-73		235
614	Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Gynecologic Oncology</i> , 2016 , 143, 3-15	4.9	141
613	Vasohibin-1 expression inhibits advancement of ovarian cancer producing various angiogenic factors. <i>Cancer Science</i> , 2016 , 107, 629-37	6.9	9

612	First-Line Chemotherapy for Ovarian Cancer: Inferences From Recent Studies. 2016 , 21, 1286-1290		1
611	BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer. 2016 , 49, 402-10		25
610	Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. 2016 , 122, 3297-3306		2
609	Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. 2016 , 34, 2881-7		80
608	Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells. <i>Scientific Reports</i> , 2016 , 6, 19449	4.9	78
607	Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues. <i>Scientific Reports</i> , 2016 , 6, 36641	4.9	58
606	Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies. 2016 , 12, 396-9		
605	The rise of genomic profiling in ovarian cancer. 2016 , 16, 1337-1351		14
604	Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas. 2016 , 78, 1283-1288		12
603	Ovarian cancer. 2016 , 2, 16061		420
602	MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib. 2016 , 16, 550		12
601	Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies. 2016 , 3, 10		0
600	Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study. 2016 , 95, e5696		2
599	Prognostic implications of reproductive and lifestyle factors in ovarian cancer. <i>Gynecologic Oncology</i> , 2016 , 142, 574-87	4.9	18
598	Induction Chemotherapy. 2016 ,		3
597	Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated. 2016 , 16, 16		33
596	Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. 2016 , 21, 954-63		22
595	T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. 2016 , 22, 6110-6117		47

594	Oral cyclophosphamide in recurrent ovarian cancer. 2016 , 12, e154-60		18
593	Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016 , 140, 436-42	4.9	75
592	Can advanced-stage ovarian cancer be cured?. 2016 , 13, 255-61		192
591	Trends in gynecologic cancer among elderly women in Denmark, 1980-2012. 2016 , 55 Suppl 1, 65-73		14
590	Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study. 2016 , 142, 949-58		15
589	The value of surrogate endpoints for predicting real-world survival across five cancer types. 2016 , 32, 731-9		6
588	Consenso Nacional Intersociedades sobre Cáncer Epitelial de Ovario -estadios avanzados- y Tumores No Epiteliales de Ovario. Junio de 2014. 2016 , 80, 219-233		
587	Gene therapy for ovarian cancer using carbonyl reductase 1 DNA with a polyamidoamine dendrimer in mouse models. 2016 , 23, 24-8		19
586	"The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period". 2016 , 25, 49-59		5
585	Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival. 2016 , 4, 399-404		3
584	In Vitro Approaches to Study Regulation of Hepatic Cytochrome P450 (CYP) 3A Expression by Paclitaxel and Rifampicin. 2016 , 1395, 55-68		7
583	Peritoneal Carcinomatosis. 2016 , 185-205		0
582	Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. 2016 , 15, 497-506		5
581	The Role of the Immune System in Ovarian Cancer and Implications on Therapy. 2016 , 12, 681-95		5
580	Cancer Drug Resistance. 2016 ,		3
579	Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy. <i>Gynecologic Oncology</i> , 2016 , 141, 134-9	4.9	30
578	Current Controversies in Cancer Care for the Surgeon. 2016 ,		1
577	Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. 2016 , 96, 249-59		46

576	E2F1: a promising regulator in ovarian carcinoma. 2016 , 37, 2823-31		24
575	Association Between Preoperative Chemotherapy and Postoperative Complications in Patients Undergoing Surgery for Ovarian Cancer. 2016 , 23, 968-74		4
574	Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer. 2016 , 81, 46-57		71
573	Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. 2016 , 24, 55-69		41
572	A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2016 , 140, 48-52	4-9	17
571	Ovarian Cancer. 2016 , 1264-1283.e5		1
570	Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways. 2016 , 10, 113-25		60
569	Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life. 2016 , 24, 1241-9		13
568	Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. 2016 , 293, 163-168		35
567	Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy. 2016 , 16, 41-6		23
566	Sequential tests for non-proportional hazards data. 2017 , 23, 339-352		7
565	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. 2017 , 23, 649-657		75
564	Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines. 2017 , 17, 49		13
563	A new anti-mesothelin antibody targets selectively the membrane-associated form. 2017 , 9, 567-577		3
562	Characterization of H type 1 and type 1 -acetyllactosamine glycan epitopes on ovarian cancer specifically recognized by the anti-glycan monoclonal antibody mAb-A4. 2017 , 292, 6163-6176		14
561	Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy. 2017 , 21, 187-198		15
560	The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer. 2017 , 66, 467-475		28
559	Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line. 2017 , 37, 219-226		5

558	Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. 2017 , 1-27		0
557	Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer. 2017 , 34, 87		9
556	Principles of Medical Oncology. 2017 , 1-9		
555	NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. <i>Gynecologic Oncology</i> , 2017 , 145, 420-425	4.9	42
554	The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer. 2017 , 16, 687-696		6
553	Ovary. 2017 , 597-617		
552	Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework. 2017 , 20, 866-875		42
551	Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study. 2017 , 27, 28-36		19
550	Molecular genetics complexity impeding research progress in breast and ovarian cancers. 2017 , 7, 3-14		8
549	Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer: A network meta-analysis. 2017 , 96, e5853		18
548	Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy. 2017 , 27, 420-429		9
547	Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells. 2017 , 13, 4974-4978		36
546	BERing the burden of damage: Pathway crosstalk and posttranslational modification of base excision repair proteins regulate DNA damage management. 2017 , 56, 51-64		33
545	Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy. <i>Japanese Journal of Clinical Oncology</i> , 2017 , 47, 494-498	2.8	6
544	Progress in the management of primary and recurrent ovarian carcinomatosis with peritonectomy procedure and HIPEC in a high volume centre. 2017 , 33, 554-561		10
543	Mucinous Carcinoma of the Ovary. 2017 , 557-563		
542	Xiaoaping combined with cisplatin can inhibit proliferation and invasion and induce cell cycle arrest and apoptosis in human ovarian cancer cell lines. 2017 , 89, 1172-1177		21
541	Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. <i>Gynecologic Oncology</i> , 2017 , 144, 266-273	4.9	30

540	A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO). 2017 , 143, 541-550		13
539	Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells. <i>Gynecologic Oncology</i> , 2017 , 144, 369-376	4.9	7
538	Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. <i>Cancer Science</i> , 2017 , 108, 2213-2220	6.9	15
537	Exosomal delivery of berry anthocyanidins for the management of ovarian cancer. 2017 , 8, 4100-4107		75
536	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. 2017 , 44, 187-197		60
535	Connexin 43 enhances paclitaxel cytotoxicity in colorectal cancer cell lines. 2017 , 14, 1212-1218		8
534	Comparison of secondary cytoreductive surgery plus chemotherapy with chemotherapy alone for recurrent epithelial ovarian, tubal, or peritoneal carcinoma: A propensity score-matched analysis of 112 consecutive patients. 2017 , 96, e8006		3
533	The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer. <i>Scientific Reports</i> , 2017 , 7, 9689	4.9	18
532	Intramedullary Spinal Cord Metastasis from Ovarian Cancer in a 50-Year-Old Female. 2017 , 106, 1049.e3-1049.e4		34
531	Continuous use of metformin can improve survival in type 2 diabetic patients with ovarian cancer: A retrospective study. 2017 , 96, e7605		25
530	Cáncer de ovario. 2017 , 12, 2024-2035		
529	MicroRNA-1 inhibits ovarian cancer cell proliferation and migration through c-Met pathway. 2017 , 473, 237-244		15
528	Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study. 2017 , 56, 302-305		7
527	Feasibility and response to nedaplatin monotherapy in older patients with ovarian cancer. 2017 , 296, 819-826		2
526	Single nucleotide variant in Nucleoporin 107 may be predictive of sensitivity to chemotherapy in patients with ovarian cancer. 2017 , 27, 264-269		8
525	Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study. 2017 , 99, 912-920		11
524	Anti-cancer effect of <i>Scutellaria baicalensis</i> in combination with cisplatin in human ovarian cancer cell. 2017 , 17, 277		20
523	Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3-year experience. 2017 , 80, 405-410		26

522	Ovarian Cancers. 2017 ,		1
521	The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma. 2017 , 21, 59-73		19
520	Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. 2017 , 41, 126-138		29
519	Front-line therapy of advanced epithelial ovarian cancer: standard treatment. 2017 , 28, viii36-viii39		45
518	Systemtherapie des Ovarialkarzinoms. 2017 , 11, 159-169		
517	Neoadjuvant, adjuvant and long-term intravenous/intraperitoneal chemotherapy, hyperthermic intraperitoneal chemotherapy, early postoperative intraperitoneal chemotherapy for ovarian cancer. 2017 ,		1
516	Knockdown of Long Noncoding RNA NR_026689 Inhibits Proliferation and Invasion and Increases Apoptosis in Ovarian Carcinoma HO-8910PM Cells. 2017 , 25, 259-265		5
515	Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer. <i>Cancers</i> , 2017 , 9,	6.6	37
514	Sertoli-Leydig Cell Tumor with Concurrent Rhabdomyosarcoma: Three Case Reports and a Review of the Literature. 2017 , 2017, 4587296		4
513	Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment. 2017 , 12, 6487-6502		76
512	Update on immune checkpoint inhibitors in gynecological cancers. 2017 , 28, e20		45
511	Timing of Cytoreductive Surgery in the Treatment of Advanced Epithelial Ovarian Carcinoma. 2017 , 59-78		
510	Extra-peritoneal hysteroneomyectomy with eventual concomitant en bloc rectal resection and cytoreductive surgery in epithelial ovarian cancer (and other peritoneal surface malignancies): technical details. 2017 ,		
509	Ovarian cancer in Manitoba: trends in incidence and survival, 1992-2011. <i>Current Oncology</i> , 2017 , 24, e78-e84	2.8	0
508	Three Combined Treatments, a Novel HDAC Inhibitor OBP-801/YM753, 5-Fluorouracil, and Paclitaxel, Induce G ₁ Phase Arrest Through the p38 Pathway in Human Ovarian Cancer Cells. 2017 , 25, 1245-1252		9
507	Exosomes as mediators of platinum resistance in ovarian cancer. 2017 , 8, 11917-11936		73
506	Adjuvant chemotherapy with bevacizumab (i.p.) can prolong survival time of patients with advanced ovarian cancer after cytoreduction. 2017 , 64, 108-113		0
505	Ovarian Cancer. 2017 , 378-382		

504	A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing. 2018 , 188, 1120-1131		18
503	SREBP2 contributes to cisplatin resistance in ovarian cancer cells. 2018 , 243, 655-662		20
502	Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial. 2018 , 15, 3646-3652		5
501	Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. <i>Oncogene</i> , 2018 , 37, 3981-3993.	3.2	17
500	The role of neoadjuvant chemotherapy in ovarian cancer. 2018 , 18, 555-566		11
499	Chemotherapy. 263-270		
498	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. 2018 , 67, 1560-1599		1460
497	Trabectedin in Ovarian Cancer: is it now a Standard of Care?. 2018 , 30, 498-503		10
496	Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy. 2018 , 26, 2471-2477		9
495	Plagioneurin B, a potent isolated compound induces apoptotic signalling pathways and cell cycle arrest in ovarian cancer cells. 2018 , 23, 152-169		5
494	Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals. 2018 , 28, 302-307		4
493	Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase. <i>Gynecologic Oncology</i> , 2018 , 148, 329-335	4.9	8
492	Residual tumour less than 0.25 centimetres and positive lymph nodes are risk factors for early relapse in recurrent ovarian peritoneal carcinomatosis treated with cytoreductive surgery, HIPEC and systemic chemotherapy. 2018 , 34, 570-577		5
491	p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. 2018 , 24, 1315-1325		28
490	Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study. <i>Gynecologic Oncology</i> , 2018 , 149, 455-463	4.9	20
489	Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. 2018 , 27, 680-688		1
488	Emerging growth factor receptor antagonists for ovarian cancer treatment. 2018 , 23, 1-16		1
487	Epithelial Ovarian Cancer. 2018 , 253-289.e14		0

486	Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review. 2018 , 57, 7-19		75
485	miRNAs and ovarian cancer: An overview. 2018 , 233, 3846-3854		102
484	Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking. <i>Oncogene</i> , 2018 , 37, 174-184	9.2	13
483	Aptamers as potential therapeutic agents for ovarian cancer. 2018 , 145, 34-44		12
482	Clinical trials in gynecologic oncology: Past, present, and future. <i>Gynecologic Oncology</i> , 2018 , 148, 393-402		6
481	Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced Ovarian Cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery. 2018 , 28, 1520-1528		8
480	Power and sample-size analysis for the Royston-Parmar combined test in clinical trials with a time-to-event outcome. 2018 , 18, 3-21		6
479	Epigenetic Modifications and Potential Treatment Approaches in Lung Cancers. 2018 ,		1
478	Treatment Decisions and Survival in Ovarian Cancer. 2018 ,		
477	Chemotherapy for Primary and Recurrent Epithelial Ovarian Cancer. 2018 ,		0
476	Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer. <i>The Cochrane Library</i> , 2018 ,	5.2	78
475	Ovarian Cancer Overview: Molecular Biology and Its Potential Clinical Application. 2018 ,		0
474	ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. <i>Cancers</i> , 2018 , 10,	6.6	14
473	Diagnosis and Treatment of Ovarian Cancer. 2018 , 32, 943-964		90
472	The Effect of Histological Subtypes on Outcomes of Stage IV Epithelial Ovarian Cancer. 2018 , 8, 577		14
471	Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. 2018 , 7, e1502905		50
470	Understanding the structure, electronic properties, solubility in water, and protein interactions of three novel nano-devices against ovarian cancer: a computational study. 2018 , 20, 1		5
469	Gamma radiation-responsive side-chain tellurium-containing polymer for cancer therapy. 2018 , 2, 2109-2115		21

468	Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma. 2018 , 18, 922		8
467	Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. 2018 , 61, 352-358		2
466	Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer. <i>Gynecologic Oncology</i> , 2018 , 151, 477-480	4.9	17
465	Cancer of the ovary, fallopian tube, and peritoneum. 2018 , 143 Suppl 2, 59-78		116
464	Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq. 2018 , 13, e0206785		42
463	Cell growth inhibitory effects of polyphenols with naphthalene skeleton against cisplatin-resistant ovarian cancer cells. 2018 , 61, 697-701		1
462	Improved survival in ovarian cancer, with widening survival gaps of races and socioeconomic status: a period analysis, 1983-2012. 2018 , 9, 3548-3556		22
461	Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?. 2018 , 29, e96		12
460	Tumor evolution and chemoresistance in ovarian cancer. 2018 , 2, 20		66
459	Surgical and Medical Management of Epithelial Ovarian Cancer. 2018 , 884-904		
458	Evaluation of the peritoneal surface disease severity score (PSDSS) in ovarian cancer patients undergoing cytoreductive surgery and HIPEC: Two pathogenetic types based study. 2018 , 117, 1806-1812		8
457	Myasthenia as a paraneoplastic manifestation of ovarian Cancer. 2018 , 25, 35-36		1
456	Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer - ESMO-MCBS scores. 2018 , 69, 233-242		7
455	Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival. <i>Gynecologic Oncology</i> , 2018 , 150, 306-310	4.9	5
454	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. 2018 , 24, 5820-5829		47
453	Cancer Biology and Survival Analysis in Cancer Trials: Restricted Mean Survival Time Analysis versus Hazard Ratios. 2018 , 30, e75-e80		5
452	Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. 2018 , 18, 601		47
451	3,3'-Diindolylmethane suppresses ovarian cancer cell viability and metastasis and enhances chemotherapy sensitivity via STAT3 and Akt signaling in vitro and in vivo. 2018 ,		7

450	WITHDRAWN: Addition of targeted agents to chemotherapy for persistent or recurrent ovarian cancer: a meta-analysis of randomized controlled trials. 2018 ,		
449	A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study. 2018 , 29, e65		16
448	Traditional Medicinal Plants and Their Therapeutic Potential Against Major Cancer Types. 2018 , 383-410		4
447	New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines. 2018 , 23,		12
446	[Surgical treatment of peritoneal metastases from gynecological primary tumors]. 2018 , 89, 678-686		
445	Intraperitoneal Chemotherapy: Historic Anomaly or Hope for the Future?. 2018 , 30, 484-492		0
444	The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies. 2018 , 9, 8614-8628		24
443	Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models. 2018 , 18, 81		
442	Fisetin and polymeric micelles encapsulating fisetin exhibit potent cytotoxic effects towards ovarian cancer cells. 2018 , 18, 91		9
441	Ovarian Cancer. 2018 , 679-691		
440	Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. 2018 , 44, 1284-1293		3
439	Fabrication of paclitaxel hybrid nanomicelles to treat resistant breast cancer via oral administration. 2018 , 13, 719-731		19
438	Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018 , 151, 18-23	4.9	13
437	Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) through a single port: alternative delivery for the control of peritoneal metastases. 2018 , 45, e1909		6
436	Unplanned hospitalizations in a racially and ethnically diverse population of women receiving chemotherapy for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2018 , 151, 134-140	4.9	0
435	Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model. 2018 , 12, 673-683		8
434	Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. 2018 , 10, 1758835918788500		2
433	Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens. 2018 , 29, e16		1

432	Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer. 2018 , 11, 49		4
431	Identification of pathway-based recurrence-associated signatures in optimally debulked patients with serous ovarian cancer. 2018 , 119, 8564-8573		
430	Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel. 2018 ,		3
429	Rare Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. 2018 , 369-432		
428	Early Postoperative Intraperitoneal Chemotherapy: Current Role and Future Perspectives. 2018 , 103-133		1
427	Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression. 2019 , 9, 571		6
426	Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer. 2019 , 37, 2386-2397		12
425	Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer. <i>Scientific Reports</i> , 2019 , 9, 11153	4.9	22
424	Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. 2019 , 21, 100155		6
423	Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer. <i>Scientific Reports</i> , 2019 , 9, 10742	4.9	6
422	A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy. <i>Gynecologic Oncology</i> , 2019 , 154, 622-630	4.9	17
421	Involvement of the MDR1 gene and glycolipids in anticancer drug-resistance of human ovarian carcinoma-derived cells. 2019 , 32, 447-452		4
420	Pharmaceutical Management of Ovarian Cancer: Current Status. 2019 , 79, 1231-1239		19
419	Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer. 2019 , 29, 1050-1056		16
418	MLH1 Is a Prognostic Biomarker for Serous Ovarian Cancer Treated With Platinum- and Taxane-based Chemotherapy. <i>Anticancer Research</i> , 2019 , 39, 5505-5513	2.3	5
417	Stability analysis of Navier-Stokes system. 2019 , 16, 1950157		5
416	Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer. 2019 , 9, 986		4
415	(3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3K/Akt. 2019 , 41, 599-606		0

414	In-wheel motor for solar electric vehicles: Challenges and opportunities. 2019 ,		0
413	Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study. 2019 , 14, 179		5
412	Hopes and failures in front-line ovarian cancer therapy. 2019 , 143, 14-19		30
411	Real-World Impact of Survival by Period of Diagnosis in Epithelial Ovarian Cancer Between 1990 and 2014. 2019 , 9, 639		12
410	Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies. 2019 , 10, 426		10
409	Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities. <i>Cancers</i> , 2019 , 11,	6.6	24
408	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 2403-2415	59.2	334
407	Paclitaxel-related nail toxicity. 2019 , 58, 709-711		5
406	Neoadjuvant therapy in gynaecological malignancies: What pathologists need to know. 2019 , 72, 102-111		1
405	Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. 2019 , 133, 245-254		17
404	Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer. 2019 , 20, 179-188		6
403	Anti-tumor efficacy of folate modified PLGA-based nanoparticles for the co-delivery of drugs in ovarian cancer. 2019 , 13, 1271-1280		11
402	The use of Cr (CO) ₆ as an alternative CO source in Pd-catalyzed C-N bond formation: Synthesis of benzamides. 2019 , 33, e5049		1
401	Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. <i>Gynecologic Oncology</i> , 2019 , 154, 420-425	4.9	7
400	Model-based analysis of treatment effects of paclitaxel microspheres in a microscopic peritoneal carcinomatosis model in mice. 2019 , 36, 127		10
399	Effects of mixtures of anticancer drugs in the benthic polychaete <i>Nereis diversicolor</i> . 2019 , 252, 1180-1192		10
398	Adding Nanotechnology to the Metastasis Treatment Arsenal. 2019 , 40, 403-418		15
397	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. 2019 , 69, 280-304		292

396	Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?. 2019 , 37, 1359-1364		7
395	Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas. 2019 , 20, 843-854		9
394	High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	156
393	Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years. <i>Gynecologic Oncology</i> , 2019 , 153, 479-486	4.9	4
392	Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression. 2019 , 10, 673-683		21
391	Prostaglandin D2 expression is prognostic in high-grade serous ovarian cancer. 2019 , 41, 2254-2264		6
390	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. 2019 , 8, R10-R26		16
389	Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study. <i>Japanese Journal of Clinical Oncology</i> , 2019 , 49, 347-353	2.8	1
388	Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma. 2019 , 16,		7
387	Poly(ethylene glycol)-block-poly(d,l-lactic acid) micelles containing oligo(lactic acid)-paclitaxel prodrug: In Vivo conversion and antitumor efficacy. 2019 , 298, 186-193		19
386	Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer. <i>Clinical and Translational Medicine</i> , 2019 , 8, 24	5.7	101
385	Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. <i>The Cochrane Library</i> , 2019 , 2019,	5.2	22
384	Photoimmunotherapy of Ovarian Cancer: A Unique Niche in the Management of Advanced Disease. <i>Cancers</i> , 2019 , 11,	6.6	18
383	Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. 2019 , 16,		11
382	Paclitaxel-related dermatological problems: Not only alopecia occurs. 2019 , 58, 877-879		9
381	Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma. 2019 , 134, 1253-1259		10
380	A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2019 , 152, 548-553	4.9	14
379	Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models. 2019 , 27, 314-325		13

378 Cancer and AIDS. **2019**,

- | | | | |
|-----|--|-----|----|
| 377 | In vitro selection of DNA aptamers recognizing drug-resistant ovarian cancer by cell-SELEX. 2019 , 194, 437-445 | | 25 |
| 376 | When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer. 2019 , 26, 902-909 | | 10 |
| 375 | Multi-Targeting by -Elemene and Its Anticancer Properties: A Good Choice for Oncotherapy and Radiochemotherapy Sensitization. 2020 , 72, 554-567 | | 7 |
| 374 | Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study. <i>Gynecologic Oncology</i> , 2020 , 156, 523-529 | 4.9 | 17 |
| 373 | Prediction of Epithelial Ovarian Cancer Outcomes With Integration of Genomic Data. 2020 , 63, 92-108 | | 4 |
| 372 | A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel. <i>Gynecologic Oncology</i> , 2020 , 156, 293-300 | 4.9 | 10 |
| 371 | Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis. 2020 , 46, 868-875 | | 10 |
| 370 | Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis. 2020 , 31, e12 | | 5 |
| 369 | Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy. 2020 , 591, 119986 | | 17 |
| 368 | Treatment of epithelial ovarian cancer. 2020 , 371, m3773 | | 88 |
| 367 | A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2020 , 159, 692-698 | 4.9 | 8 |
| 366 | Validation of the Mexican-Spanish Version of the EORTC QLQ-OV28 Instrument for the Assessment of Quality of Life in Women with Ovarian Cancer. 2020 , 51, 690-699 | | 1 |
| 365 | The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers. 2020 , 30, 1608-1618 | | 1 |
| 364 | Targeting Mitochondrial Singlet Oxygen Dynamics Offers New Perspectives for Effective Metabolic Therapies of Cancer. 2020 , 10, 573399 | | 3 |
| 363 | Successful Management of Platinum-resistant Ovarian Cancer by Weekly Nedaplatin Followed by Olaparib: Three Case Reports. <i>Anticancer Research</i> , 2020 , 40, 5263-5270 | 2.3 | 2 |
| 362 | Aggressive surgery could overcome the extent of initial peritoneal dissemination for advanced ovarian, fallopian tube, and peritoneal carcinoma. <i>Scientific Reports</i> , 2020 , 10, 21307 | 4.9 | 1 |
| 361 | MicroRNA-18a-5p Suppresses Tumor Growth Targeting Matrix Metalloproteinase-3 in Cisplatin-Resistant Ovarian Cancer. 2020 , 10, 602670 | | 5 |

360	Immunology and ovarian cancers. 2020 , 83, 425-432		7
359	CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer. 2020 , 10,		18
358	Advantages of Using Paclitaxel in Combination with Oncolytic Adenovirus Utilizing RNA Destabilization Mechanism. <i>Cancers</i> , 2020 , 12,	6.6	2
357	Current and future strategies for treatment of ovarian clear cell carcinoma. 2020 , 46, 1678-1689		3
356	Postneoadjuvant Chemotherapy Response in Advanced Ovarian Cancer: Radiological and Clinical Implications. 2020 , 27, 958-959		0
355	The Biological Role of the Collagen Alpha-3 (VI) Chain and Its Cleaved C5 Domain Fragment Endotrophin in Cancer. 2020 , 13, 5779-5793		9
354	Effect of Obesity on Hematotoxicity Induced by Carboplatin and Paclitaxel Combination Therapy in Patients with Gynecological Cancer. 2020 , 43, 669-674		0
353	Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations. 2020 , 17, 285-294		14
352	[Current advances in immunotherapy in ovarian cancer]. 2020 , 107, 465-473		4
351	Assessment of acyl-CoA cholesterol acyltransferase (ACAT-1) role in ovarian cancer progression-An in vitro study. 2020 , 15, e0228024		14
350	Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancers-Stage Challenges Categorical Assignments of Indolence & Aggressiveness. 2020 , 10,		5
349	Mesenchymal Stem Cells As Guideposts for Nanoparticle-Mediated Targeted Drug Delivery in Ovarian Cancer. <i>Cancers</i> , 2020 , 12,	6.6	12
348	Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer. 2020 , 17,		12
347	Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study. <i>Cancers</i> , 2020 , 12,	6.6	9
346	Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy. 2020 , 99, e19931		4
345	Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer. 2020 , 20, 128		7
344	Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian Cancer. 2021 , 26, 30-39		3
343	Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity. 2021 , 99, 885-899		11

342	Cancer cell-targeted cisplatin prodrug delivery metabolic labeling and bioorthogonal click reaction. 2021 , 9, 1301-1312		4
341	Platinum-based chemotherapy nanocarriers and co-delivery of multiple drugs. 2021 , 9, 6023-6036		4
340	Models of ovarian cancer to test new agents. 2021 , 97-127		
339	Epithelial Ovarian Cancer and Cancer Stem Cells. 2021 , 1330, 21-32		1
338	Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study. 2021 , 9,		3
337	Overview of mechanisms of chemoresistance in ovarian cancer. 2021 , 25-42		1
336	Epithelial ovarian cancer: Genomic landscape and evolving precision treatment. 2021 , 1-23		
335	The use of immunotherapy for treatment of chemoresistant ovarian cancer. 2021 , 79-96		
334	Potential role of tea extract in oocyte development. 2021 , 12, 10311-10323		0
333	Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. <i>The Cochrane Library</i> , 2021 , 2, CD005343	5.2	8
332	Characteristics of BRCA1/2 pathogenic germline mutations in chinese NSCLC patients and a comparison with HBOC. 2021 , 19, 16		0
331	Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment. 2021 , 11,		4
330	Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. <i>Cancers</i> , 2021 , 13,	6.6	3
329	Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. 2021 , 19, 191-226		74
328	PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
327	Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine. 2021 , 158, 103209		5
326	Cytoreductive Procedures and HIPEC in the Treatment of Advanced Ovarian Cancer.		
325	Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells. <i>Scientific Reports</i> , 2021 , 11, 7347	4.9	7

324	Treosulfan in platinum-resistant ovarian cancer. 2021 , 31, 1045-1051		
323	Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer. 2021 , 81, 109938		6
322	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 620-631	21.7	58
321	The Role of Tumour Metabolism in Cisplatin Resistance. 2021 , 8, 691795		8
320	Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in metastatic ovarian carcinoma: A retrospective study. 2021 , 15, 162		0
319	The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation. <i>Gynecologic Oncology</i> , 2021 , 162, 203-209	4.9	1
318	Efficacy of a Covalent Microtubule Stabilizer in Taxane-Resistant Ovarian Cancer Models. 2021 , 26,		0
317	Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer. 2021 ,		4
316	Diagnostic accuracy of F-FDG PET/CT scan for peritoneal metastases in advanced ovarian cancer. 2021 , 11, 3392-3398		2
315	A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA. 2021 , 1-13		1
314	Mapping Epitopes Recognised by Autoantibodies Shows Potential for the Diagnosis of High-Grade Serous Ovarian Cancer and Monitoring Response to Therapy for This Malignancy. <i>Cancers</i> , 2021 , 13,	6.6	
313	Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis. <i>Gynecologic Oncology</i> , 2021 , 163, 162-170	4.9	2
312	Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021 , 162, 339-344	4.9	1
311	Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. <i>Cancers</i> , 2021 , 13,	6.6	4
310	Role of adjuvant and post-surgical treatment in gynaecological cancer. 2021 , 78, 2-2		0
309	Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer. 2021 ,		0
308	Principles of radiation therapy and chemotherapy in gynecologic cancer. 2022 , 618-636.e1		0
307	Malignant diseases of the ovary, fallopian tube, and peritoneum. 2022 , 707-753.e7		0

306	Cancer Metastasis: Biological and Clinical Aspects, Gynaecological Cancer. 2000 , 381-420	2
305	Biomarker targets and novel therapeutics. 2009 , 149, 85-105	3
304	Systemic Therapy for Ovarian Cancer, Current Treatment, Recent Advances, and Unmet Needs. 2011 , 1-33	1
303	Angiogenesis, Vascular Imaging, and Therapeutic Approaches in Ovarian Tumors. 2001 , 187-205	1
302	Ovarian Cancer. 2013 , 85-96	1
301	Chemotherapy of ovarian cancer. 1998 , 95, 219-34	8
300	Microtubule Stabilizing Agents in Clinical Oncology. 2008 , 395-419	2
299	Clinical pharmacology and use of microtubule-targeting agents in cancer therapy. 2007 , 137, 209-34	11
298	Isolation and culture of ovarian cancer cells and cell lines. 2011 , 731, 161-80	9
297	Significance of anemia in cancer chemotherapy. 2008 , 207-248	2
296	Epidemiology of Ovarian and Endometrial Cancers. 2017 , 233-246	3
295	Introduction. 2010 , 1-6	1
294	Assay-assisted treatment selection for women with breast or ovarian cancer. 2003 , 161, 126-45	11
293	Primary and salvage therapy with LH-RH analogues in ovarian cancer. 2000 , 153, 83-94	24
292	Ovarialkarzinom. 2004 , 1057-1071	1
291	Prevalence, pathophysiology, predictive factors, and prognostic significance of anemia in cancer chemotherapy. 2002 , 63-100	5
290	Taxanes and Epothilones in Cancer Treatment. 2011 , 39-60	1
289	Ovaries and Fallopian Tubes. 2008 , 1827-1855	2

288	Decision-Making in the Management of Recurrent Epithelial Ovarian Cancer. 2004 , 447-454	1
287	Chemotherapy for Refractory Epithelial Ovarian Cancer. 2004 , 465-478	1
286	Gene Therapy of Ovarian CancerState-of-the-Art and Future Perspectives. 2003 , 277-304	1
285	Epithelial Ovarian Cancer. 2007 , 313-367	7
284	Cancer of the Ovary. 2010 , 1052-1066	0
283	Ovarian Cancer. 2012 , 1277-1297	1
282	Systemic therapy for gynecological neoplasms: Ovary, cervix, and endometrium. 2005 , 515-544	8
281	A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer.	2
280	Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. 2000 , 10, 33-41	139
279	Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies. 1998 , 21, 129-34	4
278	The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer: a phase I-II study. 1998 , 21, 491-7	11
277	Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma. 1999 , 22, 559-67	19
276	A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel. 1999 , 22, 601-5	7
275	Modern treatment options in epithelial ovarian carcinoma. 1998 , 10, 29-32	5
274	Progress in ovarian cancer. 1998 , 10, 51-5	0
273	High dose chemotherapeutic strategies in the treatment of epithelial ovarian carcinoma. 1999 , 11, 17-21	1
272	Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma. 1999 , 11, 23-7	3
271	The genetics of ovarian cancer: an assessment of current screening protocols and recommendations for counseling families at risk. 1996 , 39, 860-72	9

270	MICROPAPILLARY BLADDER CARCINOMA. 1999 , 1798-1802	8
269	Primary peritoneal carcinoma: a review of the literature. 1999 , 54, 323-35	42
268	Novel polymerase chain reaction approach for full-coding p53 mutation detection in microdissected archival tumors. 2000 , 9, 110-9	10
267	Phase II window studies: 10 years of experience and counting. 2001 , 23, 334-7	16
266	Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer. 2010 , 33, 233-7	12
265	Protocol Development for Ovarian Cancer Treatment in Kenya: A Brief Report. 2011 , 21, 424-427	9
264	Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma. 2009 , 19, 1142-6	9
263	Trials with impact on clinical management: first line. 2009 , 19 Suppl 2, S55-62	16
262	Fifth Alon Dembo memorial workshop: case 3. 2010 , 20, S24-6	1
261	Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isoforms. 1997 , 100, 1282-93	455
260	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. 2016 , 126, 1885-96	68
259	The role of cancer cooperative groups within the spectrum of cancer care. 2004 , 11, 55-63	3
258	Quality of Life in Ovarian Cancer. 2011 , 18, 52-58	6
257	Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. 2010 , 5, e9615	104
256	Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. 2012 , 7, e30550	65
255	The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling. 2016 , 11, e0156403	18
254	Increased expression of protein kinase CK2 β correlates with poor patient prognosis in epithelial ovarian cancer. 2017 , 12, e0174037	9
253	Prognostic factors in epithelial ovarian cancer: A population-based study. 2018 , 13, e0194993	39

252	Intraperitoneal treatment in ovarian cancer: the gynecologic oncology group perspective in 2012. 2012 , 345-8	3
251	Analysis of expression and prognosis of KLK7 in ovarian cancer. 2020 , 15, 932-939	2
250	[Frequency of blood transfusions for anemia caused by chemotherapy in ovarian cancer patients. Thoughts about the guidelines modified in 2006 for the treatment of anemic cancer patients by the European Organisation for Research and Treatment of Cancer]. 2007 , 148, 2133-7	1
249	High-Dose Therapy for Ovarian Carcinoma. 1997 , 2, 330-339	2
248	Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy. 1999 , 4, 87-94	85
247	Progress in Gynecologic Oncology. 1999 , 4, 293-298	6
246	Single-Agent Paclitaxel in the Treatment of Advanced Non-Small Cell Lung Cancer. 1999 , 4, 408-416	49
245	Tea polyphenol protects against cisplatin-induced meiotic defects in porcine oocytes. <i>Aging</i> , 2019 , 11, 4706-4719	5.6 12
244	Distinct plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry. 2017 , 8, 46834-46845	23
243	Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer. 2016 , 7, 77052-77070	11
242	Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer. 2018 , 9, 17735-17755	2
241	Notch3 functions as a regulator of cell self-renewal by interacting with the E-catenin pathway in hepatocellular carcinoma. 2015 , 6, 3669-79	42
240	Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. 2015 , 6, 44551-62	34
239	Impact of molecular profiling on overall survival of patients with advanced ovarian cancer. 2016 , 7, 19840-9	18
238	Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. 2016 , 7, 48577-48585	3
237	KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer. 2016 , 7, 43924-43938	24
236	Metformin and ovarian cancer: the evidence. 2020 , 8, 1711	6
235	Strategic Combination Therapies for Ovarian Cancer. 2020 , 20, 573-585	1

234	The Effects of Active Hexose Correlated Compound (AHCC) on Levels of CD4+ and CD8+ in Patients with Epithelial Ovarian Cancer or Peritoneal Cancer Receiving Platinum Based Chemotherapy. 2017 , 18, 633-638	5
233	Pathogenesis of malignant ascites in ovarian cancer patients. 2004 , 12, 115-118	14
232	Metastatic spread of mucinous cystadenocarcinoma of the ovaries into abdominal wall. 2005 , 13, 86-88	2
231	[Ovarian epithelial carcinoma--a malignant disease sparing no age group]. 2003 , 56, 157-61	2
230	Mucinous Cancer of the Ovary: Overview and Current Status. 2020 , 10,	19
229	Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience. 2020 , 17,	1
228	INHIBITION OF SKOV3 OVARIAN CANCER BY NANOMICELLES CONSTRUCTED FROM POLY(ETHYLENE GLYCOL)-b-POLY(LACTIDE-co-CARBONATE/PACLITAXEL) CONJUGATES. 2012 , 012, 915-922	1
227	A tale of two time periods: ovarian cancer trends in Ontario. <i>Current Oncology</i> , 2007 , 14, 57-60	2.8 14
226	Involved-field radiation therapy for selected cases of recurrent ovarian cancer. 2019 , 30, e67	2
225	Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. 2012 , 24, 304-9	11
224	Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role?. <i>Journal of Gastrointestinal Oncology</i> , 2016 , 7, 10-7	2.8 4
223	Palliative Surgical Approach in Advanced Nonresponsive Mucinous Ovarian Cancer: A Rare Case Report. 2016 , 22, 173-5	1
222	Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience. 2016 , 5, 59-62	5
221	Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. 2010 , 1, 209-20	38
220	Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. 2014 , 5, 25-30	104
219	Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox [®]). 2013 , 14, 2131-5	15
218	Chemotherapy of ovarian cancer in elderly patients. 2015 , 12, 292-301	9
217	Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents. 2021 , 11, 745981	0

216 Memorial Sloan-Kettering Cancer Center Experience with Intraperitoneal Chemotherapy of Ovarian Cancer. **2000**, 167-177

215 Ovarian Cancer: Current Status and Future Directions. **2000**, 135-144

214 Hat die Radiophosphorthherapie in der Behandlung des Ovarialkarzinoms noch einen Platz?. **2000**, 58-65

213 Entwicklung der Therapie des Ovarialkarzinoms. **2000**, 287-297

212 Do Patients Benefit from Autotransplants for Advanced Ovarian Cancer?. **2000**, 177-189

211 PHASE II STUDY OF PACLITAXEL AND CISPLATIN FOR ADVANCED UROTHELIAL CANCER. **2000**, 1538-1542 2

210 Gynecology. **2001**, 1923-1943

209 Gynecologic Malignancies. **2001**, 250-265

208 Ovarialcarcinom. **2001**, 85-95

207 Ovarialkarzinom aus Sicht des Viszeralchirurgen. **2001**, 899-912

206 Immunotherapy of Ovarian Cancer. **2002**, 317-331

205 Ovarialkarzinom. **2002**, 663-675

204 Current diagnosis and treatment modalities for ovarian cancer. **2002**, 107, 99-118 53

203 Der onkologische Chirurg in Kooperation mit Urologie und Gyn kologie. **2002**, 405-419

202 Molekulare Diagnostik. **2002**, 309-387

201 Ovarian Cancer: The Initial Laparotomy. **2003**, 445-452

200 The Long-Term Management of Ovarian Cancer. **2003**, 467-476

199 Chemotherapy of Ovarian Cancer. **2003**, 487-503

198 Ovarian Cancer. **2003**, 563-567

197 Chemosensitivity testing in gynecologic oncology--dream or reality?. **2003**, 161, 146-58

2

196 Chemotherapie des Ovarialkarzinoms [Neue Therapieoptionen. **2003**, 109-112

195 Cancer Management in Older Women. **2004**, 1171-1185

194 Neoplastic Diseases. **2004**, 479-504

193 Adjuvant Treatment for Early-Stage Epithelial Ovarian Cancer. **2004**, 411-428

192 Gynecologic Cancer in Pregnancy. **2004**, 921-930

1

191 Primary Peritoneal Cancer. **2004**, 527-539

190 Primary Chemotherapy for Advanced Epithelial Ovarian Cancer. **2004**, 429-445

189 Ovarian Sarcomas. **2004**, 509-517

188 Hormonal Treatment of Ovarian Cancer. **2004**, 491-497

187 The Role of Laparoscopy in the Management of Gynecologic Cancers. **2004**, 691-716

186 Gynkologische Tumoren. **2006**, 419-483

185 Tubenkarzinom. **2006**, 4544-4558

184 Neoplastic Diseases of the Ovary. **2007**, 839-881

0

183 Malignant Diseases and Pregnancy. **2007**, 1153-1177

182 Intraperitoneal Chemotherapy in the Management of Ovarian Cancer. **2007**, 165-176

181 Fallopian Tube Cancer. **2007**, 397-410

- 180 The effects of combining docetaxel and cyclooxygenase-2 inhibitors on proliferation and apoptosis in epithelial ovarian cancer. **2007**, 18, 889-96 6
- 179 Traitement des cancers bronchique, colorectal, du sein et de l'ovaire. **2008**, 621-644
- 178 Current Concepts in Chemoprevention of Ovarian Cancer. **2008**, 65-78
- 177 Staging and surgical treatment. **2009**, 149, 35-61
- 176 Extraovarian primary peritoneal carcinoma. **2009**, 279-292 1
- 175 Platinum Compounds: Key Ingredients in Ovarian Cancer Treatment and Strategies. **2009**, 317-328
- 174 Clear Cell Carcinoma of the Ovary: Prognosis Using Cytoreductive Surgery. **2010**, 85-91
- 173 Chemotherapy for Ovarian Cancer. **2010**, 143-161
- 172 Ovarian Cancer. **2010**, 527-533
- 171 Endometrial, Ovarian, and Cervical Cancer. **2010**, 1227-1232.e1
- 170 Ovarialkarzinom. **2010**, 887-902 1
- 169 Current Chemotherapy of Ovarian Cancer. **2010**, 7-25
- 168 Therapeutic advances in women's cancers. **2011**, 3, 82-97 3
- 167 Entwicklung der Chemotherapie in der Gyn kologie. **2011**, 499-512
- 166 Ovarialkarzinom: alte Probleme und neue L sungsans tze. **2011**, 425-451
- 165 Systemic Induction Chemotherapy for Advanced Stage Epithelial Ovarian Cancer. **2011**, 251-260
- 164 Th rapeutiques du cancer de l' vaire. **2011**, 531-576
- 163 Carcinoma of the ovary and fallopian tube. **2011**, 678-688

162 Ovarian Cancer Chemotherapy. **2011**, 2676-2680

161 Pelvic Masses and Ovarian Carcinoma. 361-376

160 Mucinous cystadenocarcinoma of ovary: Changing treatment paradigms. **2012**, 1, 42

159 Women's Health. **2012**, 981-1028

158 Initial chemotherapy for the treatment of ovarian cancer. **2012**, 44-55

157 Geriatric Issues in Ovarian Cancer. **2013**, 39-61

156 Ovarian Cancer: Primary Chemotherapy. **2013**, 171-181

155 Maligne Tumoren des Ovars. **2013**, 381-394

154 Zytoreduktive Chirurgie und Hypertherme Intraperitoneale Chemotherapie (HIPEC). **2013**, 165-185

153 Neoplastic Diseases of the Ovary. **2013**, 731-771

1

152 Systemische Induktionschemotherapie bei fortgeschrittenem epitheliale Ovarialkarzinom. **2013**, 279-287

151 The Epidemiology of Women's Cancers. 9-31

150 Does Intraperitoneal Therapy for Ovarian Cancer Have a Future?. **2014**, 145-153

149 Quality of Life in Patients with Ovarian Cancer. **2014**, 241-260

148 Cellular mechanisms of a new pyrazinone compound that induces apoptosis in SKOV-3 cells. **2014**, 15, 797-802

2

147 The Surgery of Ovarian Cancer. **2014**, 63-76

0

146 Cancers Arising in the Ovary. **2014**, 1592-1613.e6

1

145 Advances in the Medical Management of Ovarian Cancer. **2014**, 77-107

144 Gynecologic Cancers. **1997**, 317-335

143 Assoziierte Symposien. **1997**, 372-377

142 Maligne Tumoren des Ovars. **1998**, 1105-1160

141 Maligne Tumoren der Ovarien. **1998**, 251-301

140 High-dose chemotherapy in gynecologic malignancies. **1998**, 95, 277-85

139 Gynecologic oncology: progress not withstanding. **1998**, 10, 1-2

138 Strategies for using cytoprotective agents to improve outcomes associated with cancer chemotherapy. **1998**, 1, 155-160

137 Ovarian Cancer. **1999**, 860-868

136 Ovarialkarzinom. **1999**, 238-250

135 Preoperative Thrombocytosis Is an Independent Poor Prognostic Factor in Patients with Epithelial Ovarian Cancer. **2014**, 1, 17-21

134 Cancer of Ovary (Epithelial Ovarian Cancer). **2014**, 349-436

133 Epithelial Ovarian Cancer, Low Malignant Potential, and Sex Cord Stromal Tumors of the Ovary. **2015**, 3-53

132 Chemotherapy for Gynecologic Cancer. **2015**, 205-285

131 Cancer of the Ovary and Fallopian Tube.

130 Epithelial Ovarian Cancer. **2015**, 419-429

129 Encyclopedia of Cancer. **2015**, 1-5

128 Managing the patient. **2015**, 31-60

127 Ovarian Cancer. **2015**, 393-433

- 126 Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer. **2015**, 16, 2369-73 1
- 125 Late Recurrence of Ovarian Cancer Mimicking a Primary Lung Malignancy after Curative Resection. **2015**, 21, 201-204
- 124 36 Oncologie. **2016**, 887-936
- 123 Systemic Induction Chemotherapy for Advanced-Stage Epithelial Ovarian Cancer. **2016**, 333-342
- 122 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) **2016**, 187-211
- 121 A COMPARATIVE EVALUATION OF RADIOTHERAPY WITH CONCURRENT WEEKLY CISPLATIN VERSUS CONCURRENT WEEKLY PACLITAXEL IN PATIENTS WITH LOCALLY ADVANCED CARCINOMA CERVIX. **2016**, 5, 1667-1672
- 120 First-Line Systemic Therapy (Chemo/Antiangiogenics). **2017**, 95-112
- 119 Mucinous Carcinoma of the Ovary. **2017**, 221-232
- 118 Encyclopedia of Cancer. **2017**, 3268-3272
- 117 OBSOLETE: Ovarian cancer. **2017**,
- 116 Intraperitoneal Chemotherapy in Ovarian Cancer. **2017**, 2, 1-4
- 115 Cyclophosphamide in ovarian cancer subtypes: Time for a comeback. *Indian Journal of Medical and Paediatric Oncology*, **2018**, 39, 551 0.2
- 114 Therapy of Cancer and Retroviral Diseases. **2019**, 65-158 1
- 113 Subspecialty Training of Gynecologic Surgery in Japan. **2019**, 1-10
- 112 Gynecologic Disorders in the Older Woman. **2019**, 1-38
- 111 Gynaecological Cancer Diagnostics: 99mTc-Cisplatin Complex as a Future Approach for Early, Prompt and Efficient Diagnosis of Gynaecological Cancer. **2019**, 15, 611-621 0
- 110 ~~REVIEW/REKEN OVER KANSER IN DEN NIEUWLE HYPERTERMIE INTRAPERITONIALE KEMOTERAPI (HIPEC) UYGULADIMIZ HASTALARDAKİ PEROPERATİF TECRÜBEMİZ~~ Our peroperative experience in patients who underwent Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced stage/recurrent ovarian cancer.
- 109 Predictors of morbidity and mortality in patients submitted to cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for ovarian carcinomatosis: a multicenter study. **2021**, 6, 21-30

108 Maligne Tumoren des Ovars. **2020**, 439-454

107 Gynecologic Disorders in the Older Woman. **2020**, 683-719

106 A Matched Observational Study. **2020**, 191-199

O

105 No todo es lo que parece: miastenia gravis, una rara manifestaci3n paraneopl3sica del c3ncer de ovario: caso cl3nico. **2020**, 47, 72-74

104 Intraperitoneal chemotherapy for the treatment of ovarian cancer. **2005**, 5, 203-211

103 Chemotherapy for Epithelial Ovarian Cancer. **2006**, 188-206

102 Ovarian Cancer. **2006**, 910-936

101 La chimioth3rapie intrap3riton3ale a-t-elle une place en premi3re ligne?. **2006**, 301-314

100 Intensification de la chimioth3rapie en consolidation. **2006**, 341-359

99 La chimioth3rapie intrap3riton3ale avec hyperthermie. **2006**, 361-372

98 La chimioth3rapie des rechutes au-del3 de six mois. **2006**, 417-425

97 Ovarialkarzinom aus Sicht des Viszeralchirurgen. **2006**, 873-887

96 Antiangiogenesis Therapies in Gynecologic Malignancies. **2008**, 441-456

95 Future Directions in the Delivery of Hyperthermic Intraperitoneal Chemotherapy. **2007**, 179-186

94 Management of Ovarian Cancer: Clinical Trials. **2007**, 11-29

93 Regional Therapy in Ovarian Cancer. **2007**, 329-341

92 Targeted Therapy in Epithelial Ovarian Cancer. **2008**, 261-269

91 Stellenwert der Hochdosis-Chemotherapie mit peripherer Blutstammzelltransplantation beim fortgeschrittenen Ovarialkarzinom. 1-14

90 Current management of ovarian carcinoma. **2005**, 2, 275-286

89 Maligne Ovarialtumoren. 1184-1244

88 Maligne Tumoren des Ovars. **2007**, 347-360

87 Ovarian and Fallopian Tube Cancers. **2008**, 331-342

86 Ovarian cancer (advanced). *Clinical Evidence*, **2009**, 2009,

85 The role of in vitro directed chemotherapy in epithelial ovarian cancer. *Reviews in Obstetrics and Gynecology*, **2010**, 3, 49-54 5

84 Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know?. *Sultan Qaboos University Medical Journal*, **2008**, 8, 137-48 0.9 5

83 Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. *Current Oncology*, **2011**, 18 Suppl 2, S20-7 2.8 8

82 Targeted ovarian cancer treatment: the TRAILS of resistance. *American Journal of Cancer Research*, **2012**, 2, 75-92 4.4 25

81 The role of taxanes in the management of gastroesophageal cancer. *Journal of Gastrointestinal Oncology*, **2011**, 2, 240-9 2.8 19

80 Elemenene effectively suppresses the growth and survival of both platinum-sensitive and -resistant ovarian tumor cells. *Anticancer Research*, **2012**, 32, 3103-13 2.3 25

79 Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy. *International Journal of Clinical and Experimental Pathology*, **2013**, 6, 2121-8 1.4 9

78 3-cinnamoyl-4-hydroxy-6-methyl-2H-pyran-2-one (CHP) inhibits human ovarian cell proliferation by inducing apoptosis. *International Journal of Clinical and Experimental Pathology*, **2015**, 8, 155-63 1.4 4

77 Investigation on metabolism of cisplatin resistant ovarian cancer using a genome scale metabolic model and microarray data. *Iranian Journal of Basic Medical Sciences*, **2015**, 18, 267-76 1.8 14

76 Association analysis of a chemo-response signature identified within The Cancer Genome Atlas aimed at predicting genetic risk for chemo-response in ovarian cancer. *International Journal of Molecular Epidemiology and Genetics*, **2016**, 7, 41-4 0.9 2

75 Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment. *American Journal of Cancer Research*, **2016**, 6, 1624-35 4.4 9

74 Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based Medicine. *Medica*, **2015**, 10, 376-381 1

73 Ovarian Cancer Survival in Missouri, 1996-2014. *Missouri Medicine*, **2018**, 115, 542-547 0.8 1

72	A folic acid-modified non-viral vector combines gene therapy with chemotherapy to reverse cancer chemotherapy resistance. <i>Applied Materials Today</i> , 2021 , 26, 101277	6.6	0
71	Achieving Complete Radiological and Bio-Chemical Response as a Predictor of Long-Term Survival in Stage IV Epithelial Ovarian Cancer.. <i>Cureus</i> , 2021 , 13, e20017	1.2	1
70	Squamous cell carcinoma arising in mature cystic teratoma of the ovary. 2001 , 3, 321-323		
69	Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells.. <i>Acta Pharmacologica Sinica</i> , 2022 ,	8	1
68	Enhanced Anti-Proliferative Effect of Carboplatin in Ovarian Cancer Cells Exploiting Chitosan - Poly (lactic glycolic acid) Nanoparticles.. <i>Recent Patents on Nanotechnology</i> , 2022 ,	1.2	0
67	Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence.. <i>Oncogene</i> , 2022 ,	9.2	2
66	Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review.. <i>Future Oncology</i> , 2022 ,	3.6	2
65	Una propuesta prctica para seleccionar tratamientos quimioterpicos en pacientes oncolgicos avanzados segun su coste-efectividad. 2003 , 5, 33-36		
64	Multifunctional co-transport carriers based on cyclodextrin assembly for cancer synergistic therapy.. <i>Theranostics</i> , 2022 , 12, 2560-2579	12.1	1
63	Comparison of one-week versus three-week paclitaxel for advanced pan-carcinomas: systematic review and meta-analysis.. <i>Aging</i> , 2022 , 14,	5.6	0
62	Systemische Therapie und zielgerichtete Erhaltungstherapie in der Primrsituation beim high- und low-grade Ovarialkarzinom. <i>Der Gynakologe</i> , 2022 , 55, 164-175	0.1	
61	Gynecologic Oncology: On the Shoulders of Giants. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2022 , 43, 034-039	0.2	
60	Paclitaxel Induces Epidermal Molecular Changes and Produces Subclinical Alterations in the Skin of Gynecological Cancer Patients.. <i>Cancers</i> , 2022 , 14,	6.6	0
59	The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
58	Development of a bayesian toxo-equivalence model between docetaxel and paclitaxel.. <i>IScience</i> , 2022 , 25, 104045	6.1	
57	Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas. <i>Cancers</i> , 2021 , 13,	6.6	0
56	Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment.. <i>Cancers</i> , 2021 , 13,	6.6	2
55	Discovery and characterization of potent And-1 inhibitors for cancer treatment.. <i>Clinical and Translational Medicine</i> , 2021 , 11, e627	5.7	3

54	Current trends in chemotherapy for advanced ovarian cancer.. <i>Japanese Journal of Clinical Oncology</i> , 2022 ,	2.8	
53	DataSheet_1.docx. 2020 ,		
52	Data_Sheet_1.docx. 2019 ,		
51	Data_Sheet_1.pdf. 2019 ,		
50	Lifetime ovulations and epithelial ovarian cancer risk and survival: A systematic review and meta-analysis.. <i>Gynecologic Oncology</i> , 2022 ,	4.9	1
49	Translational development of a tumor junction opening technology.. <i>Scientific Reports</i> , 2022 , 12, 7753	4.9	0
48	Ovarian, Vaginal, and Vulvar Cancer. 2022 , 317-339		
47	State of the science: Contemporary front-line treatment of advanced ovarian cancer.. <i>Gynecologic Oncology</i> , 2022 ,	4.9	0
46	Assessment of antitumor activity of BP-C1, a platinum-based anticancer agent with a lignin-derived polymeric ligand, in autochthonous induced and spontaneous carcinogenesis rodent models. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022 , 127013	4.1	
45	Comprehensive Network Analysis of Dysregulated Genes Revealed MNX1-AS1/ hsa-miR-4697-3p/ HOXB13 Axis in OC Chemotherapy Response. <i>Cancer Science</i> ,	6.9	0
44	Characterization of rare histological subtypes of ovarian cancer based on molecular profiling. <i>Cancer Medicine</i> ,	4.8	
43	Survivin, Sonic hedgehog, Kröpel-like factors, and p53 pathway in serous ovarian cancer: an immunohistochemical study. <i>Human Pathology</i> , 2022 ,	3.7	
42	The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer. <i>Cancers</i> , 2022 , 14, 3318	6.6	
41	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2022 , 23, 919-930	21.7	3
40	Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 217-224	6.1	25
39	Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 833-838	6.1	46
38	Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer. <i>Annals of the Academy of Medicine, Singapore</i> , 2015 , 44, 421-433	2.8	2
37	Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer. <i>The Cochrane Library</i> , 2022 , 2022,	5.2	

36	Alendronate Inhibits Intraperitoneal Dissemination in In vivo Ovarian Cancer Model. 2005 , 65, 540-545	12
35	Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer. 2022 , 14, 3554	0
34	NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer.	
33	The Use of Immunotherapy for Treatment of Gynecologic Malignancies.	
32	The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future.	0
31	Mucinous ovarian carcinomas. 2023 , 77-93	
30	Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome. 2022 , 61,	0
29	Role of maintenance paclitaxel in epithelial ovarian cancer: An affordable option for poor resources countries (a Regional Cancer Institute study). 2022 , 0	0
28	Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial. 2022 , 14, 175883592211261	0
27	Extracts of the Medicinal Plants Pao Pereira and Rauwolfia vomitoria Inhibit Ovarian Cancer Stem Cells In Vitro. 2022 , 21, 153473542211230	0
26	Recently Reported Ru-Metal Organic Coordination Complexes and Their Application (A Review). 2022 , 92, 1546-1561	0
25	Advances in the management of peritoneal malignancies.	1
24	Therapy for Recurrent High-Grade Epithelial Ovarian Cancer: The Current Status and Future Trends.	0
23	Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. 2022 , 2022,	0
22	Primary mucinous ovarian cancer: options for surgery and chemotherapy. ijgc-2022-003806	0
21	Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis. ijgc-2022-003614	0
20	Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. 1-23	0
19	Epithelial ovarian cancer. 2023 , 250-281.e8	0

- 18 A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. ○
- 17 Recent Developments and Anticancer Therapeutics of Paclitaxel: An update. **2022**, 29, ○
- 16 Carboplatin enhances lymphocyte-endothelial interactions to promote CD8+ T cell trafficking into the ovarian tumor microenvironment. **2023**, 168, 92-99 ○
- 15 The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line. **2023**, 24, 97 1
- 14 Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes. **2022**, 14, 6010 ○
- 13 Conventional to Nanoscale-Based Carrier Systems in the Management of Ovarian Cancer. **2022**, 89-110 ○
- 12 Current Issues in the Management of Patients With Newly Diagnosed Advanced-Stage High-Grade Serous Carcinoma of the Ovary. ○
- 11 Ovarian, Uterine, and Vulvovaginal Cancers. **2023**, ○
- 10 Diagnostic and Therapeutic Pathway of Advanced Ovarian Cancer with Peritoneal Metastases. **2023**, 15, 407 ○
- 9 Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis. **2023**, 30, e36-e55 ○
- 8 Epithelial Ovarian Cancer. **2022**, 291-323 ○
- 7 Ferroptosis: The Entanglement between Traditional Drugs and Nanodrugs in Tumor Therapy. 2203085 ○
- 6 Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology. **2023**, 118, 16-46 ○
- 5 Proteomic analysis reveals CAAP1 negatively correlates with platinum resistance in ovarian cancer. **2023**, 277, 104864 ○
- 4 Analysis of Efficacy-To-Safety Ratio of Angiogenesis-Inhibitors Based Therapies in Ovarian Cancer: A Systematic Review and Meta-Analysis. **2023**, 13, 1040 ○
- 3 Cisplatin in Ovarian Cancer Treatment Known Limitations in Therapy Force New Solutions. **2023**, 24, 7585 ○
- 2 Olaparib and advanced ovarian cancer: Summary of the past and looking into the future. 14, ○
- 1 Nanoscale drug delivery systems for cancer therapy using paclitaxel A review of challenges and latest progressions. **2023**, 84, 104494 ○

